#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Doxazosin for the treatment of co-occurring PTSD and alcohol use disorder: Design and methodology of a randomized controlled trial in military veterans
#Text=Posttraumatic stress disorder (PTSD) and alcohol use disorders (AUD) are two of the most common mental health disorders affecting civilians as well as military populations.
1-1	0-9	Doxazosin	_	
1-2	10-13	for	_	
1-3	14-17	the	_	
1-4	18-27	treatment	_	
1-5	28-30	of	_	
1-6	31-43	co-occurring	_	
1-7	44-48	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
1-8	49-52	and	_	
1-9	53-60	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-10	61-64	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-11	65-73	disorder	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[1]	
1-12	73-74	:	_	
1-13	75-81	Design	_	
1-14	82-85	and	_	
1-15	86-97	methodology	_	
1-16	98-100	of	_	
1-17	101-102	a	_	
1-18	103-113	randomized	_	
1-19	114-124	controlled	_	
1-20	125-130	trial	_	
1-21	131-133	in	_	
1-22	134-142	military	_	
1-23	143-151	veterans	_	
1-24	152-165	Posttraumatic	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-25	166-172	stress	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-26	173-181	disorder	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-27	182-183	(	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-28	183-187	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-29	187-188	)	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[2]	
1-30	189-192	and	_	
1-31	193-200	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-32	201-204	use	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-33	205-214	disorders	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-34	215-216	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-35	216-219	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-36	219-220	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[3]	
1-37	221-224	are	_	
1-38	225-228	two	_	
1-39	229-231	of	_	
1-40	232-235	the	_	
1-41	236-240	most	_	
1-42	241-247	common	_	
1-43	248-254	mental	_	
1-44	255-261	health	_	
1-45	262-271	disorders	_	
1-46	272-281	affecting	_	
1-47	282-291	civilians	_	
1-48	292-294	as	_	
1-49	295-299	well	_	
1-50	300-302	as	_	
1-51	303-311	military	_	
1-52	312-323	populations	_	
1-53	323-324	.	_	

#Text=If left untreated, individuals with co-occurring PTSD/AUD are at increased risk for developing other mental health problems (e.g., depression, anxiety), physical health problems, reduced resiliency and military readiness, and vocational and social impairment.
2-1	325-327	If	_	
2-2	328-332	left	_	
2-3	333-342	untreated	_	
2-4	342-343	,	_	
2-5	344-355	individuals	_	
2-6	356-360	with	_	
2-7	361-373	co-occurring	_	
2-8	374-378	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
2-9	378-379	/	_	
2-10	379-382	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
2-11	383-386	are	_	
2-12	387-389	at	_	
2-13	390-399	increased	_	
2-14	400-404	risk	_	
2-15	405-408	for	_	
2-16	409-419	developing	_	
2-17	420-425	other	_	
2-18	426-432	mental	_	
2-19	433-439	health	_	
2-20	440-448	problems	_	
2-21	449-450	(	_	
2-22	450-453	e.g	_	
2-23	453-454	.	_	
2-24	454-455	,	_	
2-25	456-466	depression	_	
2-26	466-467	,	_	
2-27	468-475	anxiety	_	
2-28	475-476	)	_	
2-29	476-477	,	_	
2-30	478-486	physical	_	
2-31	487-493	health	_	
2-32	494-502	problems	_	
2-33	502-503	,	_	
2-34	504-511	reduced	_	
2-35	512-522	resiliency	_	
2-36	523-526	and	_	
2-37	527-535	military	_	
2-38	536-545	readiness	_	
2-39	545-546	,	_	
2-40	547-550	and	_	
2-41	551-561	vocational	_	
2-42	562-565	and	_	
2-43	566-572	social	_	
2-44	573-583	impairment	_	
2-45	583-584	.	_	

#Text=Substantial gaps in the treatment of co-occurring PTSD/AUD exist and there is a critical need to develop more effective pharmacological treatments.
3-1	585-596	Substantial	_	
3-2	597-601	gaps	_	
3-3	602-604	in	_	
3-4	605-608	the	_	
3-5	609-618	treatment	_	
3-6	619-621	of	_	
3-7	622-634	co-occurring	_	
3-8	635-639	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
3-9	639-640	/	_	
3-10	640-643	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
3-11	644-649	exist	_	
3-12	650-653	and	_	
3-13	654-659	there	_	
3-14	660-662	is	_	
3-15	663-664	a	_	
3-16	665-673	critical	_	
3-17	674-678	need	_	
3-18	679-681	to	_	
3-19	682-689	develop	_	
3-20	690-694	more	_	
3-21	695-704	effective	_	
3-22	705-720	pharmacological	_	
3-23	721-731	treatments	_	
3-24	731-732	.	_	

#Text=The current study addresses this gap in the literature by testing the efficacy and safety of doxazosin, a long-acting and selective alpha-1 adrenergic antagonist, as compared to placebo in reducing PTSD and AUD severity among U.S. military veterans.
4-1	733-736	The	_	
4-2	737-744	current	_	
4-3	745-750	study	_	
4-4	751-760	addresses	_	
4-5	761-765	this	_	
4-6	766-769	gap	_	
4-7	770-772	in	_	
4-8	773-776	the	_	
4-9	777-787	literature	_	
4-10	788-790	by	_	
4-11	791-798	testing	_	
4-12	799-802	the	_	
4-13	803-811	efficacy	_	
4-14	812-815	and	_	
4-15	816-822	safety	_	
4-16	823-825	of	_	
4-17	826-835	doxazosin	_	
4-18	835-836	,	_	
4-19	837-838	a	_	
4-20	839-850	long-acting	_	
4-21	851-854	and	_	
4-22	855-864	selective	_	
4-23	865-870	alpha	_	
4-24	870-871	-	_	
4-25	871-872	1	_	
4-26	873-883	adrenergic	_	
4-27	884-894	antagonist	_	
4-28	894-895	,	_	
4-29	896-898	as	_	
4-30	899-907	compared	_	
4-31	908-910	to	_	
4-32	911-918	placebo	_	
4-33	919-921	in	_	
4-34	922-930	reducing	_	
4-35	931-935	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
4-36	936-939	and	_	
4-37	940-943	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
4-38	944-952	severity	_	
4-39	953-958	among	_	
4-40	959-962	U.S	_	
4-41	962-963	.	_	
4-42	964-972	military	_	
4-43	973-981	veterans	_	
4-44	981-982	.	_	

#Text=Noradrenergic dysregulation has been implicated in the development and maintenance of PTSD and AUD, and pilot studies examining doxazosin in PTSD-only or AUD-only samples have shown promise.
5-1	983-996	Noradrenergic	_	
5-2	997-1010	dysregulation	_	
5-3	1011-1014	has	_	
5-4	1015-1019	been	_	
5-5	1020-1030	implicated	_	
5-6	1031-1033	in	_	
5-7	1034-1037	the	_	
5-8	1038-1049	development	_	
5-9	1050-1053	and	_	
5-10	1054-1065	maintenance	_	
5-11	1066-1068	of	_	
5-12	1069-1073	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
5-13	1074-1077	and	_	
5-14	1078-1081	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
5-15	1081-1082	,	_	
5-16	1083-1086	and	_	
5-17	1087-1092	pilot	_	
5-18	1093-1100	studies	_	
5-19	1101-1110	examining	_	
5-20	1111-1120	doxazosin	_	
5-21	1121-1123	in	_	
5-22	1124-1133	PTSD-only	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
5-23	1134-1136	or	_	
5-24	1137-1145	AUD-only	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
5-25	1146-1153	samples	_	
5-26	1154-1158	have	_	
5-27	1159-1164	shown	_	
5-28	1165-1172	promise	_	
5-29	1172-1173	.	_	

#Text=This is the first study, however, to evaluate doxazosin in a comorbid PTSD/AUD sample.
6-1	1174-1178	This	_	
6-2	1179-1181	is	_	
6-3	1182-1185	the	_	
6-4	1186-1191	first	_	
6-5	1192-1197	study	_	
6-6	1197-1198	,	_	
6-7	1199-1206	however	_	
6-8	1206-1207	,	_	
6-9	1208-1210	to	_	
6-10	1211-1219	evaluate	_	
6-11	1220-1229	doxazosin	_	
6-12	1230-1232	in	_	
6-13	1233-1234	a	_	
6-14	1235-1243	comorbid	_	
6-15	1244-1248	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
6-16	1248-1249	/	_	
6-17	1249-1252	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
6-18	1253-1259	sample	_	
6-19	1259-1260	.	_	

#Text=This paper describes the rationale, design and methodology of a randomized, double-blind, placebo-controlled trial of doxazosin (16 mg/day) delivered over 12 weeks among military veterans with current PTSD and AUD.
7-1	1261-1265	This	_	
7-2	1266-1271	paper	_	
7-3	1272-1281	describes	_	
7-4	1282-1285	the	_	
7-5	1286-1295	rationale	_	
7-6	1295-1296	,	_	
7-7	1297-1303	design	_	
7-8	1304-1307	and	_	
7-9	1308-1319	methodology	_	
7-10	1320-1322	of	_	
7-11	1323-1324	a	_	
7-12	1325-1335	randomized	_	
7-13	1335-1336	,	_	
7-14	1337-1349	double-blind	_	
7-15	1349-1350	,	_	
7-16	1351-1369	placebo-controlled	_	
7-17	1370-1375	trial	_	
7-18	1376-1378	of	_	
7-19	1379-1388	doxazosin	_	
7-20	1389-1390	(	_	
7-21	1390-1392	16	_	
7-22	1393-1395	mg	_	
7-23	1395-1396	/	_	
7-24	1396-1399	day	_	
7-25	1399-1400	)	_	
7-26	1401-1410	delivered	_	
7-27	1411-1415	over	_	
7-28	1416-1418	12	_	
7-29	1419-1424	weeks	_	
7-30	1425-1430	among	_	
7-31	1431-1439	military	_	
7-32	1440-1448	veterans	_	
7-33	1449-1453	with	_	
7-34	1454-1461	current	_	
7-35	1462-1466	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
7-36	1467-1470	and	_	
7-37	1471-1474	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
7-38	1474-1475	.	_	

#Text=In addition, functional magnetic resonance imaging (fMRI) is applied at pre- and post-treatment to investigate the underlying pathophysiology of comorbid PTSD/AUD and identify prognostic indicators of treatment outcome.
8-1	1476-1478	In	_	
8-2	1479-1487	addition	_	
8-3	1487-1488	,	_	
8-4	1489-1499	functional	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
8-5	1500-1508	magnetic	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
8-6	1509-1518	resonance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
8-7	1519-1526	imaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
8-8	1527-1528	(	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
8-9	1528-1532	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
8-10	1532-1533	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging[4]	
8-11	1534-1536	is	_	
8-12	1537-1544	applied	_	
8-13	1545-1547	at	_	
8-14	1548-1551	pre	_	
8-15	1551-1552	-	_	
8-16	1553-1556	and	_	
8-17	1557-1571	post-treatment	_	
8-18	1572-1574	to	_	
8-19	1575-1586	investigate	_	
8-20	1587-1590	the	_	
8-21	1591-1601	underlying	_	
8-22	1602-1617	pathophysiology	_	
8-23	1618-1620	of	_	
8-24	1621-1629	comorbid	_	
8-25	1630-1634	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
8-26	1634-1635	/	_	
8-27	1635-1638	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
8-28	1639-1642	and	_	
8-29	1643-1651	identify	_	
8-30	1652-1662	prognostic	_	
8-31	1663-1673	indicators	_	
8-32	1674-1676	of	_	
8-33	1677-1686	treatment	_	
8-34	1687-1694	outcome	_	
8-35	1694-1695	.	_	

#Text=This study is designed to accelerate research on co-occurring PTSD/AUD and provide empirical evidence to inform clinical practice.
9-1	1696-1700	This	_	
9-2	1701-1706	study	_	
9-3	1707-1709	is	_	
9-4	1710-1718	designed	_	
9-5	1719-1721	to	_	
9-6	1722-1732	accelerate	_	
9-7	1733-1741	research	_	
9-8	1742-1744	on	_	
9-9	1745-1757	co-occurring	_	
9-10	1758-1762	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
9-11	1762-1763	/	_	
9-12	1763-1766	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
9-13	1767-1770	and	_	
9-14	1771-1778	provide	_	
9-15	1779-1788	empirical	_	
9-16	1789-1797	evidence	_	
9-17	1798-1800	to	_	
9-18	1801-1807	inform	_	
9-19	1808-1816	clinical	_	
9-20	1817-1825	practice	_	
9-21	1825-1826	.	_	

#Text=Introduction
#Text=Military veterans are at increased risk of developing of posttraumatic stress disorder (PTSD) and substance use disorders (SUD).
10-1	1827-1839	Introduction	_	
10-2	1840-1848	Military	_	
10-3	1849-1857	veterans	_	
10-4	1858-1861	are	_	
10-5	1862-1864	at	_	
10-6	1865-1874	increased	_	
10-7	1875-1879	risk	_	
10-8	1880-1882	of	_	
10-9	1883-1893	developing	_	
10-10	1894-1896	of	_	
10-11	1897-1910	posttraumatic	_	
10-12	1911-1917	stress	_	
10-13	1918-1926	disorder	_	
10-14	1927-1928	(	_	
10-15	1928-1932	PTSD	_	
10-16	1932-1933	)	_	
10-17	1934-1937	and	_	
10-18	1938-1947	substance	_	
10-19	1948-1951	use	_	
10-20	1952-1961	disorders	_	
10-21	1962-1963	(	_	
10-22	1963-1966	SUD	_	
10-23	1966-1967	)	_	
10-24	1967-1968	.	_	

#Text=In comparison to the general population, rates of PTSD are almost 5 times higher, and rates of SUD are approximately twice as high among veterans.
11-1	1969-1971	In	_	
11-2	1972-1982	comparison	_	
11-3	1983-1985	to	_	
11-4	1986-1989	the	_	
11-5	1990-1997	general	_	
11-6	1998-2008	population	_	
11-7	2008-2009	,	_	
11-8	2010-2015	rates	_	
11-9	2016-2018	of	_	
11-10	2019-2023	PTSD	_	
11-11	2024-2027	are	_	
11-12	2028-2034	almost	_	
11-13	2035-2036	5	_	
11-14	2037-2042	times	_	
11-15	2043-2049	higher	_	
11-16	2049-2050	,	_	
11-17	2051-2054	and	_	
11-18	2055-2060	rates	_	
11-19	2061-2063	of	_	
11-20	2064-2067	SUD	_	
11-21	2068-2071	are	_	
11-22	2072-2085	approximately	_	
11-23	2086-2091	twice	_	
11-24	2092-2094	as	_	
11-25	2095-2099	high	_	
11-26	2100-2105	among	_	
11-27	2106-2114	veterans	_	
11-28	2114-2115	.	_	

#Text=Furthermore, extensive literature documents the frequent co-occurrence of PTSD and SUD.
12-1	2116-2127	Furthermore	_	
12-2	2127-2128	,	_	
12-3	2129-2138	extensive	_	
12-4	2139-2149	literature	_	
12-5	2150-2159	documents	_	
12-6	2160-2163	the	_	
12-7	2164-2172	frequent	_	
12-8	2173-2186	co-occurrence	_	
12-9	2187-2189	of	_	
12-10	2190-2194	PTSD	_	
12-11	2195-2198	and	_	
12-12	2199-2202	SUD	_	
12-13	2202-2203	.	_	

#Text=Initial reports among military personnel focused on Vietnam veterans with PTSD, in which up to 84% met lifetime criteria for an alcohol use disorder (AUD).
13-1	2204-2211	Initial	_	
13-2	2212-2219	reports	_	
13-3	2220-2225	among	_	
13-4	2226-2234	military	_	
13-5	2235-2244	personnel	_	
13-6	2245-2252	focused	_	
13-7	2253-2255	on	_	
13-8	2256-2263	Vietnam	_	
13-9	2264-2272	veterans	_	
13-10	2273-2277	with	_	
13-11	2278-2282	PTSD	_	
13-12	2282-2283	,	_	
13-13	2284-2286	in	_	
13-14	2287-2292	which	_	
13-15	2293-2295	up	_	
13-16	2296-2298	to	_	
13-17	2299-2302	84%	_	
13-18	2303-2306	met	_	
13-19	2307-2315	lifetime	_	
13-20	2316-2324	criteria	_	
13-21	2325-2328	for	_	
13-22	2329-2331	an	_	
13-23	2332-2339	alcohol	_	
13-24	2340-2343	use	_	
13-25	2344-2352	disorder	_	
13-26	2353-2354	(	_	
13-27	2354-2357	AUD	_	
13-28	2357-2358	)	_	
13-29	2358-2359	.	_	

#Text=More recently, data from the Department of Veterans Affairs indicate that, among veterans serving in the Vietnam era or later (N = 1,001,996), 41.4% with SUD meet criteria for current PTSD.
14-1	2360-2364	More	_	
14-2	2365-2373	recently	_	
14-3	2373-2374	,	_	
14-4	2375-2379	data	_	
14-5	2380-2384	from	_	
14-6	2385-2388	the	_	
14-7	2389-2399	Department	_	
14-8	2400-2402	of	_	
14-9	2403-2411	Veterans	_	
14-10	2412-2419	Affairs	_	
14-11	2420-2428	indicate	_	
14-12	2429-2433	that	_	
14-13	2433-2434	,	_	
14-14	2435-2440	among	_	
14-15	2441-2449	veterans	_	
14-16	2450-2457	serving	_	
14-17	2458-2460	in	_	
14-18	2461-2464	the	_	
14-19	2465-2472	Vietnam	_	
14-20	2473-2476	era	_	
14-21	2477-2479	or	_	
14-22	2480-2485	later	_	
14-23	2486-2487	(	_	
14-24	2487-2488	N	_	
14-25	2489-2490	=	_	
14-26	2491-2500	1,001,996	_	
14-27	2500-2501	)	_	
14-28	2501-2502	,	_	
14-29	2503-2508	41.4%	_	
14-30	2509-2513	with	_	
14-31	2514-2517	SUD	_	
14-32	2518-2522	meet	_	
14-33	2523-2531	criteria	_	
14-34	2532-2535	for	_	
14-35	2536-2543	current	_	
14-36	2544-2548	PTSD	_	
14-37	2548-2549	.	_	

#Text=A series of associated problems are common among individuals with dually diagnosed PTSD and SUD, including medical problems, family dysfunction, homelessness, HIV risk behavior, and poor treatment outcomes.
15-1	2550-2551	A	_	
15-2	2552-2558	series	_	
15-3	2559-2561	of	_	
15-4	2562-2572	associated	_	
15-5	2573-2581	problems	_	
15-6	2582-2585	are	_	
15-7	2586-2592	common	_	
15-8	2593-2598	among	_	
15-9	2599-2610	individuals	_	
15-10	2611-2615	with	_	
15-11	2616-2622	dually	_	
15-12	2623-2632	diagnosed	_	
15-13	2633-2637	PTSD	_	
15-14	2638-2641	and	_	
15-15	2642-2645	SUD	_	
15-16	2645-2646	,	_	
15-17	2647-2656	including	_	
15-18	2657-2664	medical	_	
15-19	2665-2673	problems	_	
15-20	2673-2674	,	_	
15-21	2675-2681	family	_	
15-22	2682-2693	dysfunction	_	
15-23	2693-2694	,	_	
15-24	2695-2707	homelessness	_	
15-25	2707-2708	,	_	
15-26	2709-2712	HIV	_	
15-27	2713-2717	risk	_	
15-28	2718-2726	behavior	_	
15-29	2726-2727	,	_	
15-30	2728-2731	and	_	
15-31	2732-2736	poor	_	
15-32	2737-2746	treatment	_	
15-33	2747-2755	outcomes	_	
15-34	2755-2756	.	_	

#Text=Despite the frequency and severity of co-occurring PTSD and addiction, there are substantial gaps in treatment, particularly pharmacotherapeutic treatment.
16-1	2757-2764	Despite	_	
16-2	2765-2768	the	_	
16-3	2769-2778	frequency	_	
16-4	2779-2782	and	_	
16-5	2783-2791	severity	_	
16-6	2792-2794	of	_	
16-7	2795-2807	co-occurring	_	
16-8	2808-2812	PTSD	_	
16-9	2813-2816	and	_	
16-10	2817-2826	addiction	_	
16-11	2826-2827	,	_	
16-12	2828-2833	there	_	
16-13	2834-2837	are	_	
16-14	2838-2849	substantial	_	
16-15	2850-2854	gaps	_	
16-16	2855-2857	in	_	
16-17	2858-2867	treatment	_	
16-18	2867-2868	,	_	
16-19	2869-2881	particularly	_	
16-20	2882-2901	pharmacotherapeutic	_	
16-21	2902-2911	treatment	_	
16-22	2911-2912	.	_	

#Text=The studies conducted to date have examined a variety of medications (e.g., sertraline, topiramate, naltrexone, nacetylcysteine) with modest therapeutic effects observed and significant room for improvement.
17-1	2913-2916	The	_	
17-2	2917-2924	studies	_	
17-3	2925-2934	conducted	_	
17-4	2935-2937	to	_	
17-5	2938-2942	date	_	
17-6	2943-2947	have	_	
17-7	2948-2956	examined	_	
17-8	2957-2958	a	_	
17-9	2959-2966	variety	_	
17-10	2967-2969	of	_	
17-11	2970-2981	medications	_	
17-12	2982-2983	(	_	
17-13	2983-2986	e.g	_	
17-14	2986-2987	.	_	
17-15	2987-2988	,	_	
17-16	2989-2999	sertraline	_	
17-17	2999-3000	,	_	
17-18	3001-3011	topiramate	_	
17-19	3011-3012	,	_	
17-20	3013-3023	naltrexone	_	
17-21	3023-3024	,	_	
17-22	3025-3040	nacetylcysteine	_	
17-23	3040-3041	)	_	
17-24	3042-3046	with	_	
17-25	3047-3053	modest	_	
17-26	3054-3065	therapeutic	_	
17-27	3066-3073	effects	_	
17-28	3074-3082	observed	_	
17-29	3083-3086	and	_	
17-30	3087-3098	significant	_	
17-31	3099-3103	room	_	
17-32	3104-3107	for	_	
17-33	3108-3119	improvement	_	
17-34	3119-3120	.	_	

#Text=The noradrenergic system has been implicated in PTSD, withdrawal states from chronic substance use, and in response to substance-related cues, suggesting that therapeutic interventions targeting the noradrenergic system may represent a promising avenue for the treatment of comorbid PTSD and SUD.
18-1	3121-3124	The	_	
18-2	3125-3138	noradrenergic	_	
18-3	3139-3145	system	_	
18-4	3146-3149	has	_	
18-5	3150-3154	been	_	
18-6	3155-3165	implicated	_	
18-7	3166-3168	in	_	
18-8	3169-3173	PTSD	_	
18-9	3173-3174	,	_	
18-10	3175-3185	withdrawal	_	
18-11	3186-3192	states	_	
18-12	3193-3197	from	_	
18-13	3198-3205	chronic	_	
18-14	3206-3215	substance	_	
18-15	3216-3219	use	_	
18-16	3219-3220	,	_	
18-17	3221-3224	and	_	
18-18	3225-3227	in	_	
18-19	3228-3236	response	_	
18-20	3237-3239	to	_	
18-21	3240-3257	substance-related	_	
18-22	3258-3262	cues	_	
18-23	3262-3263	,	_	
18-24	3264-3274	suggesting	_	
18-25	3275-3279	that	_	
18-26	3280-3291	therapeutic	_	
18-27	3292-3305	interventions	_	
18-28	3306-3315	targeting	_	
18-29	3316-3319	the	_	
18-30	3320-3333	noradrenergic	_	
18-31	3334-3340	system	_	
18-32	3341-3344	may	_	
18-33	3345-3354	represent	_	
18-34	3355-3356	a	_	
18-35	3357-3366	promising	_	
18-36	3367-3373	avenue	_	
18-37	3374-3377	for	_	
18-38	3378-3381	the	_	
18-39	3382-3391	treatment	_	
18-40	3392-3394	of	_	
18-41	3395-3403	comorbid	_	
18-42	3404-3408	PTSD	_	
18-43	3409-3412	and	_	
18-44	3413-3416	SUD	_	
18-45	3416-3417	.	_	

#Text=Previous studies have examined the use of prazosin, an alpha-1 noradrenergic blocker approved by the U.S.
19-1	3418-3426	Previous	_	
19-2	3427-3434	studies	_	
19-3	3435-3439	have	_	
19-4	3440-3448	examined	_	
19-5	3449-3452	the	_	
19-6	3453-3456	use	_	
19-7	3457-3459	of	_	
19-8	3460-3468	prazosin	_	
19-9	3468-3469	,	_	
19-10	3470-3472	an	_	
19-11	3473-3478	alpha	_	
19-12	3478-3479	-	_	
19-13	3479-3480	1	_	
19-14	3481-3494	noradrenergic	_	
19-15	3495-3502	blocker	_	
19-16	3503-3511	approved	_	
19-17	3512-3514	by	_	
19-18	3515-3518	the	_	
19-19	3519-3522	U.S	_	
19-20	3522-3523	.	_	

#Text=Food and Drug Administration (FDA) for hypertension and benign prostatic hyperplasia, in the treatment of PTSD, AUD and comorbid AUD/PTSD.
20-1	3524-3528	Food	_	
20-2	3529-3532	and	_	
20-3	3533-3537	Drug	_	
20-4	3538-3552	Administration	_	
20-5	3553-3554	(	_	
20-6	3554-3557	FDA	_	
20-7	3557-3558	)	_	
20-8	3559-3562	for	_	
20-9	3563-3575	hypertension	_	
20-10	3576-3579	and	_	
20-11	3580-3586	benign	_	
20-12	3587-3596	prostatic	_	
20-13	3597-3608	hyperplasia	_	
20-14	3608-3609	,	_	
20-15	3610-3612	in	_	
20-16	3613-3616	the	_	
20-17	3617-3626	treatment	_	
20-18	3627-3629	of	_	
20-19	3630-3634	PTSD	_	
20-20	3634-3635	,	_	
20-21	3636-3639	AUD	_	
20-22	3640-3643	and	_	
20-23	3644-3652	comorbid	_	
20-24	3653-3656	AUD	_	
20-25	3656-3657	/	_	
20-26	3657-3661	PTSD	_	
20-27	3661-3662	.	_	

#Text=The findings have been mixed with some studies showing significant reduction in AUD symptoms and reduction in PTSD symptoms, particularly nightmares, sleep disruption and daytime hyperarousal symptoms, while other studies find no significant differences in prazosin vs. placebo for AUD or PTSD symptoms.
21-1	3663-3666	The	_	
21-2	3667-3675	findings	_	
21-3	3676-3680	have	_	
21-4	3681-3685	been	_	
21-5	3686-3691	mixed	_	
21-6	3692-3696	with	_	
21-7	3697-3701	some	_	
21-8	3702-3709	studies	_	
21-9	3710-3717	showing	_	
21-10	3718-3729	significant	_	
21-11	3730-3739	reduction	_	
21-12	3740-3742	in	_	
21-13	3743-3746	AUD	_	
21-14	3747-3755	symptoms	_	
21-15	3756-3759	and	_	
21-16	3760-3769	reduction	_	
21-17	3770-3772	in	_	
21-18	3773-3777	PTSD	_	
21-19	3778-3786	symptoms	_	
21-20	3786-3787	,	_	
21-21	3788-3800	particularly	_	
21-22	3801-3811	nightmares	_	
21-23	3811-3812	,	_	
21-24	3813-3818	sleep	_	
21-25	3819-3829	disruption	_	
21-26	3830-3833	and	_	
21-27	3834-3841	daytime	_	
21-28	3842-3854	hyperarousal	_	
21-29	3855-3863	symptoms	_	
21-30	3863-3864	,	_	
21-31	3865-3870	while	_	
21-32	3871-3876	other	_	
21-33	3877-3884	studies	_	
21-34	3885-3889	find	_	
21-35	3890-3892	no	_	
21-36	3893-3904	significant	_	
21-37	3905-3916	differences	_	
21-38	3917-3919	in	_	
21-39	3920-3928	prazosin	_	
21-40	3929-3931	vs	_	
21-41	3931-3932	.	_	
21-42	3933-3940	placebo	_	
21-43	3941-3944	for	_	
21-44	3945-3948	AUD	_	
21-45	3949-3951	or	_	
21-46	3952-3956	PTSD	_	
21-47	3957-3965	symptoms	_	
21-48	3965-3966	.	_	

#Text=Several studies suggest that pre-treatment blood pressure may represent a biomarker to help identify who will respond favorably to prazosin, or potentially other alpha-1 blockers.
22-1	3967-3974	Several	_	
22-2	3975-3982	studies	_	
22-3	3983-3990	suggest	_	
22-4	3991-3995	that	_	
22-5	3996-4009	pre-treatment	_	
22-6	4010-4015	blood	_	
22-7	4016-4024	pressure	_	
22-8	4025-4028	may	_	
22-9	4029-4038	represent	_	
22-10	4039-4040	a	_	
22-11	4041-4050	biomarker	_	
22-12	4051-4053	to	_	
22-13	4054-4058	help	_	
22-14	4059-4067	identify	_	
22-15	4068-4071	who	_	
22-16	4072-4076	will	_	
22-17	4077-4084	respond	_	
22-18	4085-4094	favorably	_	
22-19	4095-4097	to	_	
22-20	4098-4106	prazosin	_	
22-21	4106-4107	,	_	
22-22	4108-4110	or	_	
22-23	4111-4122	potentially	_	
22-24	4123-4128	other	_	
22-25	4129-4134	alpha	_	
22-26	4134-4135	-	_	
22-27	4135-4136	1	_	
22-28	4137-4145	blockers	_	
22-29	4145-4146	.	_	

#Text=Doxazosin is another alpha-1 noradrenergic antagonist that is approved by the FDA for the treatment of hypertension and benign prostatic hyperplasia.
23-1	4147-4156	Doxazosin	_	
23-2	4157-4159	is	_	
23-3	4160-4167	another	_	
23-4	4168-4173	alpha	_	
23-5	4173-4174	-	_	
23-6	4174-4175	1	_	
23-7	4176-4189	noradrenergic	_	
23-8	4190-4200	antagonist	_	
23-9	4201-4205	that	_	
23-10	4206-4208	is	_	
23-11	4209-4217	approved	_	
23-12	4218-4220	by	_	
23-13	4221-4224	the	_	
23-14	4225-4228	FDA	_	
23-15	4229-4232	for	_	
23-16	4233-4236	the	_	
23-17	4237-4246	treatment	_	
23-18	4247-4249	of	_	
23-19	4250-4262	hypertension	_	
23-20	4263-4266	and	_	
23-21	4267-4273	benign	_	
23-22	4274-4283	prostatic	_	
23-23	4284-4295	hyperplasia	_	
23-24	4295-4296	.	_	

#Text=Doxazosin and prazosin have the same chemical structure, with the central element being a piperazine ring.
24-1	4297-4306	Doxazosin	_	
24-2	4307-4310	and	_	
24-3	4311-4319	prazosin	_	
24-4	4320-4324	have	_	
24-5	4325-4328	the	_	
24-6	4329-4333	same	_	
24-7	4334-4342	chemical	_	
24-8	4343-4352	structure	_	
24-9	4352-4353	,	_	
24-10	4354-4358	with	_	
24-11	4359-4362	the	_	
24-12	4363-4370	central	_	
24-13	4371-4378	element	_	
24-14	4379-4384	being	_	
24-15	4385-4386	a	_	
24-16	4387-4397	piperazine	_	
24-17	4398-4402	ring	_	
24-18	4402-4403	.	_	

#Text=However, there are several advantages of doxazosin in comparison to prazosin.
25-1	4404-4411	However	_	
25-2	4411-4412	,	_	
25-3	4413-4418	there	_	
25-4	4419-4422	are	_	
25-5	4423-4430	several	_	
25-6	4431-4441	advantages	_	
25-7	4442-4444	of	_	
25-8	4445-4454	doxazosin	_	
25-9	4455-4457	in	_	
25-10	4458-4468	comparison	_	
25-11	4469-4471	to	_	
25-12	4472-4480	prazosin	_	
25-13	4480-4481	.	_	

#Text=For example, doxazosin has a significantly longer half-life of approximately 22 h (vs. 2–3 h half-life of prazosin).
26-1	4482-4485	For	_	
26-2	4486-4493	example	_	
26-3	4493-4494	,	_	
26-4	4495-4504	doxazosin	_	
26-5	4505-4508	has	_	
26-6	4509-4510	a	_	
26-7	4511-4524	significantly	_	
26-8	4525-4531	longer	_	
26-9	4532-4541	half-life	_	
26-10	4542-4544	of	_	
26-11	4545-4558	approximately	_	
26-12	4559-4561	22	_	
26-13	4562-4563	h	_	
26-14	4564-4565	(	_	
26-15	4565-4567	vs	_	
26-16	4567-4568	.	_	
26-17	4569-4570	2	_	
26-18	4570-4571	–	_	
26-19	4571-4572	3	_	
26-20	4573-4574	h	_	
26-21	4575-4584	half-life	_	
26-22	4585-4587	of	_	
26-23	4588-4596	prazosin	_	
26-24	4596-4597	)	_	
26-25	4597-4598	.	_	

#Text=The longer half-life allows for a once-per-day dosing, rather than twice or thrice daily dosing, which is generally preferred by patients and promotes medication adherence.
27-1	4599-4602	The	_	
27-2	4603-4609	longer	_	
27-3	4610-4619	half-life	_	
27-4	4620-4626	allows	_	
27-5	4627-4630	for	_	
27-6	4631-4632	a	_	
27-7	4633-4645	once-per-day	_	
27-8	4646-4652	dosing	_	
27-9	4652-4653	,	_	
27-10	4654-4660	rather	_	
27-11	4661-4665	than	_	
27-12	4666-4671	twice	_	
27-13	4672-4674	or	_	
27-14	4675-4681	thrice	_	
27-15	4682-4687	daily	_	
27-16	4688-4694	dosing	_	
27-17	4694-4695	,	_	
27-18	4696-4701	which	_	
27-19	4702-4704	is	_	
27-20	4705-4714	generally	_	
27-21	4715-4724	preferred	_	
27-22	4725-4727	by	_	
27-23	4728-4736	patients	_	
27-24	4737-4740	and	_	
27-25	4741-4749	promotes	_	
27-26	4750-4760	medication	_	
27-27	4761-4770	adherence	_	
27-28	4770-4771	.	_	

#Text=The slower onset of action also reduces the risk of first-dose postural hypotension as compared to prazosin and doxazosin has no significant effect on blood pressure among normotensive patients, which further reduces the risk of hypotensive side effects.
28-1	4772-4775	The	_	
28-2	4776-4782	slower	_	
28-3	4783-4788	onset	_	
28-4	4789-4791	of	_	
28-5	4792-4798	action	_	
28-6	4799-4803	also	_	
28-7	4804-4811	reduces	_	
28-8	4812-4815	the	_	
28-9	4816-4820	risk	_	
28-10	4821-4823	of	_	
28-11	4824-4834	first-dose	_	
28-12	4835-4843	postural	_	
28-13	4844-4855	hypotension	_	
28-14	4856-4858	as	_	
28-15	4859-4867	compared	_	
28-16	4868-4870	to	_	
28-17	4871-4879	prazosin	_	
28-18	4880-4883	and	_	
28-19	4884-4893	doxazosin	_	
28-20	4894-4897	has	_	
28-21	4898-4900	no	_	
28-22	4901-4912	significant	_	
28-23	4913-4919	effect	_	
28-24	4920-4922	on	_	
28-25	4923-4928	blood	_	
28-26	4929-4937	pressure	_	
28-27	4938-4943	among	_	
28-28	4944-4956	normotensive	_	
28-29	4957-4965	patients	_	
28-30	4965-4966	,	_	
28-31	4967-4972	which	_	
28-32	4973-4980	further	_	
28-33	4981-4988	reduces	_	
28-34	4989-4992	the	_	
28-35	4993-4997	risk	_	
28-36	4998-5000	of	_	
28-37	5001-5012	hypotensive	_	
28-38	5013-5017	side	_	
28-39	5018-5025	effects	_	
28-40	5025-5026	.	_	

#Text=Unlike other alpha-1 blockers, doxazosin can be taken at any time during the day, with or without food, which further promotes medication adherence.
29-1	5027-5033	Unlike	_	
29-2	5034-5039	other	_	
29-3	5040-5045	alpha	_	
29-4	5045-5046	-	_	
29-5	5046-5047	1	_	
29-6	5048-5056	blockers	_	
29-7	5056-5057	,	_	
29-8	5058-5067	doxazosin	_	
29-9	5068-5071	can	_	
29-10	5072-5074	be	_	
29-11	5075-5080	taken	_	
29-12	5081-5083	at	_	
29-13	5084-5087	any	_	
29-14	5088-5092	time	_	
29-15	5093-5099	during	_	
29-16	5100-5103	the	_	
29-17	5104-5107	day	_	
29-18	5107-5108	,	_	
29-19	5109-5113	with	_	
29-20	5114-5116	or	_	
29-21	5117-5124	without	_	
29-22	5125-5129	food	_	
29-23	5129-5130	,	_	
29-24	5131-5136	which	_	
29-25	5137-5144	further	_	
29-26	5145-5153	promotes	_	
29-27	5154-5164	medication	_	
29-28	5165-5174	adherence	_	
29-29	5174-5175	.	_	

#Text=Two small studies provide initial support for doxazosin’s safety and therapeutic effects on PTSD.
30-1	5176-5179	Two	_	
30-2	5180-5185	small	_	
30-3	5186-5193	studies	_	
30-4	5194-5201	provide	_	
30-5	5202-5209	initial	_	
30-6	5210-5217	support	_	
30-7	5218-5221	for	_	
30-8	5222-5231	doxazosin	_	
30-9	5231-5232	’	_	
30-10	5232-5233	s	_	
30-11	5234-5240	safety	_	
30-12	5241-5244	and	_	
30-13	5245-5256	therapeutic	_	
30-14	5257-5264	effects	_	
30-15	5265-5267	on	_	
30-16	5268-5272	PTSD	_	
30-17	5272-5273	.	_	

#Text=In a 12-week, open-label pilot trial (N = 12 civilians and veterans) of doxazosin (8 mg/day) in individuals with PTSD, De Jong et al. found significant pre-to post-treatment reductions (baseline = 77 vs. end of treatment = 53) on the Clinician Administered PTSD Scale (CAPS).
31-1	5274-5276	In	_	
31-2	5277-5278	a	_	
31-3	5279-5281	12	_	
31-4	5281-5282	-	_	
31-5	5282-5286	week	_	
31-6	5286-5287	,	_	
31-7	5288-5298	open-label	_	
31-8	5299-5304	pilot	_	
31-9	5305-5310	trial	_	
31-10	5311-5312	(	_	
31-11	5312-5313	N	_	
31-12	5314-5315	=	_	
31-13	5316-5318	12	_	
31-14	5319-5328	civilians	_	
31-15	5329-5332	and	_	
31-16	5333-5341	veterans	_	
31-17	5341-5342	)	_	
31-18	5343-5345	of	_	
31-19	5346-5355	doxazosin	_	
31-20	5356-5357	(	_	
31-21	5357-5358	8	_	
31-22	5359-5361	mg	_	
31-23	5361-5362	/	_	
31-24	5362-5365	day	_	
31-25	5365-5366	)	_	
31-26	5367-5369	in	_	
31-27	5370-5381	individuals	_	
31-28	5382-5386	with	_	
31-29	5387-5391	PTSD	_	
31-30	5391-5392	,	_	
31-31	5393-5395	De	_	
31-32	5396-5400	Jong	_	
31-33	5401-5403	et	_	
31-34	5404-5406	al	_	
31-35	5406-5407	.	_	
31-36	5408-5413	found	_	
31-37	5414-5425	significant	_	
31-38	5426-5432	pre-to	_	
31-39	5433-5447	post-treatment	_	
31-40	5448-5458	reductions	_	
31-41	5459-5460	(	_	
31-42	5460-5468	baseline	_	
31-43	5469-5470	=	_	
31-44	5471-5473	77	_	
31-45	5474-5476	vs	_	
31-46	5476-5477	.	_	
31-47	5478-5481	end	_	
31-48	5482-5484	of	_	
31-49	5485-5494	treatment	_	
31-50	5495-5496	=	_	
31-51	5497-5499	53	_	
31-52	5499-5500	)	_	
31-53	5501-5503	on	_	
31-54	5504-5507	the	_	
31-55	5508-5517	Clinician	_	
31-56	5518-5530	Administered	_	
31-57	5531-5535	PTSD	_	
31-58	5536-5541	Scale	_	
31-59	5542-5543	(	_	
31-60	5543-5547	CAPS	_	
31-61	5547-5548	)	_	
31-62	5548-5549	.	_	

#Text=Depression severity, as measured by the Montogmery-Asberg Depression Scale also significantly decreased from baseline to end of treatment (score at baseline = 25 vs. end of treatment = 19).
32-1	5550-5560	Depression	_	
32-2	5561-5569	severity	_	
32-3	5569-5570	,	_	
32-4	5571-5573	as	_	
32-5	5574-5582	measured	_	
32-6	5583-5585	by	_	
32-7	5586-5589	the	_	
32-8	5590-5607	Montogmery-Asberg	_	
32-9	5608-5618	Depression	_	
32-10	5619-5624	Scale	_	
32-11	5625-5629	also	_	
32-12	5630-5643	significantly	_	
32-13	5644-5653	decreased	_	
32-14	5654-5658	from	_	
32-15	5659-5667	baseline	_	
32-16	5668-5670	to	_	
32-17	5671-5674	end	_	
32-18	5675-5677	of	_	
32-19	5678-5687	treatment	_	
32-20	5688-5689	(	_	
32-21	5689-5694	score	_	
32-22	5695-5697	at	_	
32-23	5698-5706	baseline	_	
32-24	5707-5708	=	_	
32-25	5709-5711	25	_	
32-26	5712-5714	vs	_	
32-27	5714-5715	.	_	
32-28	5716-5719	end	_	
32-29	5720-5722	of	_	
32-30	5723-5732	treatment	_	
32-31	5733-5734	=	_	
32-32	5735-5737	19	_	
32-33	5737-5738	)	_	
32-34	5738-5739	.	_	

#Text=More recently, a small randomized controlled study (N = 8 male veterans) demonstrated that doxazosin (16 mg/day) was effective in significantly reducing self-report PTSD symptoms as measured by the PTSD Checklist – Military Version (PCL-5) and a trend for reduction on the CAPS hyperarousal scale was observed.
33-1	5740-5744	More	_	
33-2	5745-5753	recently	_	
33-3	5753-5754	,	_	
33-4	5755-5756	a	_	
33-5	5757-5762	small	_	
33-6	5763-5773	randomized	_	
33-7	5774-5784	controlled	_	
33-8	5785-5790	study	_	
33-9	5791-5792	(	_	
33-10	5792-5793	N	_	
33-11	5794-5795	=	_	
33-12	5796-5797	8	_	
33-13	5798-5802	male	_	
33-14	5803-5811	veterans	_	
33-15	5811-5812	)	_	
33-16	5813-5825	demonstrated	_	
33-17	5826-5830	that	_	
33-18	5831-5840	doxazosin	_	
33-19	5841-5842	(	_	
33-20	5842-5844	16	_	
33-21	5845-5847	mg	_	
33-22	5847-5848	/	_	
33-23	5848-5851	day	_	
33-24	5851-5852	)	_	
33-25	5853-5856	was	_	
33-26	5857-5866	effective	_	
33-27	5867-5869	in	_	
33-28	5870-5883	significantly	_	
33-29	5884-5892	reducing	_	
33-30	5893-5904	self-report	_	
33-31	5905-5909	PTSD	_	
33-32	5910-5918	symptoms	_	
33-33	5919-5921	as	_	
33-34	5922-5930	measured	_	
33-35	5931-5933	by	_	
33-36	5934-5937	the	_	
33-37	5938-5942	PTSD	_	
33-38	5943-5952	Checklist	_	
33-39	5953-5954	–	_	
33-40	5955-5963	Military	_	
33-41	5964-5971	Version	_	
33-42	5972-5973	(	_	
33-43	5973-5976	PCL	_	
33-44	5976-5977	-	_	
33-45	5977-5978	5	_	
33-46	5978-5979	)	_	
33-47	5980-5983	and	_	
33-48	5984-5985	a	_	
33-49	5986-5991	trend	_	
33-50	5992-5995	for	_	
33-51	5996-6005	reduction	_	
33-52	6006-6008	on	_	
33-53	6009-6012	the	_	
33-54	6013-6017	CAPS	_	
33-55	6018-6030	hyperarousal	_	
33-56	6031-6036	scale	_	
33-57	6037-6040	was	_	
33-58	6041-6049	observed	_	
33-59	6049-6050	.	_	

#Text=However, both studies are limited by small samples sizes and require replication with larger samples.
34-1	6051-6058	However	_	
34-2	6058-6059	,	_	
34-3	6060-6064	both	_	
34-4	6065-6072	studies	_	
34-5	6073-6076	are	_	
34-6	6077-6084	limited	_	
34-7	6085-6087	by	_	
34-8	6088-6093	small	_	
34-9	6094-6101	samples	_	
34-10	6102-6107	sizes	_	
34-11	6108-6111	and	_	
34-12	6112-6119	require	_	
34-13	6120-6131	replication	_	
34-14	6132-6136	with	_	
34-15	6137-6143	larger	_	
34-16	6144-6151	samples	_	
34-17	6151-6152	.	_	

#Text=Several early trials have also examined doxazosin in individuals with SUD.
35-1	6153-6160	Several	_	
35-2	6161-6166	early	_	
35-3	6167-6173	trials	_	
35-4	6174-6178	have	_	
35-5	6179-6183	also	_	
35-6	6184-6192	examined	_	
35-7	6193-6202	doxazosin	_	
35-8	6203-6205	in	_	
35-9	6206-6217	individuals	_	
35-10	6218-6222	with	_	
35-11	6223-6226	SUD	_	
35-12	6226-6227	.	_	

#Text=In a 10-week, randomized controlled trial of 41 individuals with AUD, Kenna et al. found that doxazosin (16 mg/day) was associated with significantly lower reductions in drinks per week, heavy drinking days, and craving among individuals with high family history density of alcoholism.
36-1	6228-6230	In	_	
36-2	6231-6232	a	_	
36-3	6233-6235	10	_	
36-4	6235-6236	-	_	
36-5	6236-6240	week	_	
36-6	6240-6241	,	_	
36-7	6242-6252	randomized	_	
36-8	6253-6263	controlled	_	
36-9	6264-6269	trial	_	
36-10	6270-6272	of	_	
36-11	6273-6275	41	_	
36-12	6276-6287	individuals	_	
36-13	6288-6292	with	_	
36-14	6293-6296	AUD	_	
36-15	6296-6297	,	_	
36-16	6298-6303	Kenna	_	
36-17	6304-6306	et	_	
36-18	6307-6309	al	_	
36-19	6309-6310	.	_	
36-20	6311-6316	found	_	
36-21	6317-6321	that	_	
36-22	6322-6331	doxazosin	_	
36-23	6332-6333	(	_	
36-24	6333-6335	16	_	
36-25	6336-6338	mg	_	
36-26	6338-6339	/	_	
36-27	6339-6342	day	_	
36-28	6342-6343	)	_	
36-29	6344-6347	was	_	
36-30	6348-6358	associated	_	
36-31	6359-6363	with	_	
36-32	6364-6377	significantly	_	
36-33	6378-6383	lower	_	
36-34	6384-6394	reductions	_	
36-35	6395-6397	in	_	
36-36	6398-6404	drinks	_	
36-37	6405-6408	per	_	
36-38	6409-6413	week	_	
36-39	6413-6414	,	_	
36-40	6415-6420	heavy	_	
36-41	6421-6429	drinking	_	
36-42	6430-6434	days	_	
36-43	6434-6435	,	_	
36-44	6436-6439	and	_	
36-45	6440-6447	craving	_	
36-46	6448-6453	among	_	
36-47	6454-6465	individuals	_	
36-48	6466-6470	with	_	
36-49	6471-6475	high	_	
36-50	6476-6482	family	_	
36-51	6483-6490	history	_	
36-52	6491-6498	density	_	
36-53	6499-6501	of	_	
36-54	6502-6512	alcoholism	_	
36-55	6512-6513	.	_	

#Text=In a secondary analysis of the same data set (N = 41), Haass-Koffler et al. examined the role of pre-treatment standing blood pressure (BP) as a moderator of doxazosin’s effect on AUD severity and found that patients with high pre-treatment BP had the most favorable AUD outcomes.
37-1	6514-6516	In	_	
37-2	6517-6518	a	_	
37-3	6519-6528	secondary	_	
37-4	6529-6537	analysis	_	
37-5	6538-6540	of	_	
37-6	6541-6544	the	_	
37-7	6545-6549	same	_	
37-8	6550-6554	data	_	
37-9	6555-6558	set	_	
37-10	6559-6560	(	_	
37-11	6560-6561	N	_	
37-12	6562-6563	=	_	
37-13	6564-6566	41	_	
37-14	6566-6567	)	_	
37-15	6567-6568	,	_	
37-16	6569-6582	Haass-Koffler	_	
37-17	6583-6585	et	_	
37-18	6586-6588	al	_	
37-19	6588-6589	.	_	
37-20	6590-6598	examined	_	
37-21	6599-6602	the	_	
37-22	6603-6607	role	_	
37-23	6608-6610	of	_	
37-24	6611-6624	pre-treatment	_	
37-25	6625-6633	standing	_	
37-26	6634-6639	blood	_	
37-27	6640-6648	pressure	_	
37-28	6649-6650	(	_	
37-29	6650-6652	BP	_	
37-30	6652-6653	)	_	
37-31	6654-6656	as	_	
37-32	6657-6658	a	_	
37-33	6659-6668	moderator	_	
37-34	6669-6671	of	_	
37-35	6672-6681	doxazosin	_	
37-36	6681-6682	’	_	
37-37	6682-6683	s	_	
37-38	6684-6690	effect	_	
37-39	6691-6693	on	_	
37-40	6694-6697	AUD	_	
37-41	6698-6706	severity	_	
37-42	6707-6710	and	_	
37-43	6711-6716	found	_	
37-44	6717-6721	that	_	
37-45	6722-6730	patients	_	
37-46	6731-6735	with	_	
37-47	6736-6740	high	_	
37-48	6741-6754	pre-treatment	_	
37-49	6755-6757	BP	_	
37-50	6758-6761	had	_	
37-51	6762-6765	the	_	
37-52	6766-6770	most	_	
37-53	6771-6780	favorable	_	
37-54	6781-6784	AUD	_	
37-55	6785-6793	outcomes	_	
37-56	6793-6794	.	_	

#Text=Other clinical studies in patients with cocaine use disorder as well as preclinical studies suggest that doxazosin may help reduce SUD severity.
38-1	6795-6800	Other	_	
38-2	6801-6809	clinical	_	
38-3	6810-6817	studies	_	
38-4	6818-6820	in	_	
38-5	6821-6829	patients	_	
38-6	6830-6834	with	_	
38-7	6835-6842	cocaine	_	
38-8	6843-6846	use	_	
38-9	6847-6855	disorder	_	
38-10	6856-6858	as	_	
38-11	6859-6863	well	_	
38-12	6864-6866	as	_	
38-13	6867-6878	preclinical	_	
38-14	6879-6886	studies	_	
38-15	6887-6894	suggest	_	
38-16	6895-6899	that	_	
38-17	6900-6909	doxazosin	_	
38-18	6910-6913	may	_	
38-19	6914-6918	help	_	
38-20	6919-6925	reduce	_	
38-21	6926-6929	SUD	_	
38-22	6930-6938	severity	_	
38-23	6938-6939	.	_	

#Text=The current study is the first study to evaluate doxazosin among individuals with co-occurring PTSD/AUD.
39-1	6940-6943	The	_	
39-2	6944-6951	current	_	
39-3	6952-6957	study	_	
39-4	6958-6960	is	_	
39-5	6961-6964	the	_	
39-6	6965-6970	first	_	
39-7	6971-6976	study	_	
39-8	6977-6979	to	_	
39-9	6980-6988	evaluate	_	
39-10	6989-6998	doxazosin	_	
39-11	6999-7004	among	_	
39-12	7005-7016	individuals	_	
39-13	7017-7021	with	_	
39-14	7022-7034	co-occurring	_	
39-15	7035-7039	PTSD	_	
39-16	7039-7040	/	_	
39-17	7040-7043	AUD	_	
39-18	7043-7044	.	_	

#Text=This paper describes the design and methodology of an ongoing randomized controlled trial (RCT) to evaluate doxazosin in reducing PTSD and AUD severity among a sample of military veterans.
40-1	7045-7049	This	_	
40-2	7050-7055	paper	_	
40-3	7056-7065	describes	_	
40-4	7066-7069	the	_	
40-5	7070-7076	design	_	
40-6	7077-7080	and	_	
40-7	7081-7092	methodology	_	
40-8	7093-7095	of	_	
40-9	7096-7098	an	_	
40-10	7099-7106	ongoing	_	
40-11	7107-7117	randomized	_	
40-12	7118-7128	controlled	_	
40-13	7129-7134	trial	_	
40-14	7135-7136	(	_	
40-15	7136-7139	RCT	_	
40-16	7139-7140	)	_	
40-17	7141-7143	to	_	
40-18	7144-7152	evaluate	_	
40-19	7153-7162	doxazosin	_	
40-20	7163-7165	in	_	
40-21	7166-7174	reducing	_	
40-22	7175-7179	PTSD	_	
40-23	7180-7183	and	_	
40-24	7184-7187	AUD	_	
40-25	7188-7196	severity	_	
40-26	7197-7202	among	_	
40-27	7203-7204	a	_	
40-28	7205-7211	sample	_	
40-29	7212-7214	of	_	
40-30	7215-7223	military	_	
40-31	7224-7232	veterans	_	
40-32	7232-7233	.	_	

#Text=While the primary focus of the study is the medication trial, we are also employing functional magnetic resonance imaging (fMRI) at pre- and post-treatment to further investigate the underlying pathophysiology of PTSD/AUD and identify potential prognostic indicators of treatment outcome.
41-1	7234-7239	While	_	
41-2	7240-7243	the	_	
41-3	7244-7251	primary	_	
41-4	7252-7257	focus	_	
41-5	7258-7260	of	_	
41-6	7261-7264	the	_	
41-7	7265-7270	study	_	
41-8	7271-7273	is	_	
41-9	7274-7277	the	_	
41-10	7278-7288	medication	_	
41-11	7289-7294	trial	_	
41-12	7294-7295	,	_	
41-13	7296-7298	we	_	
41-14	7299-7302	are	_	
41-15	7303-7307	also	_	
41-16	7308-7317	employing	_	
41-17	7318-7328	functional	_	
41-18	7329-7337	magnetic	_	
41-19	7338-7347	resonance	_	
41-20	7348-7355	imaging	_	
41-21	7356-7357	(	_	
41-22	7357-7361	fMRI	_	
41-23	7361-7362	)	_	
41-24	7363-7365	at	_	
41-25	7366-7369	pre	_	
41-26	7369-7370	-	_	
41-27	7371-7374	and	_	
41-28	7375-7389	post-treatment	_	
41-29	7390-7392	to	_	
41-30	7393-7400	further	_	
41-31	7401-7412	investigate	_	
41-32	7413-7416	the	_	
41-33	7417-7427	underlying	_	
41-34	7428-7443	pathophysiology	_	
41-35	7444-7446	of	_	
41-36	7447-7451	PTSD	_	
41-37	7451-7452	/	_	
41-38	7452-7455	AUD	_	
41-39	7456-7459	and	_	
41-40	7460-7468	identify	_	
41-41	7469-7478	potential	_	
41-42	7479-7489	prognostic	_	
41-43	7490-7500	indicators	_	
41-44	7501-7503	of	_	
41-45	7504-7513	treatment	_	
41-46	7514-7521	outcome	_	
41-47	7521-7522	.	_	

#Text=Research objectives and hypotheses
#Text=This project is one of 11 nationwide research projects supported by the Consortium to Alleviate PTSD (CAP), which is part of a National Research Action Plan jointly issued in 2013 by the U.S.
42-1	7523-7531	Research	_	
42-2	7532-7542	objectives	_	
42-3	7543-7546	and	_	
42-4	7547-7557	hypotheses	_	
42-5	7558-7562	This	_	
42-6	7563-7570	project	_	
42-7	7571-7573	is	_	
42-8	7574-7577	one	_	
42-9	7578-7580	of	_	
42-10	7581-7583	11	_	
42-11	7584-7594	nationwide	_	
42-12	7595-7603	research	_	
42-13	7604-7612	projects	_	
42-14	7613-7622	supported	_	
42-15	7623-7625	by	_	
42-16	7626-7629	the	_	
42-17	7630-7640	Consortium	_	
42-18	7641-7643	to	_	
42-19	7644-7653	Alleviate	_	
42-20	7654-7658	PTSD	_	
42-21	7659-7660	(	_	
42-22	7660-7663	CAP	_	
42-23	7663-7664	)	_	
42-24	7664-7665	,	_	
42-25	7666-7671	which	_	
42-26	7672-7674	is	_	
42-27	7675-7679	part	_	
42-28	7680-7682	of	_	
42-29	7683-7684	a	_	
42-30	7685-7693	National	_	
42-31	7694-7702	Research	_	
42-32	7703-7709	Action	_	
42-33	7710-7714	Plan	_	
42-34	7715-7722	jointly	_	
42-35	7723-7729	issued	_	
42-36	7730-7732	in	_	
42-37	7733-7737	2013	_	
42-38	7738-7740	by	_	
42-39	7741-7744	the	_	
42-40	7745-7748	U.S	_	
42-41	7748-7749	.	_	

#Text=Department of Defense, Department of Veterans Affairs (VA), Department of Health and Human Services, and Department of Education.
43-1	7750-7760	Department	_	
43-2	7761-7763	of	_	
43-3	7764-7771	Defense	_	
43-4	7771-7772	,	_	
43-5	7773-7783	Department	_	
43-6	7784-7786	of	_	
43-7	7787-7795	Veterans	_	
43-8	7796-7803	Affairs	_	
43-9	7804-7805	(	_	
43-10	7805-7807	VA	_	
43-11	7807-7808	)	_	
43-12	7808-7809	,	_	
43-13	7810-7820	Department	_	
43-14	7821-7823	of	_	
43-15	7824-7830	Health	_	
43-16	7831-7834	and	_	
43-17	7835-7840	Human	_	
43-18	7841-7849	Services	_	
43-19	7849-7850	,	_	
43-20	7851-7854	and	_	
43-21	7855-7865	Department	_	
43-22	7866-7868	of	_	
43-23	7869-7878	Education	_	
43-24	7878-7879	.	_	

#Text=The overall aims of the CAP are: (1) develop and evaluate effective treatments for PTSD and comorbid conditions, such as alcohol and drug use disorders, in military service members and post-9/11 veterans; and (2) identify the biological causes of PTSD and changes in those biomarkers that are associated with treatment outcomes.
44-1	7880-7883	The	_	
44-2	7884-7891	overall	_	
44-3	7892-7896	aims	_	
44-4	7897-7899	of	_	
44-5	7900-7903	the	_	
44-6	7904-7907	CAP	_	
44-7	7908-7911	are	_	
44-8	7911-7912	:	_	
44-9	7913-7914	(	_	
44-10	7914-7915	1	_	
44-11	7915-7916	)	_	
44-12	7917-7924	develop	_	
44-13	7925-7928	and	_	
44-14	7929-7937	evaluate	_	
44-15	7938-7947	effective	_	
44-16	7948-7958	treatments	_	
44-17	7959-7962	for	_	
44-18	7963-7967	PTSD	_	
44-19	7968-7971	and	_	
44-20	7972-7980	comorbid	_	
44-21	7981-7991	conditions	_	
44-22	7991-7992	,	_	
44-23	7993-7997	such	_	
44-24	7998-8000	as	_	
44-25	8001-8008	alcohol	_	
44-26	8009-8012	and	_	
44-27	8013-8017	drug	_	
44-28	8018-8021	use	_	
44-29	8022-8031	disorders	_	
44-30	8031-8032	,	_	
44-31	8033-8035	in	_	
44-32	8036-8044	military	_	
44-33	8045-8052	service	_	
44-34	8053-8060	members	_	
44-35	8061-8064	and	_	
44-36	8065-8069	post	_	
44-37	8069-8070	-	_	
44-38	8070-8071	9	_	
44-39	8071-8072	/	_	
44-40	8072-8074	11	_	
44-41	8075-8083	veterans	_	
44-42	8083-8084	;	_	
44-43	8085-8088	and	_	
44-44	8089-8090	(	_	
44-45	8090-8091	2	_	
44-46	8091-8092	)	_	
44-47	8093-8101	identify	_	
44-48	8102-8105	the	_	
44-49	8106-8116	biological	_	
44-50	8117-8123	causes	_	
44-51	8124-8126	of	_	
44-52	8127-8131	PTSD	_	
44-53	8132-8135	and	_	
44-54	8136-8143	changes	_	
44-55	8144-8146	in	_	
44-56	8147-8152	those	_	
44-57	8153-8163	biomarkers	_	
44-58	8164-8168	that	_	
44-59	8169-8172	are	_	
44-60	8173-8183	associated	_	
44-61	8184-8188	with	_	
44-62	8189-8198	treatment	_	
44-63	8199-8207	outcomes	_	
44-64	8207-8208	.	_	

#Text=More information about the CAP is available at www.ConsortiumToAlleviatePTSD.org.
45-1	8209-8213	More	_	
45-2	8214-8225	information	_	
45-3	8226-8231	about	_	
45-4	8232-8235	the	_	
45-5	8236-8239	CAP	_	
45-6	8240-8242	is	_	
45-7	8243-8252	available	_	
45-8	8253-8255	at	_	
45-9	8256-8289	www.ConsortiumToAlleviatePTSD.org	_	
45-10	8289-8290	.	_	

#Text=The primary research objective of the current study is to address the gap in the evidence base regarding pharmacologic treatment of co-occurring PTSD and AUD by comparing doxazosin (16 mg/day) versus placebo in reducing PTSD symptomatology and alcohol use severity in veterans with co-occurring PTSD/AUD.
46-1	8291-8294	The	_	
46-2	8295-8302	primary	_	
46-3	8303-8311	research	_	
46-4	8312-8321	objective	_	
46-5	8322-8324	of	_	
46-6	8325-8328	the	_	
46-7	8329-8336	current	_	
46-8	8337-8342	study	_	
46-9	8343-8345	is	_	
46-10	8346-8348	to	_	
46-11	8349-8356	address	_	
46-12	8357-8360	the	_	
46-13	8361-8364	gap	_	
46-14	8365-8367	in	_	
46-15	8368-8371	the	_	
46-16	8372-8380	evidence	_	
46-17	8381-8385	base	_	
46-18	8386-8395	regarding	_	
46-19	8396-8409	pharmacologic	_	
46-20	8410-8419	treatment	_	
46-21	8420-8422	of	_	
46-22	8423-8435	co-occurring	_	
46-23	8436-8440	PTSD	_	
46-24	8441-8444	and	_	
46-25	8445-8448	AUD	_	
46-26	8449-8451	by	_	
46-27	8452-8461	comparing	_	
46-28	8462-8471	doxazosin	_	
46-29	8472-8473	(	_	
46-30	8473-8475	16	_	
46-31	8476-8478	mg	_	
46-32	8478-8479	/	_	
46-33	8479-8482	day	_	
46-34	8482-8483	)	_	
46-35	8484-8490	versus	_	
46-36	8491-8498	placebo	_	
46-37	8499-8501	in	_	
46-38	8502-8510	reducing	_	
46-39	8511-8515	PTSD	_	
46-40	8516-8530	symptomatology	_	
46-41	8531-8534	and	_	
46-42	8535-8542	alcohol	_	
46-43	8543-8546	use	_	
46-44	8547-8555	severity	_	
46-45	8556-8558	in	_	
46-46	8559-8567	veterans	_	
46-47	8568-8572	with	_	
46-48	8573-8585	co-occurring	_	
46-49	8586-8590	PTSD	_	
46-50	8590-8591	/	_	
46-51	8591-8594	AUD	_	
46-52	8594-8595	.	_	

#Text=There are three main hypotheses that pertain to changes in outcomes of interest during the treatment phase (weeks 1–12).
47-1	8596-8601	There	_	
47-2	8602-8605	are	_	
47-3	8606-8611	three	_	
47-4	8612-8616	main	_	
47-5	8617-8627	hypotheses	_	
47-6	8628-8632	that	_	
47-7	8633-8640	pertain	_	
47-8	8641-8643	to	_	
47-9	8644-8651	changes	_	
47-10	8652-8654	in	_	
47-11	8655-8663	outcomes	_	
47-12	8664-8666	of	_	
47-13	8667-8675	interest	_	
47-14	8676-8682	during	_	
47-15	8683-8686	the	_	
47-16	8687-8696	treatment	_	
47-17	8697-8702	phase	_	
47-18	8703-8704	(	_	
47-19	8704-8709	weeks	_	
47-20	8710-8711	1	_	
47-21	8711-8712	–	_	
47-22	8712-8714	12	_	
47-23	8714-8715	)	_	
47-24	8715-8716	.	_	

#Text=Hypothesis 1 proposes that participants who receive doxazosin, as compared to placebo, will evidence significantly greater reductions in PTSD severity at week 12, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) (a) and the PTSD Checklist for DSM-5 (PCL-5) (b).
48-1	8717-8727	Hypothesis	_	
48-2	8728-8729	1	_	
48-3	8730-8738	proposes	_	
48-4	8739-8743	that	_	
48-5	8744-8756	participants	_	
48-6	8757-8760	who	_	
48-7	8761-8768	receive	_	
48-8	8769-8778	doxazosin	_	
48-9	8778-8779	,	_	
48-10	8780-8782	as	_	
48-11	8783-8791	compared	_	
48-12	8792-8794	to	_	
48-13	8795-8802	placebo	_	
48-14	8802-8803	,	_	
48-15	8804-8808	will	_	
48-16	8809-8817	evidence	_	
48-17	8818-8831	significantly	_	
48-18	8832-8839	greater	_	
48-19	8840-8850	reductions	_	
48-20	8851-8853	in	_	
48-21	8854-8858	PTSD	_	
48-22	8859-8867	severity	_	
48-23	8868-8870	at	_	
48-24	8871-8875	week	_	
48-25	8876-8878	12	_	
48-26	8878-8879	,	_	
48-27	8880-8882	as	_	
48-28	8883-8891	measured	_	
48-29	8892-8894	by	_	
48-30	8895-8898	the	_	
48-31	8899-8921	Clinician-Administered	_	
48-32	8922-8926	PTSD	_	
48-33	8927-8932	Scale	_	
48-34	8933-8936	for	_	
48-35	8937-8940	DSM	_	
48-36	8940-8941	-	_	
48-37	8941-8942	5	_	
48-38	8943-8944	(	_	
48-39	8944-8948	CAPS	_	
48-40	8948-8949	-	_	
48-41	8949-8950	5	_	
48-42	8950-8951	)	_	
48-43	8952-8953	(	_	
48-44	8953-8954	a	_	
48-45	8954-8955	)	_	
48-46	8956-8959	and	_	
48-47	8960-8963	the	_	
48-48	8964-8968	PTSD	_	
48-49	8969-8978	Checklist	_	
48-50	8979-8982	for	_	
48-51	8983-8986	DSM	_	
48-52	8986-8987	-	_	
48-53	8987-8988	5	_	
48-54	8989-8990	(	_	
48-55	8990-8993	PCL	_	
48-56	8993-8994	-	_	
48-57	8994-8995	5	_	
48-58	8995-8996	)	_	
48-59	8997-8998	(	_	
48-60	8998-8999	b	_	
48-61	8999-9000	)	_	
48-62	9000-9001	.	_	

#Text=Hypothesis 2 is that participants who receive doxazosin, as compared to placebo, will evidence significantly greater reductions in AUD severity at week 12, as measured by the Timeline Follow Back (TLFB) and biological tests of alcohol consumption (e.g., breathalyzer, ethyl glucuronide).
49-1	9002-9012	Hypothesis	_	
49-2	9013-9014	2	_	
49-3	9015-9017	is	_	
49-4	9018-9022	that	_	
49-5	9023-9035	participants	_	
49-6	9036-9039	who	_	
49-7	9040-9047	receive	_	
49-8	9048-9057	doxazosin	_	
49-9	9057-9058	,	_	
49-10	9059-9061	as	_	
49-11	9062-9070	compared	_	
49-12	9071-9073	to	_	
49-13	9074-9081	placebo	_	
49-14	9081-9082	,	_	
49-15	9083-9087	will	_	
49-16	9088-9096	evidence	_	
49-17	9097-9110	significantly	_	
49-18	9111-9118	greater	_	
49-19	9119-9129	reductions	_	
49-20	9130-9132	in	_	
49-21	9133-9136	AUD	_	
49-22	9137-9145	severity	_	
49-23	9146-9148	at	_	
49-24	9149-9153	week	_	
49-25	9154-9156	12	_	
49-26	9156-9157	,	_	
49-27	9158-9160	as	_	
49-28	9161-9169	measured	_	
49-29	9170-9172	by	_	
49-30	9173-9176	the	_	
49-31	9177-9185	Timeline	_	
49-32	9186-9192	Follow	_	
49-33	9193-9197	Back	_	
49-34	9198-9199	(	_	
49-35	9199-9203	TLFB	_	
49-36	9203-9204	)	_	
49-37	9205-9208	and	_	
49-38	9209-9219	biological	_	
49-39	9220-9225	tests	_	
49-40	9226-9228	of	_	
49-41	9229-9236	alcohol	_	
49-42	9237-9248	consumption	_	
49-43	9249-9250	(	_	
49-44	9250-9253	e.g	_	
49-45	9253-9254	.	_	
49-46	9254-9255	,	_	
49-47	9256-9268	breathalyzer	_	
49-48	9268-9269	,	_	
49-49	9270-9275	ethyl	_	
49-50	9276-9287	glucuronide	_	
49-51	9287-9288	)	_	
49-52	9288-9289	.	_	

#Text=Hypothesis 3 centers on the neuroimaging component of the project and predicts that (a) connectivity between the prefrontal cortex and amygdala at rest and in response to trauma versus neutral cues will predict amount of change in PTSD symptoms as measured by the CAPS-5 at week 12; and (b) connectivity between prefrontal cortex and the amygdala at rest and in response to alcohol versus neutral cues will predict time to first use of alcohol (TLFB) during the treatment phase.
50-1	9290-9300	Hypothesis	_	
50-2	9301-9302	3	_	
50-3	9303-9310	centers	_	
50-4	9311-9313	on	_	
50-5	9314-9317	the	_	
50-6	9318-9330	neuroimaging	_	
50-7	9331-9340	component	_	
50-8	9341-9343	of	_	
50-9	9344-9347	the	_	
50-10	9348-9355	project	_	
50-11	9356-9359	and	_	
50-12	9360-9368	predicts	_	
50-13	9369-9373	that	_	
50-14	9374-9375	(	_	
50-15	9375-9376	a	_	
50-16	9376-9377	)	_	
50-17	9378-9390	connectivity	_	
50-18	9391-9398	between	_	
50-19	9399-9402	the	_	
50-20	9403-9413	prefrontal	_	
50-21	9414-9420	cortex	_	
50-22	9421-9424	and	_	
50-23	9425-9433	amygdala	_	
50-24	9434-9436	at	_	
50-25	9437-9441	rest	_	
50-26	9442-9445	and	_	
50-27	9446-9448	in	_	
50-28	9449-9457	response	_	
50-29	9458-9460	to	_	
50-30	9461-9467	trauma	_	
50-31	9468-9474	versus	_	
50-32	9475-9482	neutral	_	
50-33	9483-9487	cues	_	
50-34	9488-9492	will	_	
50-35	9493-9500	predict	_	
50-36	9501-9507	amount	_	
50-37	9508-9510	of	_	
50-38	9511-9517	change	_	
50-39	9518-9520	in	_	
50-40	9521-9525	PTSD	_	
50-41	9526-9534	symptoms	_	
50-42	9535-9537	as	_	
50-43	9538-9546	measured	_	
50-44	9547-9549	by	_	
50-45	9550-9553	the	_	
50-46	9554-9558	CAPS	_	
50-47	9558-9559	-	_	
50-48	9559-9560	5	_	
50-49	9561-9563	at	_	
50-50	9564-9568	week	_	
50-51	9569-9571	12	_	
50-52	9571-9572	;	_	
50-53	9573-9576	and	_	
50-54	9577-9578	(	_	
50-55	9578-9579	b	_	
50-56	9579-9580	)	_	
50-57	9581-9593	connectivity	_	
50-58	9594-9601	between	_	
50-59	9602-9612	prefrontal	_	
50-60	9613-9619	cortex	_	
50-61	9620-9623	and	_	
50-62	9624-9627	the	_	
50-63	9628-9636	amygdala	_	
50-64	9637-9639	at	_	
50-65	9640-9644	rest	_	
50-66	9645-9648	and	_	
50-67	9649-9651	in	_	
50-68	9652-9660	response	_	
50-69	9661-9663	to	_	
50-70	9664-9671	alcohol	_	
50-71	9672-9678	versus	_	
50-72	9679-9686	neutral	_	
50-73	9687-9691	cues	_	
50-74	9692-9696	will	_	
50-75	9697-9704	predict	_	
50-76	9705-9709	time	_	
50-77	9710-9712	to	_	
50-78	9713-9718	first	_	
50-79	9719-9722	use	_	
50-80	9723-9725	of	_	
50-81	9726-9733	alcohol	_	
50-82	9734-9735	(	_	
50-83	9735-9739	TLFB	_	
50-84	9739-9740	)	_	
50-85	9741-9747	during	_	
50-86	9748-9751	the	_	
50-87	9752-9761	treatment	_	
50-88	9762-9767	phase	_	
50-89	9767-9768	.	_	

#Text=Materials and methods
#Text=Research design
#Text=This study is a phase II, double-blind, 12-week RCT to evaluate the efficacy of the alpha-1 adrenergic antagonist doxazosin (16 mg/day, immediate release formulation), as compared to placebo in reducing PTSD and AUD severity in veterans.
51-1	9769-9778	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
51-2	9779-9782	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
51-3	9783-9790	methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[5]	
51-4	9791-9799	Research	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-5	9800-9806	design	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-6	9807-9811	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-7	9812-9817	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-8	9818-9820	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-9	9821-9822	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-10	9823-9828	phase	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-11	9829-9831	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-12	9831-9832	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-13	9833-9845	double-blind	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-14	9845-9846	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-15	9847-9849	12	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-16	9849-9850	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-17	9850-9854	week	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-18	9855-9858	RCT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-19	9859-9861	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-20	9862-9870	evaluate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-21	9871-9874	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-22	9875-9883	efficacy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-23	9884-9886	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-24	9887-9890	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-25	9891-9896	alpha	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-26	9896-9897	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-27	9897-9898	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-28	9899-9909	adrenergic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-29	9910-9920	antagonist	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-30	9921-9930	doxazosin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-31	9931-9932	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-32	9932-9934	16	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-33	9935-9937	mg	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-34	9937-9938	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-35	9938-9941	day	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-36	9941-9942	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-37	9943-9952	immediate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-38	9953-9960	release	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-39	9961-9972	formulation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-40	9972-9973	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-41	9973-9974	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-42	9975-9977	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-43	9978-9986	compared	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-44	9987-9989	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-45	9990-9997	placebo	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-46	9998-10000	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-47	10001-10009	reducing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-48	10010-10014	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[7]	
51-49	10015-10018	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-50	10019-10022	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[8]	
51-51	10023-10031	severity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-52	10032-10034	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-53	10035-10043	veterans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	
51-54	10043-10044	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[6]	

#Text=A follow-up visit is included at 6-weeks post treatment.
52-1	10045-10046	A	_	
52-2	10047-10056	follow-up	_	
52-3	10057-10062	visit	_	
52-4	10063-10065	is	_	
52-5	10066-10074	included	_	
52-6	10075-10077	at	_	
52-7	10078-10079	6	_	
52-8	10079-10080	-	_	
52-9	10080-10085	weeks	_	
52-10	10086-10090	post	_	
52-11	10091-10100	treatment	_	
52-12	10100-10101	.	_	

#Text=If eligible and interested, participants may also complete a neuroimaging scan before and after the treatment phase.
53-1	10102-10104	If	_	
53-2	10105-10113	eligible	_	
53-3	10114-10117	and	_	
53-4	10118-10128	interested	_	
53-5	10128-10129	,	_	
53-6	10130-10142	participants	_	
53-7	10143-10146	may	_	
53-8	10147-10151	also	_	
53-9	10152-10160	complete	_	
53-10	10161-10162	a	_	
53-11	10163-10175	neuroimaging	_	
53-12	10176-10180	scan	_	
53-13	10181-10187	before	_	
53-14	10188-10191	and	_	
53-15	10192-10197	after	_	
53-16	10198-10201	the	_	
53-17	10202-10211	treatment	_	
53-18	10212-10217	phase	_	
53-19	10217-10218	.	_	

#Text=The project will last for approximately four years and is illustrated in Fig. 1 (clinical trial) and Fig. 2 (neuroimaging visit).
54-1	10219-10222	The	_	
54-2	10223-10230	project	_	
54-3	10231-10235	will	_	
54-4	10236-10240	last	_	
54-5	10241-10244	for	_	
54-6	10245-10258	approximately	_	
54-7	10259-10263	four	_	
54-8	10264-10269	years	_	
54-9	10270-10273	and	_	
54-10	10274-10276	is	_	
54-11	10277-10288	illustrated	_	
54-12	10289-10291	in	_	
54-13	10292-10295	Fig	_	
54-14	10295-10296	.	_	
54-15	10297-10298	1	_	
54-16	10299-10300	(	_	
54-17	10300-10308	clinical	_	
54-18	10309-10314	trial	_	
54-19	10314-10315	)	_	
54-20	10316-10319	and	_	
54-21	10320-10323	Fig	_	
54-22	10323-10324	.	_	
54-23	10325-10326	2	_	
54-24	10327-10328	(	_	
54-25	10328-10340	neuroimaging	_	
54-26	10341-10346	visit	_	
54-27	10346-10347	)	_	
54-28	10347-10348	.	_	

#Text=Participants
#Text=Participants (N = 144) are U.S. military veterans, ages 18–65, with current PTSD and AUD.
55-1	10349-10361	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-2	10362-10374	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-3	10375-10376	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-4	10376-10377	N	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-5	10378-10379	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-6	10380-10383	144	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-7	10383-10384	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-8	10385-10388	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-9	10389-10392	U.S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-10	10392-10393	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-11	10394-10402	military	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-12	10403-10411	veterans	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-13	10411-10412	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-14	10413-10417	ages	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-15	10418-10420	18	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-16	10420-10421	–	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-17	10421-10423	65	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-18	10423-10424	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-19	10425-10429	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-20	10430-10437	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-21	10438-10442	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[10]	
55-22	10443-10446	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	
55-23	10447-10450	AUD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[11]	
55-24	10450-10451	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[9]	

#Text=Inclusion criteria include: a veteran of the U.S. military (any branch), male or female, any race or ethnicity, able to comprehend English, meet DSM-5 criteria for current (i.e., last 6 months) alcohol use disorder as assessed by the Mini International Neuropsychiatric Interview (MINI, meet DSM-5 criteria for current (i.e., last month) PTSD as assessed by the CAPS-5 (Weathers et al., 2013), and enrolled for services at the Ralph H.
56-1	10452-10461	Inclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-2	10462-10470	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-3	10471-10478	include	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-4	10478-10479	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-5	10480-10481	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-6	10482-10489	veteran	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-7	10490-10492	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-8	10493-10496	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-9	10497-10500	U.S	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-10	10500-10501	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-11	10502-10510	military	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-12	10511-10512	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-13	10512-10515	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-14	10516-10522	branch	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-15	10522-10523	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-16	10523-10524	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-17	10525-10529	male	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-18	10530-10532	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-19	10533-10539	female	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-20	10539-10540	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-21	10541-10544	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-22	10545-10549	race	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-23	10550-10552	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-24	10553-10562	ethnicity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-25	10562-10563	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-26	10564-10568	able	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-27	10569-10571	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-28	10572-10582	comprehend	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-29	10583-10590	English	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-30	10590-10591	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-31	10592-10596	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-32	10597-10600	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-33	10600-10601	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-34	10601-10602	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-35	10603-10611	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-36	10612-10615	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-37	10616-10623	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-38	10624-10625	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-39	10625-10628	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-40	10628-10629	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-41	10629-10630	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-42	10631-10635	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-43	10636-10637	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-44	10638-10644	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-45	10644-10645	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-46	10646-10653	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]	
56-47	10654-10657	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]	
56-48	10658-10666	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse[13]	
56-49	10667-10669	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-50	10670-10678	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-51	10679-10681	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-52	10682-10685	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-53	10686-10690	Mini	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-54	10691-10704	International	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-55	10705-10721	Neuropsychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-56	10722-10731	Interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-57	10732-10733	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-58	10733-10737	MINI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-59	10737-10738	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-60	10739-10743	meet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-61	10744-10747	DSM	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-62	10747-10748	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-63	10748-10749	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-64	10750-10758	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-65	10759-10762	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-66	10763-10770	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-67	10771-10772	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-68	10772-10775	i.e	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-69	10775-10776	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-70	10776-10777	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-71	10778-10782	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-72	10783-10788	month	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-73	10788-10789	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-74	10790-10794	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]|http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder[14]	
56-75	10795-10797	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-76	10798-10806	assessed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-77	10807-10809	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-78	10810-10813	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-79	10814-10818	CAPS	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-80	10818-10819	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-81	10819-10820	5	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-82	10821-10822	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-83	10822-10830	Weathers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-84	10831-10833	et	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-85	10834-10836	al	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-86	10836-10837	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-87	10837-10838	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-88	10839-10843	2013	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-89	10843-10844	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-90	10844-10845	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-91	10846-10849	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-92	10850-10858	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-93	10859-10862	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-94	10863-10871	services	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-95	10872-10874	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-96	10875-10878	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-97	10879-10884	Ralph	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-98	10885-10886	H	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	
56-99	10886-10887	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[12]	

#Text=Johnson VA Medical Center or affiliated community-based outpatient clinic.
57-1	10888-10895	Johnson	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-2	10896-10898	VA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-3	10899-10906	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-4	10907-10913	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-5	10914-10916	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-6	10917-10927	affiliated	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-7	10928-10943	community-based	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-8	10944-10954	outpatient	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-9	10955-10961	clinic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[15]	
57-10	10961-10962	.	_	

#Text=Subjects taking psychotropic medications are required to be maintained on a stable dose for at least 4 weeks before study medication initiation.
58-1	10963-10971	Subjects	_	
58-2	10972-10978	taking	_	
58-3	10979-10991	psychotropic	_	
58-4	10992-11003	medications	_	
58-5	11004-11007	are	_	
58-6	11008-11016	required	_	
58-7	11017-11019	to	_	
58-8	11020-11022	be	_	
58-9	11023-11033	maintained	_	
58-10	11034-11036	on	_	
58-11	11037-11038	a	_	
58-12	11039-11045	stable	_	
58-13	11046-11050	dose	_	
58-14	11051-11054	for	_	
58-15	11055-11057	at	_	
58-16	11058-11063	least	_	
58-17	11064-11065	4	_	
58-18	11066-11071	weeks	_	
58-19	11072-11078	before	_	
58-20	11079-11084	study	_	
58-21	11085-11095	medication	_	
58-22	11096-11106	initiation	_	
58-23	11106-11107	.	_	

#Text=Exclusion criteria include the following: previous treatment with doxazosin; women who are pregnant, nursing or not practicing an effective form of birth control; individuals with a history of adverse reactions to quinazolines or other alpha-1-antagonists; individuals currently taking alpha blockers (e.g., prazosin) or any other medication that may have a hazardous interaction if taken with doxazosin; and individuals with clinically significant medical or psychiatric conditions that in the opinion of the investigators may adversely affect safety or study participation.
59-1	11108-11117	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-2	11118-11126	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-3	11127-11134	include	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-4	11135-11138	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-5	11139-11148	following	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-6	11148-11149	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-7	11150-11158	previous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-8	11159-11168	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-9	11169-11173	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-10	11174-11183	doxazosin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-11	11183-11184	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-12	11185-11190	women	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-13	11191-11194	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-14	11195-11198	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-15	11199-11207	pregnant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-16	11207-11208	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-17	11209-11216	nursing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-18	11217-11219	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-19	11220-11223	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-20	11224-11234	practicing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-21	11235-11237	an	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-22	11238-11247	effective	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-23	11248-11252	form	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-24	11253-11255	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-25	11256-11261	birth	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-26	11262-11269	control	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-27	11269-11270	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-28	11271-11282	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-29	11283-11287	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-30	11288-11289	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-31	11290-11297	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-32	11298-11300	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-33	11301-11308	adverse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-34	11309-11318	reactions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-35	11319-11321	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-36	11322-11334	quinazolines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-37	11335-11337	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-38	11338-11343	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-39	11344-11349	alpha	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-40	11349-11350	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-41	11350-11351	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-42	11351-11352	-	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-43	11352-11363	antagonists	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-44	11363-11364	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-45	11365-11376	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-46	11377-11386	currently	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-47	11387-11393	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-48	11394-11399	alpha	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-49	11400-11408	blockers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-50	11409-11410	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-51	11410-11413	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-52	11413-11414	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-53	11414-11415	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-54	11416-11424	prazosin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-55	11424-11425	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-56	11426-11428	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-57	11429-11432	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-58	11433-11438	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-59	11439-11449	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-60	11450-11454	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-61	11455-11458	may	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-62	11459-11463	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-63	11464-11465	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-64	11466-11475	hazardous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-65	11476-11487	interaction	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-66	11488-11490	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-67	11491-11496	taken	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-68	11497-11501	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-69	11502-11511	doxazosin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-70	11511-11512	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-71	11513-11516	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-72	11517-11528	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-73	11529-11533	with	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-74	11534-11544	clinically	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-75	11545-11556	significant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-76	11557-11564	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-77	11565-11567	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-78	11568-11579	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-79	11580-11590	conditions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-80	11591-11595	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-81	11596-11598	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-82	11599-11602	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-83	11603-11610	opinion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-84	11611-11613	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-85	11614-11617	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-86	11618-11631	investigators	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-87	11632-11635	may	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-88	11636-11645	adversely	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-89	11646-11652	affect	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-90	11653-11659	safety	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-91	11660-11662	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-92	11663-11668	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-93	11669-11682	participation	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	
59-94	11682-11683	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[16]	

#Text=Individuals presenting with significant withdrawal symptoms as evidenced by a score on the revised Clinician Institute Withdrawal Assessment of Alcohol (CIWA-Ar) of ≥10 will be referred for medically supervised detoxification and may be re-assessed for study eligibility after detoxification.
60-1	11684-11695	Individuals	_	
60-2	11696-11706	presenting	_	
60-3	11707-11711	with	_	
60-4	11712-11723	significant	_	
60-5	11724-11734	withdrawal	_	
60-6	11735-11743	symptoms	_	
60-7	11744-11746	as	_	
60-8	11747-11756	evidenced	_	
60-9	11757-11759	by	_	
60-10	11760-11761	a	_	
60-11	11762-11767	score	_	
60-12	11768-11770	on	_	
60-13	11771-11774	the	_	
60-14	11775-11782	revised	_	
60-15	11783-11792	Clinician	_	
60-16	11793-11802	Institute	_	
60-17	11803-11813	Withdrawal	_	
60-18	11814-11824	Assessment	_	
60-19	11825-11827	of	_	
60-20	11828-11835	Alcohol	_	
60-21	11836-11837	(	_	
60-22	11837-11844	CIWA-Ar	_	
60-23	11844-11845	)	_	
60-24	11846-11848	of	_	
60-25	11849-11850	≥	_	
60-26	11850-11852	10	_	
60-27	11853-11857	will	_	
60-28	11858-11860	be	_	
60-29	11861-11869	referred	_	
60-30	11870-11873	for	_	
60-31	11874-11883	medically	_	
60-32	11884-11894	supervised	_	
60-33	11895-11909	detoxification	_	
60-34	11910-11913	and	_	
60-35	11914-11917	may	_	
60-36	11918-11920	be	_	
60-37	11921-11932	re-assessed	_	
60-38	11933-11936	for	_	
60-39	11937-11942	study	_	
60-40	11943-11954	eligibility	_	
60-41	11955-11960	after	_	
60-42	11961-11975	detoxification	_	
60-43	11975-11976	.	_	

#Text=Individuals taking medications thought to influence alcohol consumption or craving (e.g., naltrexone) will be excluded.
61-1	11977-11988	Individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-2	11989-11995	taking	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-3	11996-12007	medications	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-4	12008-12015	thought	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-5	12016-12018	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-6	12019-12028	influence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-7	12029-12036	alcohol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-8	12037-12048	consumption	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-9	12049-12051	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-10	12052-12059	craving	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-11	12060-12061	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-12	12061-12064	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-13	12064-12065	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-14	12065-12066	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-15	12067-12077	naltrexone	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-16	12077-12078	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-17	12079-12083	will	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-18	12084-12086	be	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-19	12087-12095	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	
61-20	12095-12096	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[17]	

#Text=MRI exclusions include claustrophobia; cardiac pacemaker; metal fragments in eye, skin, or body; heart valve replacement; brain clips; venous umbrella; history of aneurysm surgery; intracranial bypass, renal, or aortic clips; joint replacements; non-removable hearing aid, neurostimulator or insulin pump; shunts/stents; metal mesh/coil implants; metal plate/pin/screws/wires; or any other metal implants.
62-1	12097-12100	MRI	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]|http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging[19]	
62-2	12101-12111	exclusions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-3	12112-12119	include	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-4	12120-12134	claustrophobia	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-5	12134-12135	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-6	12136-12143	cardiac	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-7	12144-12153	pacemaker	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-8	12153-12154	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-9	12155-12160	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-10	12161-12170	fragments	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-11	12171-12173	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-12	12174-12177	eye	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-13	12177-12178	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-14	12179-12183	skin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-15	12183-12184	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-16	12185-12187	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-17	12188-12192	body	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-18	12192-12193	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-19	12194-12199	heart	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-20	12200-12205	valve	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-21	12206-12217	replacement	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-22	12217-12218	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-23	12219-12224	brain	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-24	12225-12230	clips	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-25	12230-12231	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-26	12232-12238	venous	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-27	12239-12247	umbrella	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-28	12247-12248	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-29	12249-12256	history	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-30	12257-12259	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-31	12260-12268	aneurysm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-32	12269-12276	surgery	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-33	12276-12277	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-34	12278-12290	intracranial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-35	12291-12297	bypass	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-36	12297-12298	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-37	12299-12304	renal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-38	12304-12305	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-39	12306-12308	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-40	12309-12315	aortic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-41	12316-12321	clips	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-42	12321-12322	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-43	12323-12328	joint	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-44	12329-12341	replacements	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-45	12341-12342	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-46	12343-12356	non-removable	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-47	12357-12364	hearing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-48	12365-12368	aid	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-49	12368-12369	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-50	12370-12385	neurostimulator	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-51	12386-12388	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-52	12389-12396	insulin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-53	12397-12401	pump	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-54	12401-12402	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-55	12403-12409	shunts	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-56	12409-12410	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-57	12410-12416	stents	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-58	12416-12417	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-59	12418-12423	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-60	12424-12428	mesh	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-61	12428-12429	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-62	12429-12433	coil	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-63	12434-12442	implants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-64	12442-12443	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-65	12444-12449	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-66	12450-12455	plate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-67	12455-12456	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-68	12456-12459	pin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-69	12459-12460	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-70	12460-12466	screws	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-71	12466-12467	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-72	12467-12472	wires	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-73	12472-12473	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-74	12474-12476	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-75	12477-12480	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-76	12481-12486	other	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-77	12487-12492	metal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-78	12493-12501	implants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	
62-79	12501-12502	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[18]	

#Text=Procedures
#Text=This study was reviewed and approved by the Institutional Review Boards (IRB) of the Medical University of South Carolina (MUSC), the Ralph H.
63-1	12503-12513	Procedures	_	
63-2	12514-12518	This	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-3	12519-12524	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-4	12525-12528	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-5	12529-12537	reviewed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-6	12538-12541	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-7	12542-12550	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-8	12551-12553	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-9	12554-12557	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-10	12558-12571	Institutional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-11	12572-12578	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-12	12579-12585	Boards	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-13	12586-12587	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-14	12587-12590	IRB	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-15	12590-12591	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-16	12592-12594	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-17	12595-12598	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-18	12599-12606	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-19	12607-12617	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-20	12618-12620	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-21	12621-12626	South	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-22	12627-12635	Carolina	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[20]	
63-23	12636-12637	(	_	
63-24	12637-12641	MUSC	_	
63-25	12641-12642	)	_	
63-26	12642-12643	,	_	
63-27	12644-12647	the	_	
63-28	12648-12653	Ralph	_	
63-29	12654-12655	H	_	
63-30	12655-12656	.	_	

#Text=Johnson VA Medical Center, and the University of Texas Health Science Center at San Antonio.
64-1	12657-12664	Johnson	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-2	12665-12667	VA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-3	12668-12675	Medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-4	12676-12682	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-5	12682-12683	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-6	12684-12687	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-7	12688-12691	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-8	12692-12702	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-9	12703-12705	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-10	12706-12711	Texas	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-11	12712-12718	Health	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-12	12719-12726	Science	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-13	12727-12733	Center	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-14	12734-12736	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-15	12737-12740	San	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-16	12741-12748	Antonio	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[21]	
64-17	12748-12749	.	_	

#Text=Potential participants are given a full description of the study and asked to read and sign IRB-approved informed consent forms before any study procedures take place.
65-1	12750-12759	Potential	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-2	12760-12772	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-3	12773-12776	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-4	12777-12782	given	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-5	12783-12784	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-6	12785-12789	full	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-7	12790-12801	description	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-8	12802-12804	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-9	12805-12808	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-10	12809-12814	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-11	12815-12818	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-12	12819-12824	asked	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-13	12825-12827	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-14	12828-12832	read	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-15	12833-12836	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-16	12837-12841	sign	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-17	12842-12854	IRB-approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-18	12855-12863	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-19	12864-12871	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-20	12872-12877	forms	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-21	12878-12884	before	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-22	12885-12888	any	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-23	12889-12894	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-24	12895-12905	procedures	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-25	12906-12910	take	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-26	12911-12916	place	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	
65-27	12916-12917	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[22]	

#Text=All participants are enrolled in the VA and have the option to receive weekly cognitive-behavioral therapy to ensure that all participants receive adequate psychosocial support and monitoring, regardless of medication arm.
66-1	12918-12921	All	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-2	12922-12934	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-3	12935-12938	are	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-4	12939-12947	enrolled	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-5	12948-12950	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-6	12951-12954	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-7	12955-12957	VA	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-8	12958-12961	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-9	12962-12966	have	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-10	12967-12970	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-11	12971-12977	option	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-12	12978-12980	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-13	12981-12988	receive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-14	12989-12995	weekly	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-15	12996-13016	cognitive-behavioral	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-16	13017-13024	therapy	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-17	13025-13027	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-18	13028-13034	ensure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-19	13035-13039	that	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-20	13040-13043	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-21	13044-13056	participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-22	13057-13064	receive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-23	13065-13073	adequate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-24	13074-13086	psychosocial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-25	13087-13094	support	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-26	13095-13098	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-27	13099-13109	monitoring	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-28	13109-13110	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-29	13111-13121	regardless	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-30	13122-13124	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-31	13125-13135	medication	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-32	13136-13139	arm	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	
66-33	13139-13140	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[23]	

#Text=Interested individuals are screened for eligibility by telephone or in person.
67-1	13141-13151	Interested	_	
67-2	13152-13163	individuals	_	
67-3	13164-13167	are	_	
67-4	13168-13176	screened	_	
67-5	13177-13180	for	_	
67-6	13181-13192	eligibility	_	
67-7	13193-13195	by	_	
67-8	13196-13205	telephone	_	
67-9	13206-13208	or	_	
67-10	13209-13211	in	_	
67-11	13212-13218	person	_	
67-12	13218-13219	.	_	

#Text=Individuals who meet inclusion/exclusion criteria are invited to come into the office for a comprehensive baseline assessment (see Table 1 for measures).
68-1	13220-13231	Individuals	_	
68-2	13232-13235	who	_	
68-3	13236-13240	meet	_	
68-4	13241-13250	inclusion	_	
68-5	13250-13251	/	_	
68-6	13251-13260	exclusion	_	
68-7	13261-13269	criteria	_	
68-8	13270-13273	are	_	
68-9	13274-13281	invited	_	
68-10	13282-13284	to	_	
68-11	13285-13289	come	_	
68-12	13290-13294	into	_	
68-13	13295-13298	the	_	
68-14	13299-13305	office	_	
68-15	13306-13309	for	_	
68-16	13310-13311	a	_	
68-17	13312-13325	comprehensive	_	
68-18	13326-13334	baseline	_	
68-19	13335-13345	assessment	_	
68-20	13346-13347	(	_	
68-21	13347-13350	see	_	
68-22	13351-13356	Table	_	
68-23	13357-13358	1	_	
68-24	13359-13362	for	_	
68-25	13363-13371	measures	_	
68-26	13371-13372	)	_	
68-27	13372-13373	.	_	

#Text=Ineligible individuals are referred clinically for treatment.
69-1	13374-13384	Ineligible	_	
69-2	13385-13396	individuals	_	
69-3	13397-13400	are	_	
69-4	13401-13409	referred	_	
69-5	13410-13420	clinically	_	
69-6	13421-13424	for	_	
69-7	13425-13434	treatment	_	
69-8	13434-13435	.	_	

#Text=Study medication
#Text=Participants are randomly assigned in a 1:1 manner to receive doxazosin (16 mg/day) or placebo.
70-1	13436-13441	Study	_	
70-2	13442-13452	medication	_	
70-3	13453-13465	Participants	_	
70-4	13466-13469	are	_	
70-5	13470-13478	randomly	_	
70-6	13479-13487	assigned	_	
70-7	13488-13490	in	_	
70-8	13491-13492	a	_	
70-9	13493-13494	1	_	
70-10	13494-13495	:	_	
70-11	13495-13496	1	_	
70-12	13497-13503	manner	_	
70-13	13504-13506	to	_	
70-14	13507-13514	receive	_	
70-15	13515-13524	doxazosin	_	
70-16	13525-13526	(	_	
70-17	13526-13528	16	_	
70-18	13529-13531	mg	_	
70-19	13531-13532	/	_	
70-20	13532-13535	day	_	
70-21	13535-13536	)	_	
70-22	13537-13539	or	_	
70-23	13540-13547	placebo	_	
70-24	13547-13548	.	_	

#Text=The dose was selected based on previous research.
71-1	13549-13552	The	_	
71-2	13553-13557	dose	_	
71-3	13558-13561	was	_	
71-4	13562-13570	selected	_	
71-5	13571-13576	based	_	
71-6	13577-13579	on	_	
71-7	13580-13588	previous	_	
71-8	13589-13597	research	_	
71-9	13597-13598	.	_	

#Text=Study medication and matching placebo are encapsulated in standard-sized gelatin capsules and are of sufficient opacity and color so as not to reveal contents inside or disclose any possible difference between placebo and active capsules.
72-1	13599-13604	Study	_	
72-2	13605-13615	medication	_	
72-3	13616-13619	and	_	
72-4	13620-13628	matching	_	
72-5	13629-13636	placebo	_	
72-6	13637-13640	are	_	
72-7	13641-13653	encapsulated	_	
72-8	13654-13656	in	_	
72-9	13657-13671	standard-sized	_	
72-10	13672-13679	gelatin	_	
72-11	13680-13688	capsules	_	
72-12	13689-13692	and	_	
72-13	13693-13696	are	_	
72-14	13697-13699	of	_	
72-15	13700-13710	sufficient	_	
72-16	13711-13718	opacity	_	
72-17	13719-13722	and	_	
72-18	13723-13728	color	_	
72-19	13729-13731	so	_	
72-20	13732-13734	as	_	
72-21	13735-13738	not	_	
72-22	13739-13741	to	_	
72-23	13742-13748	reveal	_	
72-24	13749-13757	contents	_	
72-25	13758-13764	inside	_	
72-26	13765-13767	or	_	
72-27	13768-13776	disclose	_	
72-28	13777-13780	any	_	
72-29	13781-13789	possible	_	
72-30	13790-13800	difference	_	
72-31	13801-13808	between	_	
72-32	13809-13816	placebo	_	
72-33	13817-13820	and	_	
72-34	13821-13827	active	_	
72-35	13828-13836	capsules	_	
72-36	13836-13837	.	_	

#Text=Active study medication capsules consist of USP-grade doxazosin and 25 mg riboflavin.
73-1	13838-13844	Active	_	
73-2	13845-13850	study	_	
73-3	13851-13861	medication	_	
73-4	13862-13870	capsules	_	
73-5	13871-13878	consist	_	
73-6	13879-13881	of	_	
73-7	13882-13891	USP-grade	_	
73-8	13892-13901	doxazosin	_	
73-9	13902-13905	and	_	
73-10	13906-13908	25	_	
73-11	13909-13911	mg	_	
73-12	13912-13922	riboflavin	_	
73-13	13922-13923	.	_	

#Text=All study capsules contain dextrose as the inert filling agent and are brought to proper packing level in color-matched, opaque, identically sized capsules.
74-1	13924-13927	All	_	
74-2	13928-13933	study	_	
74-3	13934-13942	capsules	_	
74-4	13943-13950	contain	_	
74-5	13951-13959	dextrose	_	
74-6	13960-13962	as	_	
74-7	13963-13966	the	_	
74-8	13967-13972	inert	_	
74-9	13973-13980	filling	_	
74-10	13981-13986	agent	_	
74-11	13987-13990	and	_	
74-12	13991-13994	are	_	
74-13	13995-14002	brought	_	
74-14	14003-14005	to	_	
74-15	14006-14012	proper	_	
74-16	14013-14020	packing	_	
74-17	14021-14026	level	_	
74-18	14027-14029	in	_	
74-19	14030-14043	color-matched	_	
74-20	14043-14044	,	_	
74-21	14045-14051	opaque	_	
74-22	14051-14052	,	_	
74-23	14053-14064	identically	_	
74-24	14065-14070	sized	_	
74-25	14071-14079	capsules	_	
74-26	14079-14080	.	_	

#Text=Participants who wish to take a multivitamin during the treatment phase of the study are given a multivitamin (TriVi-Sol) that does not contain riboflavin.
75-1	14081-14093	Participants	_	
75-2	14094-14097	who	_	
75-3	14098-14102	wish	_	
75-4	14103-14105	to	_	
75-5	14106-14110	take	_	
75-6	14111-14112	a	_	
75-7	14113-14125	multivitamin	_	
75-8	14126-14132	during	_	
75-9	14133-14136	the	_	
75-10	14137-14146	treatment	_	
75-11	14147-14152	phase	_	
75-12	14153-14155	of	_	
75-13	14156-14159	the	_	
75-14	14160-14165	study	_	
75-15	14166-14169	are	_	
75-16	14170-14175	given	_	
75-17	14176-14177	a	_	
75-18	14178-14190	multivitamin	_	
75-19	14191-14192	(	_	
75-20	14192-14201	TriVi-Sol	_	
75-21	14201-14202	)	_	
75-22	14203-14207	that	_	
75-23	14208-14212	does	_	
75-24	14213-14216	not	_	
75-25	14217-14224	contain	_	
75-26	14225-14235	riboflavin	_	
75-27	14235-14236	.	_	

#Text=Treatment assignment follows a prearranged randomization scheme and is carried out by a research pharmacist not involved in clinical management of participants in order to preserve the double-blind design.
76-1	14237-14246	Treatment	_	
76-2	14247-14257	assignment	_	
76-3	14258-14265	follows	_	
76-4	14266-14267	a	_	
76-5	14268-14279	prearranged	_	
76-6	14280-14293	randomization	_	
76-7	14294-14300	scheme	_	
76-8	14301-14304	and	_	
76-9	14305-14307	is	_	
76-10	14308-14315	carried	_	
76-11	14316-14319	out	_	
76-12	14320-14322	by	_	
76-13	14323-14324	a	_	
76-14	14325-14333	research	_	
76-15	14334-14344	pharmacist	_	
76-16	14345-14348	not	_	
76-17	14349-14357	involved	_	
76-18	14358-14360	in	_	
76-19	14361-14369	clinical	_	
76-20	14370-14380	management	_	
76-21	14381-14383	of	_	
76-22	14384-14396	participants	_	
76-23	14397-14399	in	_	
76-24	14400-14405	order	_	
76-25	14406-14408	to	_	
76-26	14409-14417	preserve	_	
76-27	14418-14421	the	_	
76-28	14422-14434	double-blind	_	
76-29	14435-14441	design	_	
76-30	14441-14442	.	_	

#Text=Doxazosin is initiated at 1 mg/day and then titrated up as follows: 2 mg at Week 2; 4 mg at Week 3; 8 mg at Week 4; and then 16 mg during Weeks 5–12.
77-1	14443-14452	Doxazosin	_	
77-2	14453-14455	is	_	
77-3	14456-14465	initiated	_	
77-4	14466-14468	at	_	
77-5	14469-14470	1	_	
77-6	14471-14473	mg	_	
77-7	14473-14474	/	_	
77-8	14474-14477	day	_	
77-9	14478-14481	and	_	
77-10	14482-14486	then	_	
77-11	14487-14495	titrated	_	
77-12	14496-14498	up	_	
77-13	14499-14501	as	_	
77-14	14502-14509	follows	_	
77-15	14509-14510	:	_	
77-16	14511-14512	2	_	
77-17	14513-14515	mg	_	
77-18	14516-14518	at	_	
77-19	14519-14523	Week	_	
77-20	14524-14525	2	_	
77-21	14525-14526	;	_	
77-22	14527-14528	4	_	
77-23	14529-14531	mg	_	
77-24	14532-14534	at	_	
77-25	14535-14539	Week	_	
77-26	14540-14541	3	_	
77-27	14541-14542	;	_	
77-28	14543-14544	8	_	
77-29	14545-14547	mg	_	
77-30	14548-14550	at	_	
77-31	14551-14555	Week	_	
77-32	14556-14557	4	_	
77-33	14557-14558	;	_	
77-34	14559-14562	and	_	
77-35	14563-14567	then	_	
77-36	14568-14570	16	_	
77-37	14571-14573	mg	_	
77-38	14574-14580	during	_	
77-39	14581-14586	Weeks	_	
77-40	14587-14588	5	_	
77-41	14588-14589	–	_	
77-42	14589-14591	12	_	
77-43	14591-14592	.	_	

#Text=A downward titration for safety occurs at the end of Week 12 and participants are titrated down to 8 mg on Day 1; 6 mg on Day 2; 4 mg on Day 3; 2 mg on Day 4; and 1 mg on Day 5.
78-1	14593-14594	A	_	
78-2	14595-14603	downward	_	
78-3	14604-14613	titration	_	
78-4	14614-14617	for	_	
78-5	14618-14624	safety	_	
78-6	14625-14631	occurs	_	
78-7	14632-14634	at	_	
78-8	14635-14638	the	_	
78-9	14639-14642	end	_	
78-10	14643-14645	of	_	
78-11	14646-14650	Week	_	
78-12	14651-14653	12	_	
78-13	14654-14657	and	_	
78-14	14658-14670	participants	_	
78-15	14671-14674	are	_	
78-16	14675-14683	titrated	_	
78-17	14684-14688	down	_	
78-18	14689-14691	to	_	
78-19	14692-14693	8	_	
78-20	14694-14696	mg	_	
78-21	14697-14699	on	_	
78-22	14700-14703	Day	_	
78-23	14704-14705	1	_	
78-24	14705-14706	;	_	
78-25	14707-14708	6	_	
78-26	14709-14711	mg	_	
78-27	14712-14714	on	_	
78-28	14715-14718	Day	_	
78-29	14719-14720	2	_	
78-30	14720-14721	;	_	
78-31	14722-14723	4	_	
78-32	14724-14726	mg	_	
78-33	14727-14729	on	_	
78-34	14730-14733	Day	_	
78-35	14734-14735	3	_	
78-36	14735-14736	;	_	
78-37	14737-14738	2	_	
78-38	14739-14741	mg	_	
78-39	14742-14744	on	_	
78-40	14745-14748	Day	_	
78-41	14749-14750	4	_	
78-42	14750-14751	;	_	
78-43	14752-14755	and	_	
78-44	14756-14757	1	_	
78-45	14758-14760	mg	_	
78-46	14761-14763	on	_	
78-47	14764-14767	Day	_	
78-48	14768-14769	5	_	
78-49	14769-14770	.	_	

#Text=Primary outcome measures
#Text=Participants complete the CAP Common Data Elements battery, which includes demographic and military history information, personality, deployment stress, trauma, psychiatric symptoms, traumatic brain injury, substance use, functional impairment, sources of support, sleep impairment, pain, relationship functioning, and treatment credibility expectancy.
79-1	14771-14778	Primary	_	
79-2	14779-14786	outcome	_	
79-3	14787-14795	measures	_	
79-4	14796-14808	Participants	_	
79-5	14809-14817	complete	_	
79-6	14818-14821	the	_	
79-7	14822-14825	CAP	_	
79-8	14826-14832	Common	_	
79-9	14833-14837	Data	_	
79-10	14838-14846	Elements	_	
79-11	14847-14854	battery	_	
79-12	14854-14855	,	_	
79-13	14856-14861	which	_	
79-14	14862-14870	includes	_	
79-15	14871-14882	demographic	_	
79-16	14883-14886	and	_	
79-17	14887-14895	military	_	
79-18	14896-14903	history	_	
79-19	14904-14915	information	_	
79-20	14915-14916	,	_	
79-21	14917-14928	personality	_	
79-22	14928-14929	,	_	
79-23	14930-14940	deployment	_	
79-24	14941-14947	stress	_	
79-25	14947-14948	,	_	
79-26	14949-14955	trauma	_	
79-27	14955-14956	,	_	
79-28	14957-14968	psychiatric	_	
79-29	14969-14977	symptoms	_	
79-30	14977-14978	,	_	
79-31	14979-14988	traumatic	_	
79-32	14989-14994	brain	_	
79-33	14995-15001	injury	_	
79-34	15001-15002	,	_	
79-35	15003-15012	substance	_	
79-36	15013-15016	use	_	
79-37	15016-15017	,	_	
79-38	15018-15028	functional	_	
79-39	15029-15039	impairment	_	
79-40	15039-15040	,	_	
79-41	15041-15048	sources	_	
79-42	15049-15051	of	_	
79-43	15052-15059	support	_	
79-44	15059-15060	,	_	
79-45	15061-15066	sleep	_	
79-46	15067-15077	impairment	_	
79-47	15077-15078	,	_	
79-48	15079-15083	pain	_	
79-49	15083-15084	,	_	
79-50	15085-15097	relationship	_	
79-51	15098-15109	functioning	_	
79-52	15109-15110	,	_	
79-53	15111-15114	and	_	
79-54	15115-15124	treatment	_	
79-55	15125-15136	credibility	_	
79-56	15137-15147	expectancy	_	
79-57	15147-15148	.	_	

#Text=The CAP Assessment Core has carefully reviewed and selected these measures to ensure that only measures with the highest levels of validity and reliability are included as part of the CAP Common Data Elements battery.
80-1	15149-15152	The	_	
80-2	15153-15156	CAP	_	
80-3	15157-15167	Assessment	_	
80-4	15168-15172	Core	_	
80-5	15173-15176	has	_	
80-6	15177-15186	carefully	_	
80-7	15187-15195	reviewed	_	
80-8	15196-15199	and	_	
80-9	15200-15208	selected	_	
80-10	15209-15214	these	_	
80-11	15215-15223	measures	_	
80-12	15224-15226	to	_	
80-13	15227-15233	ensure	_	
80-14	15234-15238	that	_	
80-15	15239-15243	only	_	
80-16	15244-15252	measures	_	
80-17	15253-15257	with	_	
80-18	15258-15261	the	_	
80-19	15262-15269	highest	_	
80-20	15270-15276	levels	_	
80-21	15277-15279	of	_	
80-22	15280-15288	validity	_	
80-23	15289-15292	and	_	
80-24	15293-15304	reliability	_	
80-25	15305-15308	are	_	
80-26	15309-15317	included	_	
80-27	15318-15320	as	_	
80-28	15321-15325	part	_	
80-29	15326-15328	of	_	
80-30	15329-15332	the	_	
80-31	15333-15336	CAP	_	
80-32	15337-15343	Common	_	
80-33	15344-15348	Data	_	
80-34	15349-15357	Elements	_	
80-35	15358-15365	battery	_	
80-36	15365-15366	.	_	

#Text=The primary outcome measures for this study are: (1) the CAPS-5, (2) the PCL-5, and (3) the TLFB.
81-1	15367-15370	The	_	
81-2	15371-15378	primary	_	
81-3	15379-15386	outcome	_	
81-4	15387-15395	measures	_	
81-5	15396-15399	for	_	
81-6	15400-15404	this	_	
81-7	15405-15410	study	_	
81-8	15411-15414	are	_	
81-9	15414-15415	:	_	
81-10	15416-15417	(	_	
81-11	15417-15418	1	_	
81-12	15418-15419	)	_	
81-13	15420-15423	the	_	
81-14	15424-15428	CAPS	_	
81-15	15428-15429	-	_	
81-16	15429-15430	5	_	
81-17	15430-15431	,	_	
81-18	15432-15433	(	_	
81-19	15433-15434	2	_	
81-20	15434-15435	)	_	
81-21	15436-15439	the	_	
81-22	15440-15443	PCL	_	
81-23	15443-15444	-	_	
81-24	15444-15445	5	_	
81-25	15445-15446	,	_	
81-26	15447-15450	and	_	
81-27	15451-15452	(	_	
81-28	15452-15453	3	_	
81-29	15453-15454	)	_	
81-30	15455-15458	the	_	
81-31	15459-15463	TLFB	_	
81-32	15463-15464	.	_	

#Text=The CAPS-5 is a semistructured interview used to assess PTSD diagnosis and symptom severity.
82-1	15465-15468	The	_	
82-2	15469-15473	CAPS	_	
82-3	15473-15474	-	_	
82-4	15474-15475	5	_	
82-5	15476-15478	is	_	
82-6	15479-15480	a	_	
82-7	15481-15495	semistructured	_	
82-8	15496-15505	interview	_	
82-9	15506-15510	used	_	
82-10	15511-15513	to	_	
82-11	15514-15520	assess	_	
82-12	15521-15525	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
82-13	15526-15535	diagnosis	_	
82-14	15536-15539	and	_	
82-15	15540-15547	symptom	_	
82-16	15548-15556	severity	_	
82-17	15556-15557	.	_	

#Text=The CAPS-5 is rated on a 5-point scale (0 = absent to 4 = extreme/incapacitating) with a total score ranging from 0 to 80.
83-1	15558-15561	The	_	
83-2	15562-15566	CAPS	_	
83-3	15566-15567	-	_	
83-4	15567-15568	5	_	
83-5	15569-15571	is	_	
83-6	15572-15577	rated	_	
83-7	15578-15580	on	_	
83-8	15581-15582	a	_	
83-9	15583-15584	5	_	
83-10	15584-15585	-	_	
83-11	15585-15590	point	_	
83-12	15591-15596	scale	_	
83-13	15597-15598	(	_	
83-14	15598-15599	0	_	
83-15	15600-15601	=	_	
83-16	15602-15608	absent	_	
83-17	15609-15611	to	_	
83-18	15612-15613	4	_	
83-19	15614-15615	=	_	
83-20	15616-15623	extreme	_	
83-21	15623-15624	/	_	
83-22	15624-15638	incapacitating	_	
83-23	15638-15639	)	_	
83-24	15640-15644	with	_	
83-25	15645-15646	a	_	
83-26	15647-15652	total	_	
83-27	15653-15658	score	_	
83-28	15659-15666	ranging	_	
83-29	15667-15671	from	_	
83-30	15672-15673	0	_	
83-31	15674-15676	to	_	
83-32	15677-15679	80	_	
83-33	15679-15680	.	_	

#Text=In this study, the CAPS-5 is administered by independent evaluators (IE) trained and certified by the CAP Assessment Core and blind to treatment status.
84-1	15681-15683	In	_	
84-2	15684-15688	this	_	
84-3	15689-15694	study	_	
84-4	15694-15695	,	_	
84-5	15696-15699	the	_	
84-6	15700-15704	CAPS	_	
84-7	15704-15705	-	_	
84-8	15705-15706	5	_	
84-9	15707-15709	is	_	
84-10	15710-15722	administered	_	
84-11	15723-15725	by	_	
84-12	15726-15737	independent	_	
84-13	15738-15748	evaluators	_	
84-14	15749-15750	(	_	
84-15	15750-15752	IE	_	
84-16	15752-15753	)	_	
84-17	15754-15761	trained	_	
84-18	15762-15765	and	_	
84-19	15766-15775	certified	_	
84-20	15776-15778	by	_	
84-21	15779-15782	the	_	
84-22	15783-15786	CAP	_	
84-23	15787-15797	Assessment	_	
84-24	15798-15802	Core	_	
84-25	15803-15806	and	_	
84-26	15807-15812	blind	_	
84-27	15813-15815	to	_	
84-28	15816-15825	treatment	_	
84-29	15826-15832	status	_	
84-30	15832-15833	.	_	

#Text=The PCL-5 is a 20-item, self-report measure that assesses PTSD severity using a Likert scale (0 = not at all to 4 = extremely).
85-1	15834-15837	The	_	
85-2	15838-15841	PCL	_	
85-3	15841-15842	-	_	
85-4	15842-15843	5	_	
85-5	15844-15846	is	_	
85-6	15847-15848	a	_	
85-7	15849-15851	20	_	
85-8	15851-15852	-	_	
85-9	15852-15856	item	_	
85-10	15856-15857	,	_	
85-11	15858-15869	self-report	_	
85-12	15870-15877	measure	_	
85-13	15878-15882	that	_	
85-14	15883-15891	assesses	_	
85-15	15892-15896	PTSD	_	
85-16	15897-15905	severity	_	
85-17	15906-15911	using	_	
85-18	15912-15913	a	_	
85-19	15914-15920	Likert	_	
85-20	15921-15926	scale	_	
85-21	15927-15928	(	_	
85-22	15928-15929	0	_	
85-23	15930-15931	=	_	
85-24	15932-15935	not	_	
85-25	15936-15938	at	_	
85-26	15939-15942	all	_	
85-27	15943-15945	to	_	
85-28	15946-15947	4	_	
85-29	15948-15949	=	_	
85-30	15950-15959	extremely	_	
85-31	15959-15960	)	_	
85-32	15960-15961	.	_	

#Text=Finally, the TLFB obtains retrospective self-report of substance use by using a calendar and memory prompts to stimulate recall.
86-1	15962-15969	Finally	_	
86-2	15969-15970	,	_	
86-3	15971-15974	the	_	
86-4	15975-15979	TLFB	_	
86-5	15980-15987	obtains	_	
86-6	15988-16001	retrospective	_	
86-7	16002-16013	self-report	_	
86-8	16014-16016	of	_	
86-9	16017-16026	substance	_	
86-10	16027-16030	use	_	
86-11	16031-16033	by	_	
86-12	16034-16039	using	_	
86-13	16040-16041	a	_	
86-14	16042-16050	calendar	_	
86-15	16051-16054	and	_	
86-16	16055-16061	memory	_	
86-17	16062-16069	prompts	_	
86-18	16070-16072	to	_	
86-19	16073-16082	stimulate	_	
86-20	16083-16089	recall	_	
86-21	16089-16090	.	_	

#Text=Quantity and frequency assessments are made using this instrument (e.g., total number of standard drink units, percent of days using) as well as abstinence (yes/no).
87-1	16091-16099	Quantity	_	
87-2	16100-16103	and	_	
87-3	16104-16113	frequency	_	
87-4	16114-16125	assessments	_	
87-5	16126-16129	are	_	
87-6	16130-16134	made	_	
87-7	16135-16140	using	_	
87-8	16141-16145	this	_	
87-9	16146-16156	instrument	_	
87-10	16157-16158	(	_	
87-11	16158-16161	e.g	_	
87-12	16161-16162	.	_	
87-13	16162-16163	,	_	
87-14	16164-16169	total	_	
87-15	16170-16176	number	_	
87-16	16177-16179	of	_	
87-17	16180-16188	standard	_	
87-18	16189-16194	drink	_	
87-19	16195-16200	units	_	
87-20	16200-16201	,	_	
87-21	16202-16209	percent	_	
87-22	16210-16212	of	_	
87-23	16213-16217	days	_	
87-24	16218-16223	using	_	
87-25	16223-16224	)	_	
87-26	16225-16227	as	_	
87-27	16228-16232	well	_	
87-28	16233-16235	as	_	
87-29	16236-16246	abstinence	_	
87-30	16247-16248	(	_	
87-31	16248-16251	yes	_	
87-32	16251-16252	/	_	
87-33	16252-16254	no	_	
87-34	16254-16255	)	_	
87-35	16255-16256	.	_	

#Text=TLFB yields consistently high test-retest correlations and correlates well with other self-reports and collateral reports.
88-1	16257-16261	TLFB	_	
88-2	16262-16268	yields	_	
88-3	16269-16281	consistently	_	
88-4	16282-16286	high	_	
88-5	16287-16298	test-retest	_	
88-6	16299-16311	correlations	_	
88-7	16312-16315	and	_	
88-8	16316-16326	correlates	_	
88-9	16327-16331	well	_	
88-10	16332-16336	with	_	
88-11	16337-16342	other	_	
88-12	16343-16355	self-reports	_	
88-13	16356-16359	and	_	
88-14	16360-16370	collateral	_	
88-15	16371-16378	reports	_	
88-16	16378-16379	.	_	

#Text=The TLFB assesses frequency and amount of substance use for 60 days prior to study entry, during the 12 weeks of treatment, and at follow-up.
89-1	16380-16383	The	_	
89-2	16384-16388	TLFB	_	
89-3	16389-16397	assesses	_	
89-4	16398-16407	frequency	_	
89-5	16408-16411	and	_	
89-6	16412-16418	amount	_	
89-7	16419-16421	of	_	
89-8	16422-16431	substance	_	
89-9	16432-16435	use	_	
89-10	16436-16439	for	_	
89-11	16440-16442	60	_	
89-12	16443-16447	days	_	
89-13	16448-16453	prior	_	
89-14	16454-16456	to	_	
89-15	16457-16462	study	_	
89-16	16463-16468	entry	_	
89-17	16468-16469	,	_	
89-18	16470-16476	during	_	
89-19	16477-16480	the	_	
89-20	16481-16483	12	_	
89-21	16484-16489	weeks	_	
89-22	16490-16492	of	_	
89-23	16493-16502	treatment	_	
89-24	16502-16503	,	_	
89-25	16504-16507	and	_	
89-26	16508-16510	at	_	
89-27	16511-16520	follow-up	_	
89-28	16520-16521	.	_	

#Text=Secondary outcome measures
#Text=Secondary outcomes related to alcohol craving and characterization of AUD are measured by using the Obsessive Compulsive Drinking Scale (OCDS), Brief Addiction Monitor (BAM), ethyl glucuronide (a conjugated alcohol metabolite biomarker of recent alcohol consumption), and family history of addiction using the Addiction Severity Index family history section.
90-1	16522-16531	Secondary	_	
90-2	16532-16539	outcome	_	
90-3	16540-16548	measures	_	
90-4	16549-16558	Secondary	_	
90-5	16559-16567	outcomes	_	
90-6	16568-16575	related	_	
90-7	16576-16578	to	_	
90-8	16579-16586	alcohol	_	
90-9	16587-16594	craving	_	
90-10	16595-16598	and	_	
90-11	16599-16615	characterization	_	
90-12	16616-16618	of	_	
90-13	16619-16622	AUD	_	
90-14	16623-16626	are	_	
90-15	16627-16635	measured	_	
90-16	16636-16638	by	_	
90-17	16639-16644	using	_	
90-18	16645-16648	the	_	
90-19	16649-16658	Obsessive	_	
90-20	16659-16669	Compulsive	_	
90-21	16670-16678	Drinking	_	
90-22	16679-16684	Scale	_	
90-23	16685-16686	(	_	
90-24	16686-16690	OCDS	_	
90-25	16690-16691	)	_	
90-26	16691-16692	,	_	
90-27	16693-16698	Brief	_	
90-28	16699-16708	Addiction	_	
90-29	16709-16716	Monitor	_	
90-30	16717-16718	(	_	
90-31	16718-16721	BAM	_	
90-32	16721-16722	)	_	
90-33	16722-16723	,	_	
90-34	16724-16729	ethyl	_	
90-35	16730-16741	glucuronide	_	
90-36	16742-16743	(	_	
90-37	16743-16744	a	_	
90-38	16745-16755	conjugated	_	
90-39	16756-16763	alcohol	_	
90-40	16764-16774	metabolite	_	
90-41	16775-16784	biomarker	_	
90-42	16785-16787	of	_	
90-43	16788-16794	recent	_	
90-44	16795-16802	alcohol	_	
90-45	16803-16814	consumption	_	
90-46	16814-16815	)	_	
90-47	16815-16816	,	_	
90-48	16817-16820	and	_	
90-49	16821-16827	family	_	
90-50	16828-16835	history	_	
90-51	16836-16838	of	_	
90-52	16839-16848	addiction	_	
90-53	16849-16854	using	_	
90-54	16855-16858	the	_	
90-55	16859-16868	Addiction	_	
90-56	16869-16877	Severity	_	
90-57	16878-16883	Index	_	
90-58	16884-16890	family	_	
90-59	16891-16898	history	_	
90-60	16899-16906	section	_	
90-61	16906-16907	.	_	

#Text=Symptoms of depression, suicidality, psychosocial functioning, and emotional regulation will be assessed using the well-validated instruments shown in Table 1.
91-1	16908-16916	Symptoms	_	
91-2	16917-16919	of	_	
91-3	16920-16930	depression	_	
91-4	16930-16931	,	_	
91-5	16932-16943	suicidality	_	
91-6	16943-16944	,	_	
91-7	16945-16957	psychosocial	_	
91-8	16958-16969	functioning	_	
91-9	16969-16970	,	_	
91-10	16971-16974	and	_	
91-11	16975-16984	emotional	_	
91-12	16985-16995	regulation	_	
91-13	16996-17000	will	_	
91-14	17001-17003	be	_	
91-15	17004-17012	assessed	_	
91-16	17013-17018	using	_	
91-17	17019-17022	the	_	
91-18	17023-17037	well-validated	_	
91-19	17038-17049	instruments	_	
91-20	17050-17055	shown	_	
91-21	17056-17058	in	_	
91-22	17059-17064	Table	_	
91-23	17065-17066	1	_	
91-24	17066-17067	.	_	

#Text=Related aspects of PTSD severity such as sleep disturbance, frequency of nightmares, and insomnia will also be regularly monitored (see Table 1).
92-1	17068-17075	Related	_	
92-2	17076-17083	aspects	_	
92-3	17084-17086	of	_	
92-4	17087-17091	PTSD	_	
92-5	17092-17100	severity	_	
92-6	17101-17105	such	_	
92-7	17106-17108	as	_	
92-8	17109-17114	sleep	_	
92-9	17115-17126	disturbance	_	
92-10	17126-17127	,	_	
92-11	17128-17137	frequency	_	
92-12	17138-17140	of	_	
92-13	17141-17151	nightmares	_	
92-14	17151-17152	,	_	
92-15	17153-17156	and	_	
92-16	17157-17165	insomnia	_	
92-17	17166-17170	will	_	
92-18	17171-17175	also	_	
92-19	17176-17178	be	_	
92-20	17179-17188	regularly	_	
92-21	17189-17198	monitored	_	
92-22	17199-17200	(	_	
92-23	17200-17203	see	_	
92-24	17204-17209	Table	_	
92-25	17210-17211	1	_	
92-26	17211-17212	)	_	
92-27	17212-17213	.	_	

#Text=Neuroimaging component
#Text=In addition to testing the safety and efficacy of doxazosin, this study will investigate neural circuitry underlying comorbid PTSD/AUD.
93-1	17214-17226	Neuroimaging	_	
93-2	17227-17236	component	_	
93-3	17237-17239	In	_	
93-4	17240-17248	addition	_	
93-5	17249-17251	to	_	
93-6	17252-17259	testing	_	
93-7	17260-17263	the	_	
93-8	17264-17270	safety	_	
93-9	17271-17274	and	_	
93-10	17275-17283	efficacy	_	
93-11	17284-17286	of	_	
93-12	17287-17296	doxazosin	_	
93-13	17296-17297	,	_	
93-14	17298-17302	this	_	
93-15	17303-17308	study	_	
93-16	17309-17313	will	_	
93-17	17314-17325	investigate	_	
93-18	17326-17332	neural	_	
93-19	17333-17342	circuitry	_	
93-20	17343-17353	underlying	_	
93-21	17354-17362	comorbid	_	
93-22	17363-17367	PTSD	_	
93-23	17367-17368	/	_	
93-24	17368-17371	AUD	_	
93-25	17371-17372	.	_	

#Text=This information may help inform the selection of treatment targets and novel therapeutic agents in future research.
94-1	17373-17377	This	_	
94-2	17378-17389	information	_	
94-3	17390-17393	may	_	
94-4	17394-17398	help	_	
94-5	17399-17405	inform	_	
94-6	17406-17409	the	_	
94-7	17410-17419	selection	_	
94-8	17420-17422	of	_	
94-9	17423-17432	treatment	_	
94-10	17433-17440	targets	_	
94-11	17441-17444	and	_	
94-12	17445-17450	novel	_	
94-13	17451-17462	therapeutic	_	
94-14	17463-17469	agents	_	
94-15	17470-17472	in	_	
94-16	17473-17479	future	_	
94-17	17480-17488	research	_	
94-18	17488-17489	.	_	

#Text=To that end, neuroimaging data is acquired immediately prior to medication initiation and medication discontinuation on all eligible participants.
95-1	17490-17492	To	_	
95-2	17493-17497	that	_	
95-3	17498-17501	end	_	
95-4	17501-17502	,	_	
95-5	17503-17515	neuroimaging	_	
95-6	17516-17520	data	_	
95-7	17521-17523	is	_	
95-8	17524-17532	acquired	_	
95-9	17533-17544	immediately	_	
95-10	17545-17550	prior	_	
95-11	17551-17553	to	_	
95-12	17554-17564	medication	_	
95-13	17565-17575	initiation	_	
95-14	17576-17579	and	_	
95-15	17580-17590	medication	_	
95-16	17591-17606	discontinuation	_	
95-17	17607-17609	on	_	
95-18	17610-17613	all	_	
95-19	17614-17622	eligible	_	
95-20	17623-17635	participants	_	
95-21	17635-17636	.	_	

#Text=As illustrated in Fig. 2, following the resting state scans, participants are exposed to neutral, trauma, and alcohol cues.
96-1	17637-17639	As	_	
96-2	17640-17651	illustrated	_	
96-3	17652-17654	in	_	
96-4	17655-17658	Fig	_	
96-5	17658-17659	.	_	
96-6	17660-17661	2	_	
96-7	17661-17662	,	_	
96-8	17663-17672	following	_	
96-9	17673-17676	the	_	
96-10	17677-17684	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
96-11	17685-17690	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[24]	
96-12	17691-17696	scans	_	
96-13	17696-17697	,	_	
96-14	17698-17710	participants	_	
96-15	17711-17714	are	_	
96-16	17715-17722	exposed	_	
96-17	17723-17725	to	_	
96-18	17726-17733	neutral	_	
96-19	17733-17734	,	_	
96-20	17735-17741	trauma	_	
96-21	17741-17742	,	_	
96-22	17743-17746	and	_	
96-23	17747-17754	alcohol	_	
96-24	17755-17759	cues	_	
96-25	17759-17760	.	_	

#Text=To minimize potential carry-over effects, the trauma and alcohol cues are counterbalanced.
97-1	17761-17763	To	_	
97-2	17764-17772	minimize	_	
97-3	17773-17782	potential	_	
97-4	17783-17793	carry-over	_	
97-5	17794-17801	effects	_	
97-6	17801-17802	,	_	
97-7	17803-17806	the	_	
97-8	17807-17813	trauma	_	
97-9	17814-17817	and	_	
97-10	17818-17825	alcohol	_	
97-11	17826-17830	cues	_	
97-12	17831-17834	are	_	
97-13	17835-17850	counterbalanced	_	
97-14	17850-17851	.	_	

#Text=For both resting state and task runs, T2*-weighted gradient-echo planar images (EPI) are acquired with the following parameters: TR = 1100 ms, TE = 30 ms, flip angle = 65°, ipat factor = 3, matrix 64 × 64, field of view = 19.2 cm, slice thickness = 3.0 mm with no gap, with 48 slices to cover the entire brain.
98-1	17852-17855	For	_	
98-2	17856-17860	both	_	
98-3	17861-17868	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]	
98-4	17869-17874	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[25]	
98-5	17875-17878	and	_	
98-6	17879-17883	task	_	
98-7	17884-17888	runs	_	
98-8	17888-17889	,	_	
98-9	17890-17892	T2	_	
98-10	17892-17893	*	_	
98-11	17893-17894	-	_	
98-12	17894-17902	weighted	_	
98-13	17903-17916	gradient-echo	_	
98-14	17917-17923	planar	_	
98-15	17924-17930	images	_	
98-16	17931-17932	(	_	
98-17	17932-17935	EPI	_	
98-18	17935-17936	)	_	
98-19	17937-17940	are	_	
98-20	17941-17949	acquired	_	
98-21	17950-17954	with	_	
98-22	17955-17958	the	_	
98-23	17959-17968	following	_	
98-24	17969-17979	parameters	_	
98-25	17979-17980	:	_	
98-26	17981-17983	TR	_	
98-27	17984-17985	=	_	
98-28	17986-17990	1100	_	
98-29	17991-17993	ms	_	
98-30	17993-17994	,	_	
98-31	17995-17997	TE	_	
98-32	17998-17999	=	_	
98-33	18000-18002	30	_	
98-34	18003-18005	ms	_	
98-35	18005-18006	,	_	
98-36	18007-18011	flip	_	
98-37	18012-18017	angle	_	
98-38	18018-18019	=	_	
98-39	18020-18022	65	_	
98-40	18022-18023	°	_	
98-41	18023-18024	,	_	
98-42	18025-18029	ipat	_	
98-43	18030-18036	factor	_	
98-44	18037-18038	=	_	
98-45	18039-18040	3	_	
98-46	18040-18041	,	_	
98-47	18042-18048	matrix	_	
98-48	18049-18051	64	_	
98-49	18052-18053	×	_	
98-50	18054-18056	64	_	
98-51	18056-18057	,	_	
98-52	18058-18063	field	_	
98-53	18064-18066	of	_	
98-54	18067-18071	view	_	
98-55	18072-18073	=	_	
98-56	18074-18078	19.2	_	
98-57	18079-18081	cm	_	
98-58	18081-18082	,	_	
98-59	18083-18088	slice	_	
98-60	18089-18098	thickness	_	
98-61	18099-18100	=	_	
98-62	18101-18104	3.0	_	
98-63	18105-18107	mm	_	
98-64	18108-18112	with	_	
98-65	18113-18115	no	_	
98-66	18116-18119	gap	_	
98-67	18119-18120	,	_	
98-68	18121-18125	with	_	
98-69	18126-18128	48	_	
98-70	18129-18135	slices	_	
98-71	18136-18138	to	_	
98-72	18139-18144	cover	_	
98-73	18145-18148	the	_	
98-74	18149-18155	entire	_	
98-75	18156-18161	brain	_	
98-76	18161-18162	.	_	

#Text=All scans are conducted at the MUSC Center for Biomedical Imaging, which houses a Siemens 3 T Prisma MRI scanner (Siemens Medical, Erlangen, Germany).
99-1	18163-18166	All	_	
99-2	18167-18172	scans	_	
99-3	18173-18176	are	_	
99-4	18177-18186	conducted	_	
99-5	18187-18189	at	_	
99-6	18190-18193	the	_	
99-7	18194-18198	MUSC	_	
99-8	18199-18205	Center	_	
99-9	18206-18209	for	_	
99-10	18210-18220	Biomedical	_	
99-11	18221-18228	Imaging	_	
99-12	18228-18229	,	_	
99-13	18230-18235	which	_	
99-14	18236-18242	houses	_	
99-15	18243-18244	a	_	
99-16	18245-18252	Siemens	_	
99-17	18253-18254	3	_	
99-18	18255-18256	T	_	
99-19	18257-18263	Prisma	_	
99-20	18264-18267	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	
99-21	18268-18275	scanner	_	
99-22	18276-18277	(	_	
99-23	18277-18284	Siemens	_	
99-24	18285-18292	Medical	_	
99-25	18292-18293	,	_	
99-26	18294-18302	Erlangen	_	
99-27	18302-18303	,	_	
99-28	18304-18311	Germany	_	
99-29	18311-18312	)	_	
99-30	18312-18313	.	_	

#Text=Data analytic plan
#Text=General considerations and power
#Text=Analyses will be performed on the intent-to-treat (ITT) sample consisting of all randomized participants who provide any outcome data.
100-1	18314-18318	Data	_	
100-2	18319-18327	analytic	_	
100-3	18328-18332	plan	_	
100-4	18333-18340	General	_	
100-5	18341-18355	considerations	_	
100-6	18356-18359	and	_	
100-7	18360-18365	power	_	
100-8	18366-18374	Analyses	_	
100-9	18375-18379	will	_	
100-10	18380-18382	be	_	
100-11	18383-18392	performed	_	
100-12	18393-18395	on	_	
100-13	18396-18399	the	_	
100-14	18400-18415	intent-to-treat	_	
100-15	18416-18417	(	_	
100-16	18417-18420	ITT	_	
100-17	18420-18421	)	_	
100-18	18422-18428	sample	_	
100-19	18429-18439	consisting	_	
100-20	18440-18442	of	_	
100-21	18443-18446	all	_	
100-22	18447-18457	randomized	_	
100-23	18458-18470	participants	_	
100-24	18471-18474	who	_	
100-25	18475-18482	provide	_	
100-26	18483-18486	any	_	
100-27	18487-18494	outcome	_	
100-28	18495-18499	data	_	
100-29	18499-18500	.	_	

#Text=Baseline clinical and demographic characteristics are collected, and contrasts will be performed between treatment groups.
101-1	18501-18509	Baseline	_	
101-2	18510-18518	clinical	_	
101-3	18519-18522	and	_	
101-4	18523-18534	demographic	_	
101-5	18535-18550	characteristics	_	
101-6	18551-18554	are	_	
101-7	18555-18564	collected	_	
101-8	18564-18565	,	_	
101-9	18566-18569	and	_	
101-10	18570-18579	contrasts	_	
101-11	18580-18584	will	_	
101-12	18585-18587	be	_	
101-13	18588-18597	performed	_	
101-14	18598-18605	between	_	
101-15	18606-18615	treatment	_	
101-16	18616-18622	groups	_	
101-17	18622-18623	.	_	

#Text=This study is powered to estimate the effects of doxazosin on significant reduction in PTSD symptoms at the end of treatment (see Hypothesis 1), and increased abstinence rates at the end of treatment (Hypothesis 2).
102-1	18624-18628	This	_	
102-2	18629-18634	study	_	
102-3	18635-18637	is	_	
102-4	18638-18645	powered	_	
102-5	18646-18648	to	_	
102-6	18649-18657	estimate	_	
102-7	18658-18661	the	_	
102-8	18662-18669	effects	_	
102-9	18670-18672	of	_	
102-10	18673-18682	doxazosin	_	
102-11	18683-18685	on	_	
102-12	18686-18697	significant	_	
102-13	18698-18707	reduction	_	
102-14	18708-18710	in	_	
102-15	18711-18715	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
102-16	18716-18724	symptoms	_	
102-17	18725-18727	at	_	
102-18	18728-18731	the	_	
102-19	18732-18735	end	_	
102-20	18736-18738	of	_	
102-21	18739-18748	treatment	_	
102-22	18749-18750	(	_	
102-23	18750-18753	see	_	
102-24	18754-18764	Hypothesis	_	
102-25	18765-18766	1	_	
102-26	18766-18767	)	_	
102-27	18767-18768	,	_	
102-28	18769-18772	and	_	
102-29	18773-18782	increased	_	
102-30	18783-18793	abstinence	_	
102-31	18794-18799	rates	_	
102-32	18800-18802	at	_	
102-33	18803-18806	the	_	
102-34	18807-18810	end	_	
102-35	18811-18813	of	_	
102-36	18814-18823	treatment	_	
102-37	18824-18825	(	_	
102-38	18825-18835	Hypothesis	_	
102-39	18836-18837	2	_	
102-40	18837-18838	)	_	
102-41	18838-18839	.	_	

#Text=Placebo rates of reduction in CAPS scores are conservatively estimated to be 20%.
103-1	18840-18847	Placebo	_	
103-2	18848-18853	rates	_	
103-3	18854-18856	of	_	
103-4	18857-18866	reduction	_	
103-5	18867-18869	in	_	
103-6	18870-18874	CAPS	_	
103-7	18875-18881	scores	_	
103-8	18882-18885	are	_	
103-9	18886-18900	conservatively	_	
103-10	18901-18910	estimated	_	
103-11	18911-18913	to	_	
103-12	18914-18916	be	_	
103-13	18917-18920	20%	_	
103-14	18920-18921	.	_	

#Text=In a small pilot study, De Jong et al. found ~31% reduction in CAPS total scores using doxazosin.
104-1	18922-18924	In	_	
104-2	18925-18926	a	_	
104-3	18927-18932	small	_	
104-4	18933-18938	pilot	_	
104-5	18939-18944	study	_	
104-6	18944-18945	,	_	
104-7	18946-18948	De	_	
104-8	18949-18953	Jong	_	
104-9	18954-18956	et	_	
104-10	18957-18959	al	_	
104-11	18959-18960	.	_	
104-12	18961-18966	found	_	
104-13	18967-18968	~	_	
104-14	18968-18971	31%	_	
104-15	18972-18981	reduction	_	
104-16	18982-18984	in	_	
104-17	18985-18989	CAPS	_	
104-18	18990-18995	total	_	
104-19	18996-19002	scores	_	
104-20	19003-19008	using	_	
104-21	19009-19018	doxazosin	_	
104-22	19018-19019	.	_	

#Text=A sample of 100 participants will provide 80% power with a 0.05 type 1 error rate to detect a difference in the reduction of CAPS scores between doxazosin (31 ± 20%) and placebo (20 ± 20%).
105-1	19020-19021	A	_	
105-2	19022-19028	sample	_	
105-3	19029-19031	of	_	
105-4	19032-19035	100	_	
105-5	19036-19048	participants	_	
105-6	19049-19053	will	_	
105-7	19054-19061	provide	_	
105-8	19062-19065	80%	_	
105-9	19066-19071	power	_	
105-10	19072-19076	with	_	
105-11	19077-19078	a	_	
105-12	19079-19083	0.05	_	
105-13	19084-19088	type	_	
105-14	19089-19090	1	_	
105-15	19091-19096	error	_	
105-16	19097-19101	rate	_	
105-17	19102-19104	to	_	
105-18	19105-19111	detect	_	
105-19	19112-19113	a	_	
105-20	19114-19124	difference	_	
105-21	19125-19127	in	_	
105-22	19128-19131	the	_	
105-23	19132-19141	reduction	_	
105-24	19142-19144	of	_	
105-25	19145-19149	CAPS	_	
105-26	19150-19156	scores	_	
105-27	19157-19164	between	_	
105-28	19165-19174	doxazosin	_	
105-29	19175-19176	(	_	
105-30	19176-19178	31	_	
105-31	19179-19180	±	_	
105-32	19181-19184	20%	_	
105-33	19184-19185	)	_	
105-34	19186-19189	and	_	
105-35	19190-19197	placebo	_	
105-36	19198-19199	(	_	
105-37	19199-19201	20	_	
105-38	19202-19203	±	_	
105-39	19204-19207	20%	_	
105-40	19207-19208	)	_	
105-41	19208-19209	.	_	

#Text=Placebo rates of abstinence are estimated from established double-blind, placebo-controlled trials.
106-1	19210-19217	Placebo	_	
106-2	19218-19223	rates	_	
106-3	19224-19226	of	_	
106-4	19227-19237	abstinence	_	
106-5	19238-19241	are	_	
106-6	19242-19251	estimated	_	
106-7	19252-19256	from	_	
106-8	19257-19268	established	_	
106-9	19269-19281	double-blind	_	
106-10	19281-19282	,	_	
106-11	19283-19301	placebo-controlled	_	
106-12	19302-19308	trials	_	
106-13	19308-19309	.	_	

#Text=Continuous abstinence from weeks 9–12 is observed in 10–15% of treatment seekers without co-occurring PTSD so we anticipate an attenuated rate of 5–10% in the placebo group.
107-1	19310-19320	Continuous	_	
107-2	19321-19331	abstinence	_	
107-3	19332-19336	from	_	
107-4	19337-19342	weeks	_	
107-5	19343-19344	9	_	
107-6	19344-19345	–	_	
107-7	19345-19347	12	_	
107-8	19348-19350	is	_	
107-9	19351-19359	observed	_	
107-10	19360-19362	in	_	
107-11	19363-19365	10	_	
107-12	19365-19366	–	_	
107-13	19366-19369	15%	_	
107-14	19370-19372	of	_	
107-15	19373-19382	treatment	_	
107-16	19383-19390	seekers	_	
107-17	19391-19398	without	_	
107-18	19399-19411	co-occurring	_	
107-19	19412-19416	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
107-20	19417-19419	so	_	
107-21	19420-19422	we	_	
107-22	19423-19433	anticipate	_	
107-23	19434-19436	an	_	
107-24	19437-19447	attenuated	_	
107-25	19448-19452	rate	_	
107-26	19453-19455	of	_	
107-27	19456-19457	5	_	
107-28	19457-19458	–	_	
107-29	19458-19461	10%	_	
107-30	19462-19464	in	_	
107-31	19465-19468	the	_	
107-32	19469-19476	placebo	_	
107-33	19477-19482	group	_	
107-34	19482-19483	.	_	

#Text=Although there is limited information on the effectiveness of doxazosin in AUD, a sample of 100 participants (50 in each arm) will provide adequate power to detect an abstinence rate as low as 32% in the doxazosin group when the placebo cessation rate is 10%, and as low as 23% when the placebo rate is 5%.
108-1	19484-19492	Although	_	
108-2	19493-19498	there	_	
108-3	19499-19501	is	_	
108-4	19502-19509	limited	_	
108-5	19510-19521	information	_	
108-6	19522-19524	on	_	
108-7	19525-19528	the	_	
108-8	19529-19542	effectiveness	_	
108-9	19543-19545	of	_	
108-10	19546-19555	doxazosin	_	
108-11	19556-19558	in	_	
108-12	19559-19562	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
108-13	19562-19563	,	_	
108-14	19564-19565	a	_	
108-15	19566-19572	sample	_	
108-16	19573-19575	of	_	
108-17	19576-19579	100	_	
108-18	19580-19592	participants	_	
108-19	19593-19594	(	_	
108-20	19594-19596	50	_	
108-21	19597-19599	in	_	
108-22	19600-19604	each	_	
108-23	19605-19608	arm	_	
108-24	19608-19609	)	_	
108-25	19610-19614	will	_	
108-26	19615-19622	provide	_	
108-27	19623-19631	adequate	_	
108-28	19632-19637	power	_	
108-29	19638-19640	to	_	
108-30	19641-19647	detect	_	
108-31	19648-19650	an	_	
108-32	19651-19661	abstinence	_	
108-33	19662-19666	rate	_	
108-34	19667-19669	as	_	
108-35	19670-19673	low	_	
108-36	19674-19676	as	_	
108-37	19677-19680	32%	_	
108-38	19681-19683	in	_	
108-39	19684-19687	the	_	
108-40	19688-19697	doxazosin	_	
108-41	19698-19703	group	_	
108-42	19704-19708	when	_	
108-43	19709-19712	the	_	
108-44	19713-19720	placebo	_	
108-45	19721-19730	cessation	_	
108-46	19731-19735	rate	_	
108-47	19736-19738	is	_	
108-48	19739-19742	10%	_	
108-49	19742-19743	,	_	
108-50	19744-19747	and	_	
108-51	19748-19750	as	_	
108-52	19751-19754	low	_	
108-53	19755-19757	as	_	
108-54	19758-19761	23%	_	
108-55	19762-19766	when	_	
108-56	19767-19770	the	_	
108-57	19771-19778	placebo	_	
108-58	19779-19783	rate	_	
108-59	19784-19786	is	_	
108-60	19787-19789	5%	_	
108-61	19789-19790	.	_	

#Text=Due to the nature of the study population, we anticipate ~30% dropout rate; thus, the number of subjects randomized is inflated to 144 with 72 participants randomized to each treatment arm of the study.
109-1	19791-19794	Due	_	
109-2	19795-19797	to	_	
109-3	19798-19801	the	_	
109-4	19802-19808	nature	_	
109-5	19809-19811	of	_	
109-6	19812-19815	the	_	
109-7	19816-19821	study	_	
109-8	19822-19832	population	_	
109-9	19832-19833	,	_	
109-10	19834-19836	we	_	
109-11	19837-19847	anticipate	_	
109-12	19848-19849	~	_	
109-13	19849-19852	30%	_	
109-14	19853-19860	dropout	_	
109-15	19861-19865	rate	_	
109-16	19865-19866	;	_	
109-17	19867-19871	thus	_	
109-18	19871-19872	,	_	
109-19	19873-19876	the	_	
109-20	19877-19883	number	_	
109-21	19884-19886	of	_	
109-22	19887-19895	subjects	_	
109-23	19896-19906	randomized	_	
109-24	19907-19909	is	_	
109-25	19910-19918	inflated	_	
109-26	19919-19921	to	_	
109-27	19922-19925	144	_	
109-28	19926-19930	with	_	
109-29	19931-19933	72	_	
109-30	19934-19946	participants	_	
109-31	19947-19957	randomized	_	
109-32	19958-19960	to	_	
109-33	19961-19965	each	_	
109-34	19966-19975	treatment	_	
109-35	19976-19979	arm	_	
109-36	19980-19982	of	_	
109-37	19983-19986	the	_	
109-38	19987-19992	study	_	
109-39	19992-19993	.	_	

#Text=Clinical outcomes
#Text=To test hypothesis 1 that participants who receive doxazosin, as compared to placebo, will evidence significantly greater reductions in PTSD severity, restricted maximum likelihood (REML) methods will be used to estimate the fixed effects and variance components, and modelbased treatment effect estimates will be used to construct group level tests over time.
110-1	19994-20002	Clinical	_	
110-2	20003-20011	outcomes	_	
110-3	20012-20014	To	_	
110-4	20015-20019	test	_	
110-5	20020-20030	hypothesis	_	
110-6	20031-20032	1	_	
110-7	20033-20037	that	_	
110-8	20038-20050	participants	_	
110-9	20051-20054	who	_	
110-10	20055-20062	receive	_	
110-11	20063-20072	doxazosin	_	
110-12	20072-20073	,	_	
110-13	20074-20076	as	_	
110-14	20077-20085	compared	_	
110-15	20086-20088	to	_	
110-16	20089-20096	placebo	_	
110-17	20096-20097	,	_	
110-18	20098-20102	will	_	
110-19	20103-20111	evidence	_	
110-20	20112-20125	significantly	_	
110-21	20126-20133	greater	_	
110-22	20134-20144	reductions	_	
110-23	20145-20147	in	_	
110-24	20148-20152	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
110-25	20153-20161	severity	_	
110-26	20161-20162	,	_	
110-27	20163-20173	restricted	_	
110-28	20174-20181	maximum	_	
110-29	20182-20192	likelihood	_	
110-30	20193-20194	(	_	
110-31	20194-20198	REML	_	
110-32	20198-20199	)	_	
110-33	20200-20207	methods	_	
110-34	20208-20212	will	_	
110-35	20213-20215	be	_	
110-36	20216-20220	used	_	
110-37	20221-20223	to	_	
110-38	20224-20232	estimate	_	
110-39	20233-20236	the	_	
110-40	20237-20242	fixed	_	
110-41	20243-20250	effects	_	
110-42	20251-20254	and	_	
110-43	20255-20263	variance	_	
110-44	20264-20274	components	_	
110-45	20274-20275	,	_	
110-46	20276-20279	and	_	
110-47	20280-20290	modelbased	_	
110-48	20291-20300	treatment	_	
110-49	20301-20307	effect	_	
110-50	20308-20317	estimates	_	
110-51	20318-20322	will	_	
110-52	20323-20325	be	_	
110-53	20326-20330	used	_	
110-54	20331-20333	to	_	
110-55	20334-20343	construct	_	
110-56	20344-20349	group	_	
110-57	20350-20355	level	_	
110-58	20356-20361	tests	_	
110-59	20362-20366	over	_	
110-60	20367-20371	time	_	
110-61	20371-20372	.	_	

#Text=To test hypothesis 2 that participants who receive doxazosin, as compared to placebo, will evidence significantly greater reductions in AUD severity, logistic regression analysis will be used to examine rates of abstinence.
111-1	20373-20375	To	_	
111-2	20376-20380	test	_	
111-3	20381-20391	hypothesis	_	
111-4	20392-20393	2	_	
111-5	20394-20398	that	_	
111-6	20399-20411	participants	_	
111-7	20412-20415	who	_	
111-8	20416-20423	receive	_	
111-9	20424-20433	doxazosin	_	
111-10	20433-20434	,	_	
111-11	20435-20437	as	_	
111-12	20438-20446	compared	_	
111-13	20447-20449	to	_	
111-14	20450-20457	placebo	_	
111-15	20457-20458	,	_	
111-16	20459-20463	will	_	
111-17	20464-20472	evidence	_	
111-18	20473-20486	significantly	_	
111-19	20487-20494	greater	_	
111-20	20495-20505	reductions	_	
111-21	20506-20508	in	_	
111-22	20509-20512	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
111-23	20513-20521	severity	_	
111-24	20521-20522	,	_	
111-25	20523-20531	logistic	_	
111-26	20532-20542	regression	_	
111-27	20543-20551	analysis	_	
111-28	20552-20556	will	_	
111-29	20557-20559	be	_	
111-30	20560-20564	used	_	
111-31	20565-20567	to	_	
111-32	20568-20575	examine	_	
111-33	20576-20581	rates	_	
111-34	20582-20584	of	_	
111-35	20585-20595	abstinence	_	
111-36	20595-20596	.	_	

#Text=Weekly point prevalence abstinence will be examined using generalized linear models under a generalized estimating equations (GEE) framework.
112-1	20597-20603	Weekly	_	
112-2	20604-20609	point	_	
112-3	20610-20620	prevalence	_	
112-4	20621-20631	abstinence	_	
112-5	20632-20636	will	_	
112-6	20637-20639	be	_	
112-7	20640-20648	examined	_	
112-8	20649-20654	using	_	
112-9	20655-20666	generalized	_	
112-10	20667-20673	linear	_	
112-11	20674-20680	models	_	
112-12	20681-20686	under	_	
112-13	20687-20688	a	_	
112-14	20689-20700	generalized	_	
112-15	20701-20711	estimating	_	
112-16	20712-20721	equations	_	
112-17	20722-20723	(	_	
112-18	20723-20726	GEE	_	
112-19	20726-20727	)	_	
112-20	20728-20737	framework	_	
112-21	20737-20738	.	_	

#Text=Weekly abstinence (yes/no) as well as amounts of alcohol use (standard drink units) will be examined over time to determine if treatment is effective in reducing alcohol consumption when abstinence is not achieved.
113-1	20739-20745	Weekly	_	
113-2	20746-20756	abstinence	_	
113-3	20757-20758	(	_	
113-4	20758-20761	yes	_	
113-5	20761-20762	/	_	
113-6	20762-20764	no	_	
113-7	20764-20765	)	_	
113-8	20766-20768	as	_	
113-9	20769-20773	well	_	
113-10	20774-20776	as	_	
113-11	20777-20784	amounts	_	
113-12	20785-20787	of	_	
113-13	20788-20795	alcohol	_	
113-14	20796-20799	use	_	
113-15	20800-20801	(	_	
113-16	20801-20809	standard	_	
113-17	20810-20815	drink	_	
113-18	20816-20821	units	_	
113-19	20821-20822	)	_	
113-20	20823-20827	will	_	
113-21	20828-20830	be	_	
113-22	20831-20839	examined	_	
113-23	20840-20844	over	_	
113-24	20845-20849	time	_	
113-25	20850-20852	to	_	
113-26	20853-20862	determine	_	
113-27	20863-20865	if	_	
113-28	20866-20875	treatment	_	
113-29	20876-20878	is	_	
113-30	20879-20888	effective	_	
113-31	20889-20891	in	_	
113-32	20892-20900	reducing	_	
113-33	20901-20908	alcohol	_	
113-34	20909-20920	consumption	_	
113-35	20921-20925	when	_	
113-36	20926-20936	abstinence	_	
113-37	20937-20939	is	_	
113-38	20940-20943	not	_	
113-39	20944-20952	achieved	_	
113-40	20952-20953	.	_	

#Text=Neuroimaging outcomes
#Text=We will measure functional connectivity using a psychophysiological interaction (PPI) seed-based approach.
114-1	20954-20966	Neuroimaging	_	
114-2	20967-20975	outcomes	_	
114-3	20976-20978	We	_	
114-4	20979-20983	will	_	
114-5	20984-20991	measure	_	
114-6	20992-21002	functional	_	
114-7	21003-21015	connectivity	_	
114-8	21016-21021	using	_	
114-9	21022-21023	a	_	
114-10	21024-21043	psychophysiological	_	
114-11	21044-21055	interaction	_	
114-12	21056-21057	(	_	
114-13	21057-21060	PPI	_	
114-14	21060-21061	)	_	
114-15	21062-21072	seed-based	_	
114-16	21073-21081	approach	_	
114-17	21081-21082	.	_	

#Text=PPI is a method for investigating task-specific changes in the relationship between activity in different brain areas.
115-1	21083-21086	PPI	_	
115-2	21087-21089	is	_	
115-3	21090-21091	a	_	
115-4	21092-21098	method	_	
115-5	21099-21102	for	_	
115-6	21103-21116	investigating	_	
115-7	21117-21130	task-specific	_	
115-8	21131-21138	changes	_	
115-9	21139-21141	in	_	
115-10	21142-21145	the	_	
115-11	21146-21158	relationship	_	
115-12	21159-21166	between	_	
115-13	21167-21175	activity	_	
115-14	21176-21178	in	_	
115-15	21179-21188	different	_	
115-16	21189-21194	brain	_	
115-17	21195-21200	areas	_	
115-18	21200-21201	.	_	

#Text=Following acquisition, preprocessing of the imaging data will correct for geometric distortion, head motion or other artifacts.
116-1	21202-21211	Following	_	
116-2	21212-21223	acquisition	_	
116-3	21223-21224	,	_	
116-4	21225-21238	preprocessing	_	
116-5	21239-21241	of	_	
116-6	21242-21245	the	_	
116-7	21246-21253	imaging	_	
116-8	21254-21258	data	_	
116-9	21259-21263	will	_	
116-10	21264-21271	correct	_	
116-11	21272-21275	for	_	
116-12	21276-21285	geometric	_	
116-13	21286-21296	distortion	_	
116-14	21296-21297	,	_	
116-15	21298-21302	head	_	
116-16	21303-21309	motion	_	
116-17	21310-21312	or	_	
116-18	21313-21318	other	_	
116-19	21319-21328	artifacts	_	
116-20	21328-21329	.	_	

#Text=A mask of the two seed regions will be made using a 12-mm diameter sphere located in the center of the left and right amygdala using the Montreal Neurological Institute coordinates (x, y, z = ± 22, 0, −22).
117-1	21330-21331	A	_	
117-2	21332-21336	mask	_	
117-3	21337-21339	of	_	
117-4	21340-21343	the	_	
117-5	21344-21347	two	_	
117-6	21348-21352	seed	_	
117-7	21353-21360	regions	_	
117-8	21361-21365	will	_	
117-9	21366-21368	be	_	
117-10	21369-21373	made	_	
117-11	21374-21379	using	_	
117-12	21380-21381	a	_	
117-13	21382-21384	12	_	
117-14	21384-21385	-	_	
117-15	21385-21387	mm	_	
117-16	21388-21396	diameter	_	
117-17	21397-21403	sphere	_	
117-18	21404-21411	located	_	
117-19	21412-21414	in	_	
117-20	21415-21418	the	_	
117-21	21419-21425	center	_	
117-22	21426-21428	of	_	
117-23	21429-21432	the	_	
117-24	21433-21437	left	_	
117-25	21438-21441	and	_	
117-26	21442-21447	right	_	
117-27	21448-21456	amygdala	_	
117-28	21457-21462	using	_	
117-29	21463-21466	the	_	
117-30	21467-21475	Montreal	_	
117-31	21476-21488	Neurological	_	
117-32	21489-21498	Institute	_	
117-33	21499-21510	coordinates	_	
117-34	21511-21512	(	_	
117-35	21512-21513	x	_	
117-36	21513-21514	,	_	
117-37	21515-21516	y	_	
117-38	21516-21517	,	_	
117-39	21518-21519	z	_	
117-40	21520-21521	=	_	
117-41	21522-21523	±	_	
117-42	21524-21526	22	_	
117-43	21526-21527	,	_	
117-44	21528-21529	0	_	
117-45	21529-21530	,	_	
117-46	21531-21532	−	_	
117-47	21532-21534	22	_	
117-48	21534-21535	)	_	
117-49	21535-21536	.	_	

#Text=For each participant, the mean corrected and high pass temporal filtered time series of the blood-oxygen-level dependent (BOLD) signal in the amygdala will be extracted using ‘fslmeants’ and used in a single subject whole brain PPI analysis.
118-1	21537-21540	For	_	
118-2	21541-21545	each	_	
118-3	21546-21557	participant	_	
118-4	21557-21558	,	_	
118-5	21559-21562	the	_	
118-6	21563-21567	mean	_	
118-7	21568-21577	corrected	_	
118-8	21578-21581	and	_	
118-9	21582-21586	high	_	
118-10	21587-21591	pass	_	
118-11	21592-21600	temporal	_	
118-12	21601-21609	filtered	_	
118-13	21610-21614	time	_	
118-14	21615-21621	series	_	
118-15	21622-21624	of	_	
118-16	21625-21628	the	_	
118-17	21629-21647	blood-oxygen-level	_	
118-18	21648-21657	dependent	_	
118-19	21658-21659	(	_	
118-20	21659-21663	BOLD	_	
118-21	21663-21664	)	_	
118-22	21665-21671	signal	_	
118-23	21672-21674	in	_	
118-24	21675-21678	the	_	
118-25	21679-21687	amygdala	_	
118-26	21688-21692	will	_	
118-27	21693-21695	be	_	
118-28	21696-21705	extracted	_	
118-29	21706-21711	using	_	
118-30	21712-21713	‘	_	
118-31	21713-21722	fslmeants	_	
118-32	21722-21723	’	_	
118-33	21724-21727	and	_	
118-34	21728-21732	used	_	
118-35	21733-21735	in	_	
118-36	21736-21737	a	_	
118-37	21738-21744	single	_	
118-38	21745-21752	subject	_	
118-39	21753-21758	whole	_	
118-40	21759-21764	brain	_	
118-41	21765-21768	PPI	_	
118-42	21769-21777	analysis	_	
118-43	21777-21778	.	_	

#Text=Statistical analysis will be performed at the individual-subject level using FEAT (FMRI Expert Analysis Tool).
119-1	21779-21790	Statistical	_	
119-2	21791-21799	analysis	_	
119-3	21800-21804	will	_	
119-4	21805-21807	be	_	
119-5	21808-21817	performed	_	
119-6	21818-21820	at	_	
119-7	21821-21824	the	_	
119-8	21825-21843	individual-subject	_	
119-9	21844-21849	level	_	
119-10	21850-21855	using	_	
119-11	21856-21860	FEAT	_	
119-12	21861-21862	(	_	
119-13	21862-21866	FMRI	_	
119-14	21867-21873	Expert	_	
119-15	21874-21882	Analysis	_	
119-16	21883-21887	Tool	_	
119-17	21887-21888	)	_	
119-18	21888-21889	.	_	

#Text=The interactions of interest are the trauma (v. neutral) × (left or right) amygdala time series and the alcohol (v. neutral) × (left or right) amygdala.
120-1	21890-21893	The	_	
120-2	21894-21906	interactions	_	
120-3	21907-21909	of	_	
120-4	21910-21918	interest	_	
120-5	21919-21922	are	_	
120-6	21923-21926	the	_	
120-7	21927-21933	trauma	_	
120-8	21934-21935	(	_	
120-9	21935-21936	v	_	
120-10	21936-21937	.	_	
120-11	21938-21945	neutral	_	
120-12	21945-21946	)	_	
120-13	21947-21948	×	_	
120-14	21949-21950	(	_	
120-15	21950-21954	left	_	
120-16	21955-21957	or	_	
120-17	21958-21963	right	_	
120-18	21963-21964	)	_	
120-19	21965-21973	amygdala	_	
120-20	21974-21978	time	_	
120-21	21979-21985	series	_	
120-22	21986-21989	and	_	
120-23	21990-21993	the	_	
120-24	21994-22001	alcohol	_	
120-25	22002-22003	(	_	
120-26	22003-22004	v	_	
120-27	22004-22005	.	_	
120-28	22006-22013	neutral	_	
120-29	22013-22014	)	_	
120-30	22015-22016	×	_	
120-31	22017-22018	(	_	
120-32	22018-22022	left	_	
120-33	22023-22025	or	_	
120-34	22026-22031	right	_	
120-35	22031-22032	)	_	
120-36	22033-22041	amygdala	_	
120-37	22041-22042	.	_	

#Text=A group-level analysis will use a mixed effects approach, with separate group analyses for left and right amygdala.
121-1	22043-22044	A	_	
121-2	22045-22056	group-level	_	
121-3	22057-22065	analysis	_	
121-4	22066-22070	will	_	
121-5	22071-22074	use	_	
121-6	22075-22076	a	_	
121-7	22077-22082	mixed	_	
121-8	22083-22090	effects	_	
121-9	22091-22099	approach	_	
121-10	22099-22100	,	_	
121-11	22101-22105	with	_	
121-12	22106-22114	separate	_	
121-13	22115-22120	group	_	
121-14	22121-22129	analyses	_	
121-15	22130-22133	for	_	
121-16	22134-22138	left	_	
121-17	22139-22142	and	_	
121-18	22143-22148	right	_	
121-19	22149-22157	amygdala	_	
121-20	22157-22158	.	_	

#Text=For resting state fMRI analysis, a seed-based approach will also be used with the same amygdala seed regions used in the PPI analysis.
122-1	22159-22162	For	_	
122-2	22163-22170	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
122-3	22171-22176	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
122-4	22177-22181	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging[26]	
122-5	22182-22190	analysis	_	
122-6	22190-22191	,	_	
122-7	22192-22193	a	_	
122-8	22194-22204	seed-based	_	
122-9	22205-22213	approach	_	
122-10	22214-22218	will	_	
122-11	22219-22223	also	_	
122-12	22224-22226	be	_	
122-13	22227-22231	used	_	
122-14	22232-22236	with	_	
122-15	22237-22240	the	_	
122-16	22241-22245	same	_	
122-17	22246-22254	amygdala	_	
122-18	22255-22259	seed	_	
122-19	22260-22267	regions	_	
122-20	22268-22272	used	_	
122-21	22273-22275	in	_	
122-22	22276-22279	the	_	
122-23	22280-22283	PPI	_	
122-24	22284-22292	analysis	_	
122-25	22292-22293	.	_	

#Text=Group level analyses and extraction of parameter estimates from prefrontal cortex (PFC) regions will be the same as for the PPI analysis.
123-1	22294-22299	Group	_	
123-2	22300-22305	level	_	
123-3	22306-22314	analyses	_	
123-4	22315-22318	and	_	
123-5	22319-22329	extraction	_	
123-6	22330-22332	of	_	
123-7	22333-22342	parameter	_	
123-8	22343-22352	estimates	_	
123-9	22353-22357	from	_	
123-10	22358-22368	prefrontal	_	
123-11	22369-22375	cortex	_	
123-12	22376-22377	(	_	
123-13	22377-22380	PFC	_	
123-14	22380-22381	)	_	
123-15	22382-22389	regions	_	
123-16	22390-22394	will	_	
123-17	22395-22397	be	_	
123-18	22398-22401	the	_	
123-19	22402-22406	same	_	
123-20	22407-22409	as	_	
123-21	22410-22413	for	_	
123-22	22414-22417	the	_	
123-23	22418-22421	PPI	_	
123-24	22422-22430	analysis	_	
123-25	22430-22431	.	_	

#Text=To test hypotheses 3A and 3B that connectivity between the PFC and the left or right amygdala in response to cues at baseline will predict change in PTSD and AUD severity due to treatment, separate linear regression tests will be used.
124-1	22432-22434	To	_	
124-2	22435-22439	test	_	
124-3	22440-22450	hypotheses	_	
124-4	22451-22453	3A	_	
124-5	22454-22457	and	_	
124-6	22458-22460	3B	_	
124-7	22461-22465	that	_	
124-8	22466-22478	connectivity	_	
124-9	22479-22486	between	_	
124-10	22487-22490	the	_	
124-11	22491-22494	PFC	_	
124-12	22495-22498	and	_	
124-13	22499-22502	the	_	
124-14	22503-22507	left	_	
124-15	22508-22510	or	_	
124-16	22511-22516	right	_	
124-17	22517-22525	amygdala	_	
124-18	22526-22528	in	_	
124-19	22529-22537	response	_	
124-20	22538-22540	to	_	
124-21	22541-22545	cues	_	
124-22	22546-22548	at	_	
124-23	22549-22557	baseline	_	
124-24	22558-22562	will	_	
124-25	22563-22570	predict	_	
124-26	22571-22577	change	_	
124-27	22578-22580	in	_	
124-28	22581-22585	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
124-29	22586-22589	and	_	
124-30	22590-22593	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
124-31	22594-22602	severity	_	
124-32	22603-22606	due	_	
124-33	22607-22609	to	_	
124-34	22610-22619	treatment	_	
124-35	22619-22620	,	_	
124-36	22621-22629	separate	_	
124-37	22630-22636	linear	_	
124-38	22637-22647	regression	_	
124-39	22648-22653	tests	_	
124-40	22654-22658	will	_	
124-41	22659-22661	be	_	
124-42	22662-22666	used	_	
124-43	22666-22667	.	_	

#Text=Changes in PTSD and AUD severity will be regressed against the parameter estimate obtained from the voxel with the maximum Z-score from each PFC cluster that exhibited a significant association with the amygdala time series at rest, and a significant task × seed interaction with the amygdala in response to the trauma cue (Hypothesis 3A) and alcohol cue (Hypothesis 3B).
125-1	22668-22675	Changes	_	
125-2	22676-22678	in	_	
125-3	22679-22683	PTSD	http://maven.renci.org/NeuroBridge/neurobridge#PostTraumaticStressDisorder	
125-4	22684-22687	and	_	
125-5	22688-22691	AUD	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	
125-6	22692-22700	severity	_	
125-7	22701-22705	will	_	
125-8	22706-22708	be	_	
125-9	22709-22718	regressed	_	
125-10	22719-22726	against	_	
125-11	22727-22730	the	_	
125-12	22731-22740	parameter	_	
125-13	22741-22749	estimate	_	
125-14	22750-22758	obtained	_	
125-15	22759-22763	from	_	
125-16	22764-22767	the	_	
125-17	22768-22773	voxel	_	
125-18	22774-22778	with	_	
125-19	22779-22782	the	_	
125-20	22783-22790	maximum	_	
125-21	22791-22798	Z-score	_	
125-22	22799-22803	from	_	
125-23	22804-22808	each	_	
125-24	22809-22812	PFC	_	
125-25	22813-22820	cluster	_	
125-26	22821-22825	that	_	
125-27	22826-22835	exhibited	_	
125-28	22836-22837	a	_	
125-29	22838-22849	significant	_	
125-30	22850-22861	association	_	
125-31	22862-22866	with	_	
125-32	22867-22870	the	_	
125-33	22871-22879	amygdala	_	
125-34	22880-22884	time	_	
125-35	22885-22891	series	_	
125-36	22892-22894	at	_	
125-37	22895-22899	rest	_	
125-38	22899-22900	,	_	
125-39	22901-22904	and	_	
125-40	22905-22906	a	_	
125-41	22907-22918	significant	_	
125-42	22919-22923	task	_	
125-43	22924-22925	×	_	
125-44	22926-22930	seed	_	
125-45	22931-22942	interaction	_	
125-46	22943-22947	with	_	
125-47	22948-22951	the	_	
125-48	22952-22960	amygdala	_	
125-49	22961-22963	in	_	
125-50	22964-22972	response	_	
125-51	22973-22975	to	_	
125-52	22976-22979	the	_	
125-53	22980-22986	trauma	_	
125-54	22987-22990	cue	_	
125-55	22991-22992	(	_	
125-56	22992-23002	Hypothesis	_	
125-57	23003-23005	3A	_	
125-58	23005-23006	)	_	
125-59	23007-23010	and	_	
125-60	23011-23018	alcohol	_	
125-61	23019-23022	cue	_	
125-62	23023-23024	(	_	
125-63	23024-23034	Hypothesis	_	
125-64	23035-23037	3B	_	
125-65	23037-23038	)	_	
125-66	23038-23039	.	_	

#Text=Discussion
#Text=This paper presents the research design and methodology for an ongoing RCT that is part of the national Consortium to Alleviate PTSD and is the first to investigate doxazosin in the treatment of comorbid PTSD/AUD.
126-1	23040-23050	Discussion	_	
126-2	23051-23055	This	_	
126-3	23056-23061	paper	_	
126-4	23062-23070	presents	_	
126-5	23071-23074	the	_	
126-6	23075-23083	research	_	
126-7	23084-23090	design	_	
126-8	23091-23094	and	_	
126-9	23095-23106	methodology	_	
126-10	23107-23110	for	_	
126-11	23111-23113	an	_	
126-12	23114-23121	ongoing	_	
126-13	23122-23125	RCT	_	
126-14	23126-23130	that	_	
126-15	23131-23133	is	_	
126-16	23134-23138	part	_	
126-17	23139-23141	of	_	
126-18	23142-23145	the	_	
126-19	23146-23154	national	_	
126-20	23155-23165	Consortium	_	
126-21	23166-23168	to	_	
126-22	23169-23178	Alleviate	_	
126-23	23179-23183	PTSD	_	
126-24	23184-23187	and	_	
126-25	23188-23190	is	_	
126-26	23191-23194	the	_	
126-27	23195-23200	first	_	
126-28	23201-23203	to	_	
126-29	23204-23215	investigate	_	
126-30	23216-23225	doxazosin	_	
126-31	23226-23228	in	_	
126-32	23229-23232	the	_	
126-33	23233-23242	treatment	_	
126-34	23243-23245	of	_	
126-35	23246-23254	comorbid	_	
126-36	23255-23259	PTSD	_	
126-37	23259-23260	/	_	
126-38	23260-23263	AUD	_	
126-39	23263-23264	.	_	

#Text=PTSD and AUD are chronic, debilitating and common psychiatric conditions observed in civilian and military populations.
127-1	23265-23269	PTSD	_	
127-2	23270-23273	and	_	
127-3	23274-23277	AUD	_	
127-4	23278-23281	are	_	
127-5	23282-23289	chronic	_	
127-6	23289-23290	,	_	
127-7	23291-23303	debilitating	_	
127-8	23304-23307	and	_	
127-9	23308-23314	common	_	
127-10	23315-23326	psychiatric	_	
127-11	23327-23337	conditions	_	
127-12	23338-23346	observed	_	
127-13	23347-23349	in	_	
127-14	23350-23358	civilian	_	
127-15	23359-23362	and	_	
127-16	23363-23371	military	_	
127-17	23372-23383	populations	_	
127-18	23383-23384	.	_	

#Text=The co-occurrence of PTSD and AUD is also highly prevalent, and military veterans incur a uniquely high risk of developing this complex dual diagnosis.
128-1	23385-23388	The	_	
128-2	23389-23402	co-occurrence	_	
128-3	23403-23405	of	_	
128-4	23406-23410	PTSD	_	
128-5	23411-23414	and	_	
128-6	23415-23418	AUD	_	
128-7	23419-23421	is	_	
128-8	23422-23426	also	_	
128-9	23427-23433	highly	_	
128-10	23434-23443	prevalent	_	
128-11	23443-23444	,	_	
128-12	23445-23448	and	_	
128-13	23449-23457	military	_	
128-14	23458-23466	veterans	_	
128-15	23467-23472	incur	_	
128-16	23473-23474	a	_	
128-17	23475-23483	uniquely	_	
128-18	23484-23488	high	_	
128-19	23489-23493	risk	_	
128-20	23494-23496	of	_	
128-21	23497-23507	developing	_	
128-22	23508-23512	this	_	
128-23	23513-23520	complex	_	
128-24	23521-23525	dual	_	
128-25	23526-23535	diagnosis	_	
128-26	23535-23536	.	_	

#Text=While mental health services are in place for U.S. military personnel and veterans, there are substantial gaps in the evidence base to guide the pharmacological treatment of co-occurring PTSD/AUD.
129-1	23537-23542	While	_	
129-2	23543-23549	mental	_	
129-3	23550-23556	health	_	
129-4	23557-23565	services	_	
129-5	23566-23569	are	_	
129-6	23570-23572	in	_	
129-7	23573-23578	place	_	
129-8	23579-23582	for	_	
129-9	23583-23586	U.S	_	
129-10	23586-23587	.	_	
129-11	23588-23596	military	_	
129-12	23597-23606	personnel	_	
129-13	23607-23610	and	_	
129-14	23611-23619	veterans	_	
129-15	23619-23620	,	_	
129-16	23621-23626	there	_	
129-17	23627-23630	are	_	
129-18	23631-23642	substantial	_	
129-19	23643-23647	gaps	_	
129-20	23648-23650	in	_	
129-21	23651-23654	the	_	
129-22	23655-23663	evidence	_	
129-23	23664-23668	base	_	
129-24	23669-23671	to	_	
129-25	23672-23677	guide	_	
129-26	23678-23681	the	_	
129-27	23682-23697	pharmacological	_	
129-28	23698-23707	treatment	_	
129-29	23708-23710	of	_	
129-30	23711-23723	co-occurring	_	
129-31	23724-23728	PTSD	_	
129-32	23728-23729	/	_	
129-33	23729-23732	AUD	_	
129-34	23732-23733	.	_	

#Text=Recent findings regarding several medications to treat AUD are encouraging.
130-1	23734-23740	Recent	_	
130-2	23741-23749	findings	_	
130-3	23750-23759	regarding	_	
130-4	23760-23767	several	_	
130-5	23768-23779	medications	_	
130-6	23780-23782	to	_	
130-7	23783-23788	treat	_	
130-8	23789-23792	AUD	_	
130-9	23793-23796	are	_	
130-10	23797-23808	encouraging	_	
130-11	23808-23809	.	_	

#Text=However, the only FDA-approved medications to treat substance use problems target relapse prevention.
131-1	23810-23817	However	_	
131-2	23817-23818	,	_	
131-3	23819-23822	the	_	
131-4	23823-23827	only	_	
131-5	23828-23840	FDA-approved	_	
131-6	23841-23852	medications	_	
131-7	23853-23855	to	_	
131-8	23856-23861	treat	_	
131-9	23862-23871	substance	_	
131-10	23872-23875	use	_	
131-11	23876-23884	problems	_	
131-12	23885-23891	target	_	
131-13	23892-23899	relapse	_	
131-14	23900-23910	prevention	_	
131-15	23910-23911	.	_	

#Text=While many medications have been investigated to treat PTSD, only selective serotonin reuptake inhibitors (SSRI) have received FDA approval.
132-1	23912-23917	While	_	
132-2	23918-23922	many	_	
132-3	23923-23934	medications	_	
132-4	23935-23939	have	_	
132-5	23940-23944	been	_	
132-6	23945-23957	investigated	_	
132-7	23958-23960	to	_	
132-8	23961-23966	treat	_	
132-9	23967-23971	PTSD	_	
132-10	23971-23972	,	_	
132-11	23973-23977	only	_	
132-12	23978-23987	selective	_	
132-13	23988-23997	serotonin	_	
132-14	23998-24006	reuptake	_	
132-15	24007-24017	inhibitors	_	
132-16	24018-24019	(	_	
132-17	24019-24023	SSRI	_	
132-18	24023-24024	)	_	
132-19	24025-24029	have	_	
132-20	24030-24038	received	_	
132-21	24039-24042	FDA	_	
132-22	24043-24051	approval	_	
132-23	24051-24052	.	_	

#Text=Just 20–30% of patients achieve PTSD remission with SSRI treatment.
133-1	24053-24057	Just	_	
133-2	24058-24060	20	_	
133-3	24060-24061	–	_	
133-4	24061-24064	30%	_	
133-5	24065-24067	of	_	
133-6	24068-24076	patients	_	
133-7	24077-24084	achieve	_	
133-8	24085-24089	PTSD	_	
133-9	24090-24099	remission	_	
133-10	24100-24104	with	_	
133-11	24105-24109	SSRI	_	
133-12	24110-24119	treatment	_	
133-13	24119-24120	.	_	

#Text=Few investigations have examined pharmacotherapies for co-occurring PTSD/ SUD, and those that have been conducted suggest only a modest response.
134-1	24121-24124	Few	_	
134-2	24125-24139	investigations	_	
134-3	24140-24144	have	_	
134-4	24145-24153	examined	_	
134-5	24154-24171	pharmacotherapies	_	
134-6	24172-24175	for	_	
134-7	24176-24188	co-occurring	_	
134-8	24189-24193	PTSD	_	
134-9	24193-24194	/	_	
134-10	24195-24198	SUD	_	
134-11	24198-24199	,	_	
134-12	24200-24203	and	_	
134-13	24204-24209	those	_	
134-14	24210-24214	that	_	
134-15	24215-24219	have	_	
134-16	24220-24224	been	_	
134-17	24225-24234	conducted	_	
134-18	24235-24242	suggest	_	
134-19	24243-24247	only	_	
134-20	24248-24249	a	_	
134-21	24250-24256	modest	_	
134-22	24257-24265	response	_	
134-23	24265-24266	.	_	

#Text=Therefore, identifying effective medications to treat co-occurring PTSD and SUD, particularly among military veterans, is a national public health priority.
135-1	24267-24276	Therefore	_	
135-2	24276-24277	,	_	
135-3	24278-24289	identifying	_	
135-4	24290-24299	effective	_	
135-5	24300-24311	medications	_	
135-6	24312-24314	to	_	
135-7	24315-24320	treat	_	
135-8	24321-24333	co-occurring	_	
135-9	24334-24338	PTSD	_	
135-10	24339-24342	and	_	
135-11	24343-24346	SUD	_	
135-12	24346-24347	,	_	
135-13	24348-24360	particularly	_	
135-14	24361-24366	among	_	
135-15	24367-24375	military	_	
135-16	24376-24384	veterans	_	
135-17	24384-24385	,	_	
135-18	24386-24388	is	_	
135-19	24389-24390	a	_	
135-20	24391-24399	national	_	
135-21	24400-24406	public	_	
135-22	24407-24413	health	_	
135-23	24414-24422	priority	_	
135-24	24422-24423	.	_	

#Text=One potential medication for the treatment of PTSD and co-occurring SUD is the alpha-1 adrenergic antagonist prazosin.
136-1	24424-24427	One	_	
136-2	24428-24437	potential	_	
136-3	24438-24448	medication	_	
136-4	24449-24452	for	_	
136-5	24453-24456	the	_	
136-6	24457-24466	treatment	_	
136-7	24467-24469	of	_	
136-8	24470-24474	PTSD	_	
136-9	24475-24478	and	_	
136-10	24479-24491	co-occurring	_	
136-11	24492-24495	SUD	_	
136-12	24496-24498	is	_	
136-13	24499-24502	the	_	
136-14	24503-24508	alpha	_	
136-15	24508-24509	-	_	
136-16	24509-24510	1	_	
136-17	24511-24521	adrenergic	_	
136-18	24522-24532	antagonist	_	
136-19	24533-24541	prazosin	_	
136-20	24541-24542	.	_	

#Text=Several RCTs with varying sample sizes of veterans and civilians demonstrate safety, tolerability and efficacy of prazosin to reduce nightmares, sleep impairment, and overall PTSD symptom severity, as well as AUD severity.
137-1	24543-24550	Several	_	
137-2	24551-24555	RCTs	_	
137-3	24556-24560	with	_	
137-4	24561-24568	varying	_	
137-5	24569-24575	sample	_	
137-6	24576-24581	sizes	_	
137-7	24582-24584	of	_	
137-8	24585-24593	veterans	_	
137-9	24594-24597	and	_	
137-10	24598-24607	civilians	_	
137-11	24608-24619	demonstrate	_	
137-12	24620-24626	safety	_	
137-13	24626-24627	,	_	
137-14	24628-24640	tolerability	_	
137-15	24641-24644	and	_	
137-16	24645-24653	efficacy	_	
137-17	24654-24656	of	_	
137-18	24657-24665	prazosin	_	
137-19	24666-24668	to	_	
137-20	24669-24675	reduce	_	
137-21	24676-24686	nightmares	_	
137-22	24686-24687	,	_	
137-23	24688-24693	sleep	_	
137-24	24694-24704	impairment	_	
137-25	24704-24705	,	_	
137-26	24706-24709	and	_	
137-27	24710-24717	overall	_	
137-28	24718-24722	PTSD	_	
137-29	24723-24730	symptom	_	
137-30	24731-24739	severity	_	
137-31	24739-24740	,	_	
137-32	24741-24743	as	_	
137-33	24744-24748	well	_	
137-34	24749-24751	as	_	
137-35	24752-24755	AUD	_	
137-36	24756-24764	severity	_	
137-37	24764-24765	.	_	

#Text=However, the largest RCT to date examining prazosin in the treatment of PTSD (N = 304) resulted in null findings.
138-1	24766-24773	However	_	
138-2	24773-24774	,	_	
138-3	24775-24778	the	_	
138-4	24779-24786	largest	_	
138-5	24787-24790	RCT	_	
138-6	24791-24793	to	_	
138-7	24794-24798	date	_	
138-8	24799-24808	examining	_	
138-9	24809-24817	prazosin	_	
138-10	24818-24820	in	_	
138-11	24821-24824	the	_	
138-12	24825-24834	treatment	_	
138-13	24835-24837	of	_	
138-14	24838-24842	PTSD	_	
138-15	24843-24844	(	_	
138-16	24844-24845	N	_	
138-17	24846-24847	=	_	
138-18	24848-24851	304	_	
138-19	24851-24852	)	_	
138-20	24853-24861	resulted	_	
138-21	24862-24864	in	_	
138-22	24865-24869	null	_	
138-23	24870-24878	findings	_	
138-24	24878-24879	.	_	

#Text=Veterans in this study were recruited from 13 VA hospitals across the nation.
139-1	24880-24888	Veterans	_	
139-2	24889-24891	in	_	
139-3	24892-24896	this	_	
139-4	24897-24902	study	_	
139-5	24903-24907	were	_	
139-6	24908-24917	recruited	_	
139-7	24918-24922	from	_	
139-8	24923-24925	13	_	
139-9	24926-24928	VA	_	
139-10	24929-24938	hospitals	_	
139-11	24939-24945	across	_	
139-12	24946-24949	the	_	
139-13	24950-24956	nation	_	
139-14	24956-24957	.	_	

#Text=Participants completed a 16-week treatment phase following a 10-week maintenance phase in which participants were stabilized on their current new medications and continued to participate in ongoing psychotherapy, but no new interventions were added during the study apart from prazosin or placebo.
140-1	24958-24970	Participants	_	
140-2	24971-24980	completed	_	
140-3	24981-24982	a	_	
140-4	24983-24985	16	_	
140-5	24985-24986	-	_	
140-6	24986-24990	week	_	
140-7	24991-25000	treatment	_	
140-8	25001-25006	phase	_	
140-9	25007-25016	following	_	
140-10	25017-25018	a	_	
140-11	25019-25021	10	_	
140-12	25021-25022	-	_	
140-13	25022-25026	week	_	
140-14	25027-25038	maintenance	_	
140-15	25039-25044	phase	_	
140-16	25045-25047	in	_	
140-17	25048-25053	which	_	
140-18	25054-25066	participants	_	
140-19	25067-25071	were	_	
140-20	25072-25082	stabilized	_	
140-21	25083-25085	on	_	
140-22	25086-25091	their	_	
140-23	25092-25099	current	_	
140-24	25100-25103	new	_	
140-25	25104-25115	medications	_	
140-26	25116-25119	and	_	
140-27	25120-25129	continued	_	
140-28	25130-25132	to	_	
140-29	25133-25144	participate	_	
140-30	25145-25147	in	_	
140-31	25148-25155	ongoing	_	
140-32	25156-25169	psychotherapy	_	
140-33	25169-25170	,	_	
140-34	25171-25174	but	_	
140-35	25175-25177	no	_	
140-36	25178-25181	new	_	
140-37	25182-25195	interventions	_	
140-38	25196-25200	were	_	
140-39	25201-25206	added	_	
140-40	25207-25213	during	_	
140-41	25214-25217	the	_	
140-42	25218-25223	study	_	
140-43	25224-25229	apart	_	
140-44	25230-25234	from	_	
140-45	25235-25243	prazosin	_	
140-46	25244-25246	or	_	
140-47	25247-25254	placebo	_	
140-48	25254-25255	.	_	

#Text=The lengthy stabilization phase in this trial is a substantial distinguishing factor between this and previous smaller prazosin trials.
141-1	25256-25259	The	_	
141-2	25260-25267	lengthy	_	
141-3	25268-25281	stabilization	_	
141-4	25282-25287	phase	_	
141-5	25288-25290	in	_	
141-6	25291-25295	this	_	
141-7	25296-25301	trial	_	
141-8	25302-25304	is	_	
141-9	25305-25306	a	_	
141-10	25307-25318	substantial	_	
141-11	25319-25333	distinguishing	_	
141-12	25334-25340	factor	_	
141-13	25341-25348	between	_	
141-14	25349-25353	this	_	
141-15	25354-25357	and	_	
141-16	25358-25366	previous	_	
141-17	25367-25374	smaller	_	
141-18	25375-25383	prazosin	_	
141-19	25384-25390	trials	_	
141-20	25390-25391	.	_	

#Text=The authors hypothesize that the null findings might be attributable, in part, to an a priori inclusion criterion requiring participants to demonstrate psychiatric stability prior to the treatment phase.
142-1	25392-25395	The	_	
142-2	25396-25403	authors	_	
142-3	25404-25415	hypothesize	_	
142-4	25416-25420	that	_	
142-5	25421-25424	the	_	
142-6	25425-25429	null	_	
142-7	25430-25438	findings	_	
142-8	25439-25444	might	_	
142-9	25445-25447	be	_	
142-10	25448-25460	attributable	_	
142-11	25460-25461	,	_	
142-12	25462-25464	in	_	
142-13	25465-25469	part	_	
142-14	25469-25470	,	_	
142-15	25471-25473	to	_	
142-16	25474-25476	an	_	
142-17	25477-25478	a	_	
142-18	25479-25485	priori	_	
142-19	25486-25495	inclusion	_	
142-20	25496-25505	criterion	_	
142-21	25506-25515	requiring	_	
142-22	25516-25528	participants	_	
142-23	25529-25531	to	_	
142-24	25532-25543	demonstrate	_	
142-25	25544-25555	psychiatric	_	
142-26	25556-25565	stability	_	
142-27	25566-25571	prior	_	
142-28	25572-25574	to	_	
142-29	25575-25578	the	_	
142-30	25579-25588	treatment	_	
142-31	25589-25594	phase	_	
142-32	25594-25595	.	_	

#Text=It is necessary for future studies to explore the possibility that some Veterans might benefit from initiating prazosin earlier in their course of treatment or sooner after PTSD onset.
143-1	25596-25598	It	_	
143-2	25599-25601	is	_	
143-3	25602-25611	necessary	_	
143-4	25612-25615	for	_	
143-5	25616-25622	future	_	
143-6	25623-25630	studies	_	
143-7	25631-25633	to	_	
143-8	25634-25641	explore	_	
143-9	25642-25645	the	_	
143-10	25646-25657	possibility	_	
143-11	25658-25662	that	_	
143-12	25663-25667	some	_	
143-13	25668-25676	Veterans	_	
143-14	25677-25682	might	_	
143-15	25683-25690	benefit	_	
143-16	25691-25695	from	_	
143-17	25696-25706	initiating	_	
143-18	25707-25715	prazosin	_	
143-19	25716-25723	earlier	_	
143-20	25724-25726	in	_	
143-21	25727-25732	their	_	
143-22	25733-25739	course	_	
143-23	25740-25742	of	_	
143-24	25743-25752	treatment	_	
143-25	25753-25755	or	_	
143-26	25756-25762	sooner	_	
143-27	25763-25768	after	_	
143-28	25769-25773	PTSD	_	
143-29	25774-25779	onset	_	
143-30	25779-25780	.	_	

#Text=In the study, approximately one third of participants with similar distributions between medication conditions received individual or group psychotherapy (n = 43; 28%) and the majority of participants were prescribed antidepressants (95% and 89% in the prazosin vs. placebo group, respectively).
144-1	25781-25783	In	_	
144-2	25784-25787	the	_	
144-3	25788-25793	study	_	
144-4	25793-25794	,	_	
144-5	25795-25808	approximately	_	
144-6	25809-25812	one	_	
144-7	25813-25818	third	_	
144-8	25819-25821	of	_	
144-9	25822-25834	participants	_	
144-10	25835-25839	with	_	
144-11	25840-25847	similar	_	
144-12	25848-25861	distributions	_	
144-13	25862-25869	between	_	
144-14	25870-25880	medication	_	
144-15	25881-25891	conditions	_	
144-16	25892-25900	received	_	
144-17	25901-25911	individual	_	
144-18	25912-25914	or	_	
144-19	25915-25920	group	_	
144-20	25921-25934	psychotherapy	_	
144-21	25935-25936	(	_	
144-22	25936-25937	n	_	
144-23	25938-25939	=	_	
144-24	25940-25942	43	_	
144-25	25942-25943	;	_	
144-26	25944-25947	28%	_	
144-27	25947-25948	)	_	
144-28	25949-25952	and	_	
144-29	25953-25956	the	_	
144-30	25957-25965	majority	_	
144-31	25966-25968	of	_	
144-32	25969-25981	participants	_	
144-33	25982-25986	were	_	
144-34	25987-25997	prescribed	_	
144-35	25998-26013	antidepressants	_	
144-36	26014-26015	(	_	
144-37	26015-26018	95%	_	
144-38	26019-26022	and	_	
144-39	26023-26026	89%	_	
144-40	26027-26029	in	_	
144-41	26030-26033	the	_	
144-42	26034-26042	prazosin	_	
144-43	26043-26045	vs	_	
144-44	26045-26046	.	_	
144-45	26047-26054	placebo	_	
144-46	26055-26060	group	_	
144-47	26060-26061	,	_	
144-48	26062-26074	respectively	_	
144-49	26074-26075	)	_	
144-50	26075-26076	.	_	

#Text=Thus, an additional consideration posed by the authors is that prazosin is less efficacious in the context of an established course of evidence-supported medications and/or psychotherapy to treat PTSD.
145-1	26077-26081	Thus	_	
145-2	26081-26082	,	_	
145-3	26083-26085	an	_	
145-4	26086-26096	additional	_	
145-5	26097-26110	consideration	_	
145-6	26111-26116	posed	_	
145-7	26117-26119	by	_	
145-8	26120-26123	the	_	
145-9	26124-26131	authors	_	
145-10	26132-26134	is	_	
145-11	26135-26139	that	_	
145-12	26140-26148	prazosin	_	
145-13	26149-26151	is	_	
145-14	26152-26156	less	_	
145-15	26157-26168	efficacious	_	
145-16	26169-26171	in	_	
145-17	26172-26175	the	_	
145-18	26176-26183	context	_	
145-19	26184-26186	of	_	
145-20	26187-26189	an	_	
145-21	26190-26201	established	_	
145-22	26202-26208	course	_	
145-23	26209-26211	of	_	
145-24	26212-26230	evidence-supported	_	
145-25	26231-26242	medications	_	
145-26	26243-26246	and	_	
145-27	26246-26247	/	_	
145-28	26247-26249	or	_	
145-29	26250-26263	psychotherapy	_	
145-30	26264-26266	to	_	
145-31	26267-26272	treat	_	
145-32	26273-26277	PTSD	_	
145-33	26277-26278	.	_	

#Text=Because hyperactivity of the noradrenergic system is also identified as a neurobiological mechanism underlying AUD, the findings from the collective prazosin literature lend support to the notion that alpha-1 adrenergic antagonists may also be effective in the treatment of co-occurring PTSD and AUD.
146-1	26279-26286	Because	_	
146-2	26287-26300	hyperactivity	_	
146-3	26301-26303	of	_	
146-4	26304-26307	the	_	
146-5	26308-26321	noradrenergic	_	
146-6	26322-26328	system	_	
146-7	26329-26331	is	_	
146-8	26332-26336	also	_	
146-9	26337-26347	identified	_	
146-10	26348-26350	as	_	
146-11	26351-26352	a	_	
146-12	26353-26368	neurobiological	_	
146-13	26369-26378	mechanism	_	
146-14	26379-26389	underlying	_	
146-15	26390-26393	AUD	_	
146-16	26393-26394	,	_	
146-17	26395-26398	the	_	
146-18	26399-26407	findings	_	
146-19	26408-26412	from	_	
146-20	26413-26416	the	_	
146-21	26417-26427	collective	_	
146-22	26428-26436	prazosin	_	
146-23	26437-26447	literature	_	
146-24	26448-26452	lend	_	
146-25	26453-26460	support	_	
146-26	26461-26463	to	_	
146-27	26464-26467	the	_	
146-28	26468-26474	notion	_	
146-29	26475-26479	that	_	
146-30	26480-26485	alpha	_	
146-31	26485-26486	-	_	
146-32	26486-26487	1	_	
146-33	26488-26498	adrenergic	_	
146-34	26499-26510	antagonists	_	
146-35	26511-26514	may	_	
146-36	26515-26519	also	_	
146-37	26520-26522	be	_	
146-38	26523-26532	effective	_	
146-39	26533-26535	in	_	
146-40	26536-26539	the	_	
146-41	26540-26549	treatment	_	
146-42	26550-26552	of	_	
146-43	26553-26565	co-occurring	_	
146-44	26566-26570	PTSD	_	
146-45	26571-26574	and	_	
146-46	26575-26578	AUD	_	
146-47	26578-26579	.	_	

#Text=One limitation of prazosin is its relatively short half-life, which commonly results in challenges to medication adherence in order to obtain a therapeutic dose.
147-1	26580-26583	One	_	
147-2	26584-26594	limitation	_	
147-3	26595-26597	of	_	
147-4	26598-26606	prazosin	_	
147-5	26607-26609	is	_	
147-6	26610-26613	its	_	
147-7	26614-26624	relatively	_	
147-8	26625-26630	short	_	
147-9	26631-26640	half-life	_	
147-10	26640-26641	,	_	
147-11	26642-26647	which	_	
147-12	26648-26656	commonly	_	
147-13	26657-26664	results	_	
147-14	26665-26667	in	_	
147-15	26668-26678	challenges	_	
147-16	26679-26681	to	_	
147-17	26682-26692	medication	_	
147-18	26693-26702	adherence	_	
147-19	26703-26705	in	_	
147-20	26706-26711	order	_	
147-21	26712-26714	to	_	
147-22	26715-26721	obtain	_	
147-23	26722-26723	a	_	
147-24	26724-26735	therapeutic	_	
147-25	26736-26740	dose	_	
147-26	26740-26741	.	_	

#Text=Some literature has also demonstrated substantial and persistent geographic differences in the effective prescribing of prazosin.
148-1	26742-26746	Some	_	
148-2	26747-26757	literature	_	
148-3	26758-26761	has	_	
148-4	26762-26766	also	_	
148-5	26767-26779	demonstrated	_	
148-6	26780-26791	substantial	_	
148-7	26792-26795	and	_	
148-8	26796-26806	persistent	_	
148-9	26807-26817	geographic	_	
148-10	26818-26829	differences	_	
148-11	26830-26832	in	_	
148-12	26833-26836	the	_	
148-13	26837-26846	effective	_	
148-14	26847-26858	prescribing	_	
148-15	26859-26861	of	_	
148-16	26862-26870	prazosin	_	
148-17	26870-26871	.	_	

#Text=In order to address these gaps in the literature and add to the ongoing investigation of the clinical utility and efficacy of alpha-1 blockers in the treatment of PTSD and SUD, the current study will examine the ability of doxazosin versus placebo in reducing co-occurring PTSD and AUD symptom severity among U.S. military veterans.
149-1	26872-26874	In	_	
149-2	26875-26880	order	_	
149-3	26881-26883	to	_	
149-4	26884-26891	address	_	
149-5	26892-26897	these	_	
149-6	26898-26902	gaps	_	
149-7	26903-26905	in	_	
149-8	26906-26909	the	_	
149-9	26910-26920	literature	_	
149-10	26921-26924	and	_	
149-11	26925-26928	add	_	
149-12	26929-26931	to	_	
149-13	26932-26935	the	_	
149-14	26936-26943	ongoing	_	
149-15	26944-26957	investigation	_	
149-16	26958-26960	of	_	
149-17	26961-26964	the	_	
149-18	26965-26973	clinical	_	
149-19	26974-26981	utility	_	
149-20	26982-26985	and	_	
149-21	26986-26994	efficacy	_	
149-22	26995-26997	of	_	
149-23	26998-27003	alpha	_	
149-24	27003-27004	-	_	
149-25	27004-27005	1	_	
149-26	27006-27014	blockers	_	
149-27	27015-27017	in	_	
149-28	27018-27021	the	_	
149-29	27022-27031	treatment	_	
149-30	27032-27034	of	_	
149-31	27035-27039	PTSD	_	
149-32	27040-27043	and	_	
149-33	27044-27047	SUD	_	
149-34	27047-27048	,	_	
149-35	27049-27052	the	_	
149-36	27053-27060	current	_	
149-37	27061-27066	study	_	
149-38	27067-27071	will	_	
149-39	27072-27079	examine	_	
149-40	27080-27083	the	_	
149-41	27084-27091	ability	_	
149-42	27092-27094	of	_	
149-43	27095-27104	doxazosin	_	
149-44	27105-27111	versus	_	
149-45	27112-27119	placebo	_	
149-46	27120-27122	in	_	
149-47	27123-27131	reducing	_	
149-48	27132-27144	co-occurring	_	
149-49	27145-27149	PTSD	_	
149-50	27150-27153	and	_	
149-51	27154-27157	AUD	_	
149-52	27158-27165	symptom	_	
149-53	27166-27174	severity	_	
149-54	27175-27180	among	_	
149-55	27181-27184	U.S	_	
149-56	27184-27185	.	_	
149-57	27186-27194	military	_	
149-58	27195-27203	veterans	_	
149-59	27203-27204	.	_	

#Text=Previous clinical studies, described in more detail in the Introduction section, support the ability of doxazosin to reduce PTSD symptoms, although they are based on small sample sizes.
150-1	27205-27213	Previous	_	
150-2	27214-27222	clinical	_	
150-3	27223-27230	studies	_	
150-4	27230-27231	,	_	
150-5	27232-27241	described	_	
150-6	27242-27244	in	_	
150-7	27245-27249	more	_	
150-8	27250-27256	detail	_	
150-9	27257-27259	in	_	
150-10	27260-27263	the	_	
150-11	27264-27276	Introduction	_	
150-12	27277-27284	section	_	
150-13	27284-27285	,	_	
150-14	27286-27293	support	_	
150-15	27294-27297	the	_	
150-16	27298-27305	ability	_	
150-17	27306-27308	of	_	
150-18	27309-27318	doxazosin	_	
150-19	27319-27321	to	_	
150-20	27322-27328	reduce	_	
150-21	27329-27333	PTSD	_	
150-22	27334-27342	symptoms	_	
150-23	27342-27343	,	_	
150-24	27344-27352	although	_	
150-25	27353-27357	they	_	
150-26	27358-27361	are	_	
150-27	27362-27367	based	_	
150-28	27368-27370	on	_	
150-29	27371-27376	small	_	
150-30	27377-27383	sample	_	
150-31	27384-27389	sizes	_	
150-32	27389-27390	.	_	

#Text=A proof-ofconcept study found preliminary support for the ability of doxazosin to reduce alcohol consumption among individuals with AUD and high (versus low) family history density of alcoholism.
151-1	27391-27392	A	_	
151-2	27393-27408	proof-ofconcept	_	
151-3	27409-27414	study	_	
151-4	27415-27420	found	_	
151-5	27421-27432	preliminary	_	
151-6	27433-27440	support	_	
151-7	27441-27444	for	_	
151-8	27445-27448	the	_	
151-9	27449-27456	ability	_	
151-10	27457-27459	of	_	
151-11	27460-27469	doxazosin	_	
151-12	27470-27472	to	_	
151-13	27473-27479	reduce	_	
151-14	27480-27487	alcohol	_	
151-15	27488-27499	consumption	_	
151-16	27500-27505	among	_	
151-17	27506-27517	individuals	_	
151-18	27518-27522	with	_	
151-19	27523-27526	AUD	_	
151-20	27527-27530	and	_	
151-21	27531-27535	high	_	
151-22	27536-27537	(	_	
151-23	27537-27543	versus	_	
151-24	27544-27547	low	_	
151-25	27547-27548	)	_	
151-26	27549-27555	family	_	
151-27	27556-27563	history	_	
151-28	27564-27571	density	_	
151-29	27572-27574	of	_	
151-30	27575-27585	alcoholism	_	
151-31	27585-27586	.	_	

#Text=This effect was also moderated by higher pretreatment BP such that participants with higher pretreatment BP yielded greater reduction in alcohol consumption during treatment.
152-1	27587-27591	This	_	
152-2	27592-27598	effect	_	
152-3	27599-27602	was	_	
152-4	27603-27607	also	_	
152-5	27608-27617	moderated	_	
152-6	27618-27620	by	_	
152-7	27621-27627	higher	_	
152-8	27628-27640	pretreatment	_	
152-9	27641-27643	BP	_	
152-10	27644-27648	such	_	
152-11	27649-27653	that	_	
152-12	27654-27666	participants	_	
152-13	27667-27671	with	_	
152-14	27672-27678	higher	_	
152-15	27679-27691	pretreatment	_	
152-16	27692-27694	BP	_	
152-17	27695-27702	yielded	_	
152-18	27703-27710	greater	_	
152-19	27711-27720	reduction	_	
152-20	27721-27723	in	_	
152-21	27724-27731	alcohol	_	
152-22	27732-27743	consumption	_	
152-23	27744-27750	during	_	
152-24	27751-27760	treatment	_	
152-25	27760-27761	.	_	

#Text=Both family history and BP are being measured in the current study.
153-1	27762-27766	Both	_	
153-2	27767-27773	family	_	
153-3	27774-27781	history	_	
153-4	27782-27785	and	_	
153-5	27786-27788	BP	_	
153-6	27789-27792	are	_	
153-7	27793-27798	being	_	
153-8	27799-27807	measured	_	
153-9	27808-27810	in	_	
153-10	27811-27814	the	_	
153-11	27815-27822	current	_	
153-12	27823-27828	study	_	
153-13	27828-27829	.	_	

#Text=Future research in this area should include measurements of pre-treatment BP, family history of AUD, as well as genetic data.
154-1	27830-27836	Future	_	
154-2	27837-27845	research	_	
154-3	27846-27848	in	_	
154-4	27849-27853	this	_	
154-5	27854-27858	area	_	
154-6	27859-27865	should	_	
154-7	27866-27873	include	_	
154-8	27874-27886	measurements	_	
154-9	27887-27889	of	_	
154-10	27890-27903	pre-treatment	_	
154-11	27904-27906	BP	_	
154-12	27906-27907	,	_	
154-13	27908-27914	family	_	
154-14	27915-27922	history	_	
154-15	27923-27925	of	_	
154-16	27926-27929	AUD	_	
154-17	27929-27930	,	_	
154-18	27931-27933	as	_	
154-19	27934-27938	well	_	
154-20	27939-27941	as	_	
154-21	27942-27949	genetic	_	
154-22	27950-27954	data	_	
154-23	27954-27955	.	_	

#Text=The current study is designed and adequately powered to examine the effects of treatment group (doxazosin vs. placebo) on PTSD and AUD severity at the end of treatment.
155-1	27956-27959	The	_	
155-2	27960-27967	current	_	
155-3	27968-27973	study	_	
155-4	27974-27976	is	_	
155-5	27977-27985	designed	_	
155-6	27986-27989	and	_	
155-7	27990-28000	adequately	_	
155-8	28001-28008	powered	_	
155-9	28009-28011	to	_	
155-10	28012-28019	examine	_	
155-11	28020-28023	the	_	
155-12	28024-28031	effects	_	
155-13	28032-28034	of	_	
155-14	28035-28044	treatment	_	
155-15	28045-28050	group	_	
155-16	28051-28052	(	_	
155-17	28052-28061	doxazosin	_	
155-18	28062-28064	vs	_	
155-19	28064-28065	.	_	
155-20	28066-28073	placebo	_	
155-21	28073-28074	)	_	
155-22	28075-28077	on	_	
155-23	28078-28082	PTSD	_	
155-24	28083-28086	and	_	
155-25	28087-28090	AUD	_	
155-26	28091-28099	severity	_	
155-27	28100-28102	at	_	
155-28	28103-28106	the	_	
155-29	28107-28110	end	_	
155-30	28111-28113	of	_	
155-31	28114-28123	treatment	_	
155-32	28123-28124	.	_	

#Text=The findings may inform future investigations of doxazosin and its potential translation to treatment settings.
156-1	28125-28128	The	_	
156-2	28129-28137	findings	_	
156-3	28138-28141	may	_	
156-4	28142-28148	inform	_	
156-5	28149-28155	future	_	
156-6	28156-28170	investigations	_	
156-7	28171-28173	of	_	
156-8	28174-28183	doxazosin	_	
156-9	28184-28187	and	_	
156-10	28188-28191	its	_	
156-11	28192-28201	potential	_	
156-12	28202-28213	translation	_	
156-13	28214-28216	to	_	
156-14	28217-28226	treatment	_	
156-15	28227-28235	settings	_	
156-16	28235-28236	.	_	

#Text=Adverse events are monitored, recorded, and reviewed by the investigative team, study prescribers, and safety monitor at regular intervals.
157-1	28237-28244	Adverse	_	
157-2	28245-28251	events	_	
157-3	28252-28255	are	_	
157-4	28256-28265	monitored	_	
157-5	28265-28266	,	_	
157-6	28267-28275	recorded	_	
157-7	28275-28276	,	_	
157-8	28277-28280	and	_	
157-9	28281-28289	reviewed	_	
157-10	28290-28292	by	_	
157-11	28293-28296	the	_	
157-12	28297-28310	investigative	_	
157-13	28311-28315	team	_	
157-14	28315-28316	,	_	
157-15	28317-28322	study	_	
157-16	28323-28334	prescribers	_	
157-17	28334-28335	,	_	
157-18	28336-28339	and	_	
157-19	28340-28346	safety	_	
157-20	28347-28354	monitor	_	
157-21	28355-28357	at	_	
157-22	28358-28365	regular	_	
157-23	28366-28375	intervals	_	
157-24	28375-28376	.	_	

#Text=Other important considerations being examined include medication adherence and the effects of medication on secondary outcomes such as depression, sleep, and anxiety.
158-1	28377-28382	Other	_	
158-2	28383-28392	important	_	
158-3	28393-28407	considerations	_	
158-4	28408-28413	being	_	
158-5	28414-28422	examined	_	
158-6	28423-28430	include	_	
158-7	28431-28441	medication	_	
158-8	28442-28451	adherence	_	
158-9	28452-28455	and	_	
158-10	28456-28459	the	_	
158-11	28460-28467	effects	_	
158-12	28468-28470	of	_	
158-13	28471-28481	medication	_	
158-14	28482-28484	on	_	
158-15	28485-28494	secondary	_	
158-16	28495-28503	outcomes	_	
158-17	28504-28508	such	_	
158-18	28509-28511	as	_	
158-19	28512-28522	depression	_	
158-20	28522-28523	,	_	
158-21	28524-28529	sleep	_	
158-22	28529-28530	,	_	
158-23	28531-28534	and	_	
158-24	28535-28542	anxiety	_	
158-25	28542-28543	.	_	

#Text=Notably, participants in the current study are permitted to maintain or initiate behavioral intervention as needed in order to maximize generalizability of study findings.
159-1	28544-28551	Notably	_	
159-2	28551-28552	,	_	
159-3	28553-28565	participants	_	
159-4	28566-28568	in	_	
159-5	28569-28572	the	_	
159-6	28573-28580	current	_	
159-7	28581-28586	study	_	
159-8	28587-28590	are	_	
159-9	28591-28600	permitted	_	
159-10	28601-28603	to	_	
159-11	28604-28612	maintain	_	
159-12	28613-28615	or	_	
159-13	28616-28624	initiate	_	
159-14	28625-28635	behavioral	_	
159-15	28636-28648	intervention	_	
159-16	28649-28651	as	_	
159-17	28652-28658	needed	_	
159-18	28659-28661	in	_	
159-19	28662-28667	order	_	
159-20	28668-28670	to	_	
159-21	28671-28679	maximize	_	
159-22	28680-28696	generalizability	_	
159-23	28697-28699	of	_	
159-24	28700-28705	study	_	
159-25	28706-28714	findings	_	
159-26	28714-28715	.	_	

#Text=Concurrent treatment engagement is monitored closely by the study team at weekly visits.
160-1	28716-28726	Concurrent	_	
160-2	28727-28736	treatment	_	
160-3	28737-28747	engagement	_	
160-4	28748-28750	is	_	
160-5	28751-28760	monitored	_	
160-6	28761-28768	closely	_	
160-7	28769-28771	by	_	
160-8	28772-28775	the	_	
160-9	28776-28781	study	_	
160-10	28782-28786	team	_	
160-11	28787-28789	at	_	
160-12	28790-28796	weekly	_	
160-13	28797-28803	visits	_	
160-14	28803-28804	.	_	

#Text=The neuroimaging component of this study will allow us to identify possible neurobiological mechanisms underlying treatment response (or nonresponse).
161-1	28805-28808	The	_	
161-2	28809-28821	neuroimaging	_	
161-3	28822-28831	component	_	
161-4	28832-28834	of	_	
161-5	28835-28839	this	_	
161-6	28840-28845	study	_	
161-7	28846-28850	will	_	
161-8	28851-28856	allow	_	
161-9	28857-28859	us	_	
161-10	28860-28862	to	_	
161-11	28863-28871	identify	_	
161-12	28872-28880	possible	_	
161-13	28881-28896	neurobiological	_	
161-14	28897-28907	mechanisms	_	
161-15	28908-28918	underlying	_	
161-16	28919-28928	treatment	_	
161-17	28929-28937	response	_	
161-18	28938-28939	(	_	
161-19	28939-28941	or	_	
161-20	28942-28953	nonresponse	_	
161-21	28953-28954	)	_	
161-22	28954-28955	.	_	

#Text=Considering the significant heterogeneity in the etiology and course of PTSD and AUD, as well as the complexity of individual treatment needs, the findings from this study might allow us to maximize treatment outcomes and more effectively identify and treat individuals with this complex and detrimental dual diagnosis.
162-1	28956-28967	Considering	_	
162-2	28968-28971	the	_	
162-3	28972-28983	significant	_	
162-4	28984-28997	heterogeneity	_	
162-5	28998-29000	in	_	
162-6	29001-29004	the	_	
162-7	29005-29013	etiology	_	
162-8	29014-29017	and	_	
162-9	29018-29024	course	_	
162-10	29025-29027	of	_	
162-11	29028-29032	PTSD	_	
162-12	29033-29036	and	_	
162-13	29037-29040	AUD	_	
162-14	29040-29041	,	_	
162-15	29042-29044	as	_	
162-16	29045-29049	well	_	
162-17	29050-29052	as	_	
162-18	29053-29056	the	_	
162-19	29057-29067	complexity	_	
162-20	29068-29070	of	_	
162-21	29071-29081	individual	_	
162-22	29082-29091	treatment	_	
162-23	29092-29097	needs	_	
162-24	29097-29098	,	_	
162-25	29099-29102	the	_	
162-26	29103-29111	findings	_	
162-27	29112-29116	from	_	
162-28	29117-29121	this	_	
162-29	29122-29127	study	_	
162-30	29128-29133	might	_	
162-31	29134-29139	allow	_	
162-32	29140-29142	us	_	
162-33	29143-29145	to	_	
162-34	29146-29154	maximize	_	
162-35	29155-29164	treatment	_	
162-36	29165-29173	outcomes	_	
162-37	29174-29177	and	_	
162-38	29178-29182	more	_	
162-39	29183-29194	effectively	_	
162-40	29195-29203	identify	_	
162-41	29204-29207	and	_	
162-42	29208-29213	treat	_	
162-43	29214-29225	individuals	_	
162-44	29226-29230	with	_	
162-45	29231-29235	this	_	
162-46	29236-29243	complex	_	
162-47	29244-29247	and	_	
162-48	29248-29259	detrimental	_	
162-49	29260-29264	dual	_	
162-50	29265-29274	diagnosis	_	
162-51	29274-29275	.	_	

#Text=Another important aspect of this study’s design is the rigorous coordination of our assessment procedures under the guidance of the Consortium to Alleviate PTSD (CAP).
163-1	29276-29283	Another	_	
163-2	29284-29293	important	_	
163-3	29294-29300	aspect	_	
163-4	29301-29303	of	_	
163-5	29304-29308	this	_	
163-6	29309-29314	study	_	
163-7	29314-29315	’	_	
163-8	29315-29316	s	_	
163-9	29317-29323	design	_	
163-10	29324-29326	is	_	
163-11	29327-29330	the	_	
163-12	29331-29339	rigorous	_	
163-13	29340-29352	coordination	_	
163-14	29353-29355	of	_	
163-15	29356-29359	our	_	
163-16	29360-29370	assessment	_	
163-17	29371-29381	procedures	_	
163-18	29382-29387	under	_	
163-19	29388-29391	the	_	
163-20	29392-29400	guidance	_	
163-21	29401-29403	of	_	
163-22	29404-29407	the	_	
163-23	29408-29418	Consortium	_	
163-24	29419-29421	to	_	
163-25	29422-29431	Alleviate	_	
163-26	29432-29436	PTSD	_	
163-27	29437-29438	(	_	
163-28	29438-29441	CAP	_	
163-29	29441-29442	)	_	
163-30	29442-29443	.	_	

#Text=Joining our study’s findings with those of other ongoing CAP projects not only ensures reliable and valid assessment of primary and secondary outcomes; it also improves the ability of this study to contribute to the larger literature examining PTSD and SUD comorbidity among military veterans.
164-1	29444-29451	Joining	_	
164-2	29452-29455	our	_	
164-3	29456-29461	study	_	
164-4	29461-29462	’	_	
164-5	29462-29463	s	_	
164-6	29464-29472	findings	_	
164-7	29473-29477	with	_	
164-8	29478-29483	those	_	
164-9	29484-29486	of	_	
164-10	29487-29492	other	_	
164-11	29493-29500	ongoing	_	
164-12	29501-29504	CAP	_	
164-13	29505-29513	projects	_	
164-14	29514-29517	not	_	
164-15	29518-29522	only	_	
164-16	29523-29530	ensures	_	
164-17	29531-29539	reliable	_	
164-18	29540-29543	and	_	
164-19	29544-29549	valid	_	
164-20	29550-29560	assessment	_	
164-21	29561-29563	of	_	
164-22	29564-29571	primary	_	
164-23	29572-29575	and	_	
164-24	29576-29585	secondary	_	
164-25	29586-29594	outcomes	_	
164-26	29594-29595	;	_	
164-27	29596-29598	it	_	
164-28	29599-29603	also	_	
164-29	29604-29612	improves	_	
164-30	29613-29616	the	_	
164-31	29617-29624	ability	_	
164-32	29625-29627	of	_	
164-33	29628-29632	this	_	
164-34	29633-29638	study	_	
164-35	29639-29641	to	_	
164-36	29642-29652	contribute	_	
164-37	29653-29655	to	_	
164-38	29656-29659	the	_	
164-39	29660-29666	larger	_	
164-40	29667-29677	literature	_	
164-41	29678-29687	examining	_	
164-42	29688-29692	PTSD	_	
164-43	29693-29696	and	_	
164-44	29697-29700	SUD	_	
164-45	29701-29712	comorbidity	_	
164-46	29713-29718	among	_	
164-47	29719-29727	military	_	
164-48	29728-29736	veterans	_	
164-49	29736-29737	.	_	

#Text=Disclaimer
#Text=The views expressed herein are solely those of the authors and do not reflect an endorsement by or the official policy or position of the Ralph H.
165-1	29738-29748	Disclaimer	_	
165-2	29749-29752	The	_	
165-3	29753-29758	views	_	
165-4	29759-29768	expressed	_	
165-5	29769-29775	herein	_	
165-6	29776-29779	are	_	
165-7	29780-29786	solely	_	
165-8	29787-29792	those	_	
165-9	29793-29795	of	_	
165-10	29796-29799	the	_	
165-11	29800-29807	authors	_	
165-12	29808-29811	and	_	
165-13	29812-29814	do	_	
165-14	29815-29818	not	_	
165-15	29819-29826	reflect	_	
165-16	29827-29829	an	_	
165-17	29830-29841	endorsement	_	
165-18	29842-29844	by	_	
165-19	29845-29847	or	_	
165-20	29848-29851	the	_	
165-21	29852-29860	official	_	
165-22	29861-29867	policy	_	
165-23	29868-29870	or	_	
165-24	29871-29879	position	_	
165-25	29880-29882	of	_	
165-26	29883-29886	the	_	
165-27	29887-29892	Ralph	_	
165-28	29893-29894	H	_	
165-29	29894-29895	.	_	

#Text=Johnson VA, the U.S.
166-1	29896-29903	Johnson	_	
166-2	29904-29906	VA	_	
166-3	29906-29907	,	_	
166-4	29908-29911	the	_	
166-5	29912-29915	U.S	_	
166-6	29915-29916	.	_	

#Text=Army Office of the Surgeon General, the Department of the Army, the Department of the Air Force, the Department of Defense, the Department of Veterans Affairs, or the U.S.
167-1	29917-29921	Army	_	
167-2	29922-29928	Office	_	
167-3	29929-29931	of	_	
167-4	29932-29935	the	_	
167-5	29936-29943	Surgeon	_	
167-6	29944-29951	General	_	
167-7	29951-29952	,	_	
167-8	29953-29956	the	_	
167-9	29957-29967	Department	_	
167-10	29968-29970	of	_	
167-11	29971-29974	the	_	
167-12	29975-29979	Army	_	
167-13	29979-29980	,	_	
167-14	29981-29984	the	_	
167-15	29985-29995	Department	_	
167-16	29996-29998	of	_	
167-17	29999-30002	the	_	
167-18	30003-30006	Air	_	
167-19	30007-30012	Force	_	
167-20	30012-30013	,	_	
167-21	30014-30017	the	_	
167-22	30018-30028	Department	_	
167-23	30029-30031	of	_	
167-24	30032-30039	Defense	_	
167-25	30039-30040	,	_	
167-26	30041-30044	the	_	
167-27	30045-30055	Department	_	
167-28	30056-30058	of	_	
167-29	30059-30067	Veterans	_	
167-30	30068-30075	Affairs	_	
167-31	30075-30076	,	_	
167-32	30077-30079	or	_	
167-33	30080-30083	the	_	
167-34	30084-30087	U.S	_	
167-35	30087-30088	.	_	

#Text=Government.
168-1	30089-30099	Government	_	
168-2	30099-30100	.	_	

#Text=Abbreviations:
#Text=AMY
#Text=amygdala
#Text=AUD
#Text=alcohol use disorder
#Text=BAM
#Text=Brief Addiction Monitor
#Text=BP
#Text=blood pressure
#Text=CAP
#Text=Consortium to Alleviate PTSD
#Text=CAPS-5
#Text=Clinician-Administered PTSD Scale for DSM-5
#Text=CIWA
#Text=ArRevised Clinician Institute Withdrawal Assessment of Alcohol
#Text=DSM-5
#Text=Diagnostic and Statistical Manual of Mental Disorders Fifth Edition
#Text=EPI
#Text=gradient-echo planar images
#Text=FDA
#Text=U.S.
169-1	30101-30114	Abbreviations	_	
169-2	30114-30115	:	_	
169-3	30116-30119	AMY	_	
169-4	30120-30128	amygdala	_	
169-5	30129-30132	AUD	_	
169-6	30133-30140	alcohol	_	
169-7	30141-30144	use	_	
169-8	30145-30153	disorder	_	
169-9	30154-30157	BAM	_	
169-10	30158-30163	Brief	_	
169-11	30164-30173	Addiction	_	
169-12	30174-30181	Monitor	_	
169-13	30182-30184	BP	_	
169-14	30185-30190	blood	_	
169-15	30191-30199	pressure	_	
169-16	30200-30203	CAP	_	
169-17	30204-30214	Consortium	_	
169-18	30215-30217	to	_	
169-19	30218-30227	Alleviate	_	
169-20	30228-30232	PTSD	_	
169-21	30233-30237	CAPS	_	
169-22	30237-30238	-	_	
169-23	30238-30239	5	_	
169-24	30240-30262	Clinician-Administered	_	
169-25	30263-30267	PTSD	_	
169-26	30268-30273	Scale	_	
169-27	30274-30277	for	_	
169-28	30278-30281	DSM	_	
169-29	30281-30282	-	_	
169-30	30282-30283	5	_	
169-31	30284-30288	CIWA	_	
169-32	30289-30298	ArRevised	_	
169-33	30299-30308	Clinician	_	
169-34	30309-30318	Institute	_	
169-35	30319-30329	Withdrawal	_	
169-36	30330-30340	Assessment	_	
169-37	30341-30343	of	_	
169-38	30344-30351	Alcohol	_	
169-39	30352-30355	DSM	_	
169-40	30355-30356	-	_	
169-41	30356-30357	5	_	
169-42	30358-30368	Diagnostic	_	
169-43	30369-30372	and	_	
169-44	30373-30384	Statistical	_	
169-45	30385-30391	Manual	_	
169-46	30392-30394	of	_	
169-47	30395-30401	Mental	_	
169-48	30402-30411	Disorders	_	
169-49	30412-30417	Fifth	_	
169-50	30418-30425	Edition	_	
169-51	30426-30429	EPI	_	
169-52	30430-30443	gradient-echo	_	
169-53	30444-30450	planar	_	
169-54	30451-30457	images	_	
169-55	30458-30461	FDA	_	
169-56	30462-30465	U.S	_	
169-57	30465-30466	.	_	

#Text=Food and Drug Administration
#Text=fMRI
#Text=functional magnetic resonance imaging
#Text=HIV
#Text=human immunodeficiency virus
#Text=IRB
#Text=Institutional Review Board
#Text=MINI
#Text=Mini International Neuropsychiatric Interview
#Text=MPRAGE
#Text=magnetization-prepared rapid gradientecho
#Text=MRI
#Text=magnetic resonance imaging
#Text=MUSC
#Text=Medical University of South Carolina
#Text=OCDS
#Text=Obsessive Compulsive Drinking Scale
#Text=PCL-5
#Text=PTSD Checklist for DSM-5
#Text=PFC
#Text=prefrontal cortex
#Text=PPI
#Text=psychophysiological interaction
#Text=PTSD
#Text=posttraumatic stress disorder
#Text=RCT
#Text=randomized controlled trial
#Text=SSRI
#Text=selective serotonin reuptake inhibitors
#Text=TLFB
#Text=Timeline Follow Back
#Text=USP
#Text=grade, meets or exceeds requirements of the United States Pharmacopeia
#Text=VA
#Text=U.S.
170-1	30467-30471	Food	_	
170-2	30472-30475	and	_	
170-3	30476-30480	Drug	_	
170-4	30481-30495	Administration	_	
170-5	30496-30500	fMRI	_	
170-6	30501-30511	functional	_	
170-7	30512-30520	magnetic	_	
170-8	30521-30530	resonance	_	
170-9	30531-30538	imaging	_	
170-10	30539-30542	HIV	_	
170-11	30543-30548	human	_	
170-12	30549-30565	immunodeficiency	_	
170-13	30566-30571	virus	_	
170-14	30572-30575	IRB	_	
170-15	30576-30589	Institutional	_	
170-16	30590-30596	Review	_	
170-17	30597-30602	Board	_	
170-18	30603-30607	MINI	_	
170-19	30608-30612	Mini	_	
170-20	30613-30626	International	_	
170-21	30627-30643	Neuropsychiatric	_	
170-22	30644-30653	Interview	_	
170-23	30654-30660	MPRAGE	_	
170-24	30661-30683	magnetization-prepared	_	
170-25	30684-30689	rapid	_	
170-26	30690-30702	gradientecho	_	
170-27	30703-30706	MRI	_	
170-28	30707-30715	magnetic	_	
170-29	30716-30725	resonance	_	
170-30	30726-30733	imaging	_	
170-31	30734-30738	MUSC	_	
170-32	30739-30746	Medical	_	
170-33	30747-30757	University	_	
170-34	30758-30760	of	_	
170-35	30761-30766	South	_	
170-36	30767-30775	Carolina	_	
170-37	30776-30780	OCDS	_	
170-38	30781-30790	Obsessive	_	
170-39	30791-30801	Compulsive	_	
170-40	30802-30810	Drinking	_	
170-41	30811-30816	Scale	_	
170-42	30817-30820	PCL	_	
170-43	30820-30821	-	_	
170-44	30821-30822	5	_	
170-45	30823-30827	PTSD	_	
170-46	30828-30837	Checklist	_	
170-47	30838-30841	for	_	
170-48	30842-30845	DSM	_	
170-49	30845-30846	-	_	
170-50	30846-30847	5	_	
170-51	30848-30851	PFC	_	
170-52	30852-30862	prefrontal	_	
170-53	30863-30869	cortex	_	
170-54	30870-30873	PPI	_	
170-55	30874-30893	psychophysiological	_	
170-56	30894-30905	interaction	_	
170-57	30906-30910	PTSD	_	
170-58	30911-30924	posttraumatic	_	
170-59	30925-30931	stress	_	
170-60	30932-30940	disorder	_	
170-61	30941-30944	RCT	_	
170-62	30945-30955	randomized	_	
170-63	30956-30966	controlled	_	
170-64	30967-30972	trial	_	
170-65	30973-30977	SSRI	_	
170-66	30978-30987	selective	_	
170-67	30988-30997	serotonin	_	
170-68	30998-31006	reuptake	_	
170-69	31007-31017	inhibitors	_	
170-70	31018-31022	TLFB	_	
170-71	31023-31031	Timeline	_	
170-72	31032-31038	Follow	_	
170-73	31039-31043	Back	_	
170-74	31044-31047	USP	_	
170-75	31048-31053	grade	_	
170-76	31053-31054	,	_	
170-77	31055-31060	meets	_	
170-78	31061-31063	or	_	
170-79	31064-31071	exceeds	_	
170-80	31072-31084	requirements	_	
170-81	31085-31087	of	_	
170-82	31088-31091	the	_	
170-83	31092-31098	United	_	
170-84	31099-31105	States	_	
170-85	31106-31118	Pharmacopeia	_	
170-86	31119-31121	VA	_	
170-87	31122-31125	U.S	_	
170-88	31125-31126	.	_	

#Text=Department of Veterans Affairs
#Text=U.S.
171-1	31127-31137	Department	_	
171-2	31138-31140	of	_	
171-3	31141-31149	Veterans	_	
171-4	31150-31157	Affairs	_	
171-5	31158-31161	U.S	_	
171-6	31161-31162	.	_	

#Text=United States
#Text=References
#Text=Comparing the effect of prazosin and hydroxyzine on sleep quality in patients suffering from posttraumatic stress disorder
#Text=The Obsessive Compulsive Drinking Scale: a self-rated instrument for the quantification of thoughts about alcohol and drinking behavior
#Text=The Consortium to Alleviate PTSD.
172-1	31163-31169	United	_	
172-2	31170-31176	States	_	
172-3	31177-31187	References	_	
172-4	31188-31197	Comparing	_	
172-5	31198-31201	the	_	
172-6	31202-31208	effect	_	
172-7	31209-31211	of	_	
172-8	31212-31220	prazosin	_	
172-9	31221-31224	and	_	
172-10	31225-31236	hydroxyzine	_	
172-11	31237-31239	on	_	
172-12	31240-31245	sleep	_	
172-13	31246-31253	quality	_	
172-14	31254-31256	in	_	
172-15	31257-31265	patients	_	
172-16	31266-31275	suffering	_	
172-17	31276-31280	from	_	
172-18	31281-31294	posttraumatic	_	
172-19	31295-31301	stress	_	
172-20	31302-31310	disorder	_	
172-21	31311-31314	The	_	
172-22	31315-31324	Obsessive	_	
172-23	31325-31335	Compulsive	_	
172-24	31336-31344	Drinking	_	
172-25	31345-31350	Scale	_	
172-26	31350-31351	:	_	
172-27	31352-31353	a	_	
172-28	31354-31364	self-rated	_	
172-29	31365-31375	instrument	_	
172-30	31376-31379	for	_	
172-31	31380-31383	the	_	
172-32	31384-31398	quantification	_	
172-33	31399-31401	of	_	
172-34	31402-31410	thoughts	_	
172-35	31411-31416	about	_	
172-36	31417-31424	alcohol	_	
172-37	31425-31428	and	_	
172-38	31429-31437	drinking	_	
172-39	31438-31446	behavior	_	
172-40	31447-31450	The	_	
172-41	31451-31461	Consortium	_	
172-42	31462-31464	to	_	
172-43	31465-31474	Alleviate	_	
172-44	31475-31479	PTSD	_	
172-45	31479-31480	.	_	

#Text=(under review)
#Text=Topiramate treatment of alcohol use disorder in veterans with posttraumatic stress disorder: a randomized controlled pilot trial
#Text=Treatment of Alcohol Abuse: an Evidence-based Review
#Text=Comorbidity of posttraumatic stress disorder with alcohol dependence among US adults: results from National epidemiological survey on alcohol and related conditions
#Text=Psychometric properties of the PTSD Checklist for Diagnostic and Statistical Manual of Mental Disorders–Fifth Edition (PCL-5) in veterans
#Text=Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial
#Text=Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder
#Text=Development and initial evaluation of the Brief Addiction Monitor (BAM)
#Text=Does acamprosate improve reduction of drinking as well as aiding abstinence?
173-1	31481-31482	(	_	
173-2	31482-31487	under	_	
173-3	31488-31494	review	_	
173-4	31494-31495	)	_	
173-5	31496-31506	Topiramate	_	
173-6	31507-31516	treatment	_	
173-7	31517-31519	of	_	
173-8	31520-31527	alcohol	_	
173-9	31528-31531	use	_	
173-10	31532-31540	disorder	_	
173-11	31541-31543	in	_	
173-12	31544-31552	veterans	_	
173-13	31553-31557	with	_	
173-14	31558-31571	posttraumatic	_	
173-15	31572-31578	stress	_	
173-16	31579-31587	disorder	_	
173-17	31587-31588	:	_	
173-18	31589-31590	a	_	
173-19	31591-31601	randomized	_	
173-20	31602-31612	controlled	_	
173-21	31613-31618	pilot	_	
173-22	31619-31624	trial	_	
173-23	31625-31634	Treatment	_	
173-24	31635-31637	of	_	
173-25	31638-31645	Alcohol	_	
173-26	31646-31651	Abuse	_	
173-27	31651-31652	:	_	
173-28	31653-31655	an	_	
173-29	31656-31670	Evidence-based	_	
173-30	31671-31677	Review	_	
173-31	31678-31689	Comorbidity	_	
173-32	31690-31692	of	_	
173-33	31693-31706	posttraumatic	_	
173-34	31707-31713	stress	_	
173-35	31714-31722	disorder	_	
173-36	31723-31727	with	_	
173-37	31728-31735	alcohol	_	
173-38	31736-31746	dependence	_	
173-39	31747-31752	among	_	
173-40	31753-31755	US	_	
173-41	31756-31762	adults	_	
173-42	31762-31763	:	_	
173-43	31764-31771	results	_	
173-44	31772-31776	from	_	
173-45	31777-31785	National	_	
173-46	31786-31801	epidemiological	_	
173-47	31802-31808	survey	_	
173-48	31809-31811	on	_	
173-49	31812-31819	alcohol	_	
173-50	31820-31823	and	_	
173-51	31824-31831	related	_	
173-52	31832-31842	conditions	_	
173-53	31843-31855	Psychometric	_	
173-54	31856-31866	properties	_	
173-55	31867-31869	of	_	
173-56	31870-31873	the	_	
173-57	31874-31878	PTSD	_	
173-58	31879-31888	Checklist	_	
173-59	31889-31892	for	_	
173-60	31893-31903	Diagnostic	_	
173-61	31904-31907	and	_	
173-62	31908-31919	Statistical	_	
173-63	31920-31926	Manual	_	
173-64	31927-31929	of	_	
173-65	31930-31936	Mental	_	
173-66	31937-31952	Disorders–Fifth	_	
173-67	31953-31960	Edition	_	
173-68	31961-31962	(	_	
173-69	31962-31965	PCL	_	
173-70	31965-31966	-	_	
173-71	31966-31967	5	_	
173-72	31967-31968	)	_	
173-73	31969-31971	in	_	
173-74	31972-31980	veterans	_	
173-75	31981-31989	Efficacy	_	
173-76	31990-31993	and	_	
173-77	31994-32000	safety	_	
173-78	32001-32003	of	_	
173-79	32004-32014	sertraline	_	
173-80	32015-32024	treatment	_	
173-81	32025-32027	of	_	
173-82	32028-32041	posttraumatic	_	
173-83	32042-32048	stress	_	
173-84	32049-32057	disorder	_	
173-85	32057-32058	:	_	
173-86	32059-32060	a	_	
173-87	32061-32071	randomized	_	
173-88	32072-32082	controlled	_	
173-89	32083-32088	trial	_	
173-90	32089-32099	Sertraline	_	
173-91	32100-32102	in	_	
173-92	32103-32106	the	_	
173-93	32107-32116	treatment	_	
173-94	32117-32119	of	_	
173-95	32120-32132	co-occurring	_	
173-96	32133-32140	alcohol	_	
173-97	32141-32151	dependence	_	
173-98	32152-32155	and	_	
173-99	32156-32169	posttraumatic	_	
173-100	32170-32176	stress	_	
173-101	32177-32185	disorder	_	
173-102	32186-32197	Development	_	
173-103	32198-32201	and	_	
173-104	32202-32209	initial	_	
173-105	32210-32220	evaluation	_	
173-106	32221-32223	of	_	
173-107	32224-32227	the	_	
173-108	32228-32233	Brief	_	
173-109	32234-32243	Addiction	_	
173-110	32244-32251	Monitor	_	
173-111	32252-32253	(	_	
173-112	32253-32256	BAM	_	
173-113	32256-32257	)	_	
173-114	32258-32262	Does	_	
173-115	32263-32274	acamprosate	_	
173-116	32275-32282	improve	_	
173-117	32283-32292	reduction	_	
173-118	32293-32295	of	_	
173-119	32296-32304	drinking	_	
173-120	32305-32307	as	_	
173-121	32308-32312	well	_	
173-122	32313-32315	as	_	
173-123	32316-32322	aiding	_	
173-124	32323-32333	abstinence	_	
173-125	32333-32334	?	_	

#Text=Multicenter, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder
#Text=Doxazosin treatment for posttraumatic stress disorder
#Text=Concurrent naltrexone and prolonged exposure therapy for patients with comorbid alcohol dependence and PTSD: a randomized clinical trial
#Text=Prazosin effects on stress-and cue-induced craving and stress response in alcohol-dependent individuals: preliminary findings
#Text=Psychophysiological and modulatory interactions in neuroimaging
#Text=Doxazosin
#Text=Placebo-controlled comparison of prazosin and cognitive-behavioral treatments for sleep disturbances in US military veterans
#Text=Epidemiology of DSM-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions III
#Text=Higher pretreatment blood pressure is associated with greater alcohol drinking reduction in alcohol-dependent individuals treated with doxazosin
#Text=Noradrenergic targets for the treatment of alcohol use disorder
#Text=Tracing the flow of knowledge: geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs
#Text=Diffusion of prazosin treatment for PTSD
#Text=Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD)
#Text=The role of central noradrenergic dysregulation in anxiety disorders: evidence from clinical studies
#Text=Terazosin and doxazosin in normotensive men with symptomatic prostatism: a pilot study to determine the effect of dosing regimen on efficacy and safety
#Text=VA Cooperative Study# 334: Summary of findings on the psychophysiological assessment of PTSD
#Text=Role of the α1 blocker doxazosin in alcoholism: a proof-ofconcept randomized controlled trial
#Text=Prevalence and treatment of mental disorders, 1990 to 2003
#Text=Morning vs evening dosing with doxazosin in benign prostatic hyperplasia: efficacy and safety
#Text=Drugs of abuse specifically sensitize noradrenergic and serotonergic neurons via a non-dopaminergic mechanism
#Text=Doxazosin for Alcohol Dependence: a pilot Double-blind Placebocontrolled Trial
#Text=Meta-analysis of naltrexone and acamprosate for treating alcohol use disorders: when are these medications most helpful?
174-1	32335-32346	Multicenter	_	
174-2	32346-32347	,	_	
174-3	32348-32360	double-blind	_	
174-4	32361-32371	comparison	_	
174-5	32372-32374	of	_	
174-6	32375-32385	sertraline	_	
174-7	32386-32389	and	_	
174-8	32390-32397	placebo	_	
174-9	32398-32400	in	_	
174-10	32401-32404	the	_	
174-11	32405-32414	treatment	_	
174-12	32415-32417	of	_	
174-13	32418-32431	posttraumatic	_	
174-14	32432-32438	stress	_	
174-15	32439-32447	disorder	_	
174-16	32448-32457	Doxazosin	_	
174-17	32458-32467	treatment	_	
174-18	32468-32471	for	_	
174-19	32472-32485	posttraumatic	_	
174-20	32486-32492	stress	_	
174-21	32493-32501	disorder	_	
174-22	32502-32512	Concurrent	_	
174-23	32513-32523	naltrexone	_	
174-24	32524-32527	and	_	
174-25	32528-32537	prolonged	_	
174-26	32538-32546	exposure	_	
174-27	32547-32554	therapy	_	
174-28	32555-32558	for	_	
174-29	32559-32567	patients	_	
174-30	32568-32572	with	_	
174-31	32573-32581	comorbid	_	
174-32	32582-32589	alcohol	_	
174-33	32590-32600	dependence	_	
174-34	32601-32604	and	_	
174-35	32605-32609	PTSD	_	
174-36	32609-32610	:	_	
174-37	32611-32612	a	_	
174-38	32613-32623	randomized	_	
174-39	32624-32632	clinical	_	
174-40	32633-32638	trial	_	
174-41	32639-32647	Prazosin	_	
174-42	32648-32655	effects	_	
174-43	32656-32658	on	_	
174-44	32659-32669	stress-and	_	
174-45	32670-32681	cue-induced	_	
174-46	32682-32689	craving	_	
174-47	32690-32693	and	_	
174-48	32694-32700	stress	_	
174-49	32701-32709	response	_	
174-50	32710-32712	in	_	
174-51	32713-32730	alcohol-dependent	_	
174-52	32731-32742	individuals	_	
174-53	32742-32743	:	_	
174-54	32744-32755	preliminary	_	
174-55	32756-32764	findings	_	
174-56	32765-32784	Psychophysiological	_	
174-57	32785-32788	and	_	
174-58	32789-32799	modulatory	_	
174-59	32800-32812	interactions	_	
174-60	32813-32815	in	_	
174-61	32816-32828	neuroimaging	_	
174-62	32829-32838	Doxazosin	_	
174-63	32839-32857	Placebo-controlled	_	
174-64	32858-32868	comparison	_	
174-65	32869-32871	of	_	
174-66	32872-32880	prazosin	_	
174-67	32881-32884	and	_	
174-68	32885-32905	cognitive-behavioral	_	
174-69	32906-32916	treatments	_	
174-70	32917-32920	for	_	
174-71	32921-32926	sleep	_	
174-72	32927-32939	disturbances	_	
174-73	32940-32942	in	_	
174-74	32943-32945	US	_	
174-75	32946-32954	military	_	
174-76	32955-32963	veterans	_	
174-77	32964-32976	Epidemiology	_	
174-78	32977-32979	of	_	
174-79	32980-32983	DSM	_	
174-80	32983-32984	-	_	
174-81	32984-32985	5	_	
174-82	32986-32993	alcohol	_	
174-83	32994-32997	use	_	
174-84	32998-33006	disorder	_	
174-85	33006-33007	:	_	
174-86	33008-33015	results	_	
174-87	33016-33020	from	_	
174-88	33021-33024	the	_	
174-89	33025-33033	national	_	
174-90	33034-33047	epidemiologic	_	
174-91	33048-33054	survey	_	
174-92	33055-33057	on	_	
174-93	33058-33065	alcohol	_	
174-94	33066-33069	and	_	
174-95	33070-33077	related	_	
174-96	33078-33088	conditions	_	
174-97	33089-33092	III	_	
174-98	33093-33099	Higher	_	
174-99	33100-33112	pretreatment	_	
174-100	33113-33118	blood	_	
174-101	33119-33127	pressure	_	
174-102	33128-33130	is	_	
174-103	33131-33141	associated	_	
174-104	33142-33146	with	_	
174-105	33147-33154	greater	_	
174-106	33155-33162	alcohol	_	
174-107	33163-33171	drinking	_	
174-108	33172-33181	reduction	_	
174-109	33182-33184	in	_	
174-110	33185-33202	alcohol-dependent	_	
174-111	33203-33214	individuals	_	
174-112	33215-33222	treated	_	
174-113	33223-33227	with	_	
174-114	33228-33237	doxazosin	_	
174-115	33238-33251	Noradrenergic	_	
174-116	33252-33259	targets	_	
174-117	33260-33263	for	_	
174-118	33264-33267	the	_	
174-119	33268-33277	treatment	_	
174-120	33278-33280	of	_	
174-121	33281-33288	alcohol	_	
174-122	33289-33292	use	_	
174-123	33293-33301	disorder	_	
174-124	33302-33309	Tracing	_	
174-125	33310-33313	the	_	
174-126	33314-33318	flow	_	
174-127	33319-33321	of	_	
174-128	33322-33331	knowledge	_	
174-129	33331-33332	:	_	
174-130	33333-33343	geographic	_	
174-131	33344-33355	variability	_	
174-132	33356-33358	in	_	
174-133	33359-33362	the	_	
174-134	33363-33372	diffusion	_	
174-135	33373-33375	of	_	
174-136	33376-33384	prazosin	_	
174-137	33385-33388	use	_	
174-138	33389-33392	for	_	
174-139	33393-33396	the	_	
174-140	33397-33406	treatment	_	
174-141	33407-33409	of	_	
174-142	33410-33423	posttraumatic	_	
174-143	33424-33430	stress	_	
174-144	33431-33439	disorder	_	
174-145	33440-33450	nationally	_	
174-146	33451-33453	in	_	
174-147	33454-33457	the	_	
174-148	33458-33468	Department	_	
174-149	33469-33471	of	_	
174-150	33472-33480	Veterans	_	
174-151	33481-33488	Affairs	_	
174-152	33489-33498	Diffusion	_	
174-153	33499-33501	of	_	
174-154	33502-33510	prazosin	_	
174-155	33511-33520	treatment	_	
174-156	33521-33524	for	_	
174-157	33525-33529	PTSD	_	
174-158	33530-33544	Evidence-based	_	
174-159	33545-33560	pharmacotherapy	_	
174-160	33561-33563	of	_	
174-161	33564-33578	post-traumatic	_	
174-162	33579-33585	stress	_	
174-163	33586-33594	disorder	_	
174-164	33595-33596	(	_	
174-165	33596-33600	PTSD	_	
174-166	33600-33601	)	_	
174-167	33602-33605	The	_	
174-168	33606-33610	role	_	
174-169	33611-33613	of	_	
174-170	33614-33621	central	_	
174-171	33622-33635	noradrenergic	_	
174-172	33636-33649	dysregulation	_	
174-173	33650-33652	in	_	
174-174	33653-33660	anxiety	_	
174-175	33661-33670	disorders	_	
174-176	33670-33671	:	_	
174-177	33672-33680	evidence	_	
174-178	33681-33685	from	_	
174-179	33686-33694	clinical	_	
174-180	33695-33702	studies	_	
174-181	33703-33712	Terazosin	_	
174-182	33713-33716	and	_	
174-183	33717-33726	doxazosin	_	
174-184	33727-33729	in	_	
174-185	33730-33742	normotensive	_	
174-186	33743-33746	men	_	
174-187	33747-33751	with	_	
174-188	33752-33763	symptomatic	_	
174-189	33764-33774	prostatism	_	
174-190	33774-33775	:	_	
174-191	33776-33777	a	_	
174-192	33778-33783	pilot	_	
174-193	33784-33789	study	_	
174-194	33790-33792	to	_	
174-195	33793-33802	determine	_	
174-196	33803-33806	the	_	
174-197	33807-33813	effect	_	
174-198	33814-33816	of	_	
174-199	33817-33823	dosing	_	
174-200	33824-33831	regimen	_	
174-201	33832-33834	on	_	
174-202	33835-33843	efficacy	_	
174-203	33844-33847	and	_	
174-204	33848-33854	safety	_	
174-205	33855-33857	VA	_	
174-206	33858-33869	Cooperative	_	
174-207	33870-33875	Study	_	
174-208	33875-33876	#	_	
174-209	33877-33880	334	_	
174-210	33880-33881	:	_	
174-211	33882-33889	Summary	_	
174-212	33890-33892	of	_	
174-213	33893-33901	findings	_	
174-214	33902-33904	on	_	
174-215	33905-33908	the	_	
174-216	33909-33928	psychophysiological	_	
174-217	33929-33939	assessment	_	
174-218	33940-33942	of	_	
174-219	33943-33947	PTSD	_	
174-220	33948-33952	Role	_	
174-221	33953-33955	of	_	
174-222	33956-33959	the	_	
174-223	33960-33962	α1	_	
174-224	33963-33970	blocker	_	
174-225	33971-33980	doxazosin	_	
174-226	33981-33983	in	_	
174-227	33984-33994	alcoholism	_	
174-228	33994-33995	:	_	
174-229	33996-33997	a	_	
174-230	33998-34013	proof-ofconcept	_	
174-231	34014-34024	randomized	_	
174-232	34025-34035	controlled	_	
174-233	34036-34041	trial	_	
174-234	34042-34052	Prevalence	_	
174-235	34053-34056	and	_	
174-236	34057-34066	treatment	_	
174-237	34067-34069	of	_	
174-238	34070-34076	mental	_	
174-239	34077-34086	disorders	_	
174-240	34086-34087	,	_	
174-241	34088-34092	1990	_	
174-242	34093-34095	to	_	
174-243	34096-34100	2003	_	
174-244	34101-34108	Morning	_	
174-245	34109-34111	vs	_	
174-246	34112-34119	evening	_	
174-247	34120-34126	dosing	_	
174-248	34127-34131	with	_	
174-249	34132-34141	doxazosin	_	
174-250	34142-34144	in	_	
174-251	34145-34151	benign	_	
174-252	34152-34161	prostatic	_	
174-253	34162-34173	hyperplasia	_	
174-254	34173-34174	:	_	
174-255	34175-34183	efficacy	_	
174-256	34184-34187	and	_	
174-257	34188-34194	safety	_	
174-258	34195-34200	Drugs	_	
174-259	34201-34203	of	_	
174-260	34204-34209	abuse	_	
174-261	34210-34222	specifically	_	
174-262	34223-34232	sensitize	_	
174-263	34233-34246	noradrenergic	_	
174-264	34247-34250	and	_	
174-265	34251-34263	serotonergic	_	
174-266	34264-34271	neurons	_	
174-267	34272-34275	via	_	
174-268	34276-34277	a	_	
174-269	34278-34294	non-dopaminergic	_	
174-270	34295-34304	mechanism	_	
174-271	34305-34314	Doxazosin	_	
174-272	34315-34318	for	_	
174-273	34319-34326	Alcohol	_	
174-274	34327-34337	Dependence	_	
174-275	34337-34338	:	_	
174-276	34339-34340	a	_	
174-277	34341-34346	pilot	_	
174-278	34347-34359	Double-blind	_	
174-279	34360-34377	Placebocontrolled	_	
174-280	34378-34383	Trial	_	
174-281	34384-34397	Meta-analysis	_	
174-282	34398-34400	of	_	
174-283	34401-34411	naltrexone	_	
174-284	34412-34415	and	_	
174-285	34416-34427	acamprosate	_	
174-286	34428-34431	for	_	
174-287	34432-34440	treating	_	
174-288	34441-34448	alcohol	_	
174-289	34449-34452	use	_	
174-290	34453-34462	disorders	_	
174-291	34462-34463	:	_	
174-292	34464-34468	when	_	
174-293	34469-34472	are	_	
174-294	34473-34478	these	_	
174-295	34479-34490	medications	_	
174-296	34491-34495	most	_	
174-297	34496-34503	helpful	_	
174-298	34503-34504	?	_	

#Text=Association of time since deployment, combat intensity, and posttraumatic stress symptoms with neuropsychological outcomes following Iraq war deployment
#Text=The fifth edition of the Addiction Severity Index
#Text=Military-related PTSD and intimate relationships: from description to theory-driven research and intervention development
#Text=The α1-Adrenergic Receptor Antagonist, Doxazosin, Reduces Alcohol Drinking in Alcohol-Preferring (P) Rats
#Text=Tools of the trade: psychophysiological interactions and functional connectivity
#Text=PTSD treatment and 5-year remission among patients with substance use and posttraumatic stress disorders
#Text=Changes in plasma noradrenaline and serotonin levels and craving during alcohol withdrawal
#Text=Prazosin for veterans with Posttraumatic stress disorder and comorbid alcohol dependence: a clinical trial
#Text=Noradrenergic vs serotonergic antidepressant with or without naltrexone for veterans with PTSD and comorbid alcohol dependence
#Text=Substance Use Comorbidity among Veterans with Posttraumatic stress Disorder and Other Psychiatric Illness
#Text=Posttraumatic stress disorder and alcohol use disorder: a critical review of pharmacologic treatments
#Text=Subsyndromal posttraumatic stress disorder is associated with health and psychosocial difficulties in veterans of Operations Enduring Freedom and Iraqi Freedom
#Text=Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions
#Text=Prevalence and Axis I comorbidity of full and partial posttraumatic stress disorder in the United States: results from Wave 2 of the National Epidemiologic Survey on Alcohol and Related Conditions
#Text=Higher pretreatment blood pressure is associated with greater posttraumatic stress disorder symptom reduction in soldiers treated with prazosin
#Text=Trial of prazosin for post-traumatic stress disorder in military veterans
#Text=A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder
#Text=A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder
#Text=Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study
#Text=A trial of prazosin for combat trauma PTSD with nightmares in activeduty soldiers returned from Iraq and Afghanistan
#Text=Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial
#Text=Doxazosin XL reduces symptoms of posttraumatic stress disorder in veterans with PTSD: a pilot clinical trial
#Text=Bringing the war back home: Mental health disorders among 103 788 US veterans returning from Iraq and Afghanistan seen at Department of Veterans Affairs Facilities
#Text=The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSMIV and ICD-10
#Text=The alpha-1 adrenergic antagonist doxazosin for treatment of cocaine dependence: a pilot study
#Text=A.J.
175-1	34505-34516	Association	_	
175-2	34517-34519	of	_	
175-3	34520-34524	time	_	
175-4	34525-34530	since	_	
175-5	34531-34541	deployment	_	
175-6	34541-34542	,	_	
175-7	34543-34549	combat	_	
175-8	34550-34559	intensity	_	
175-9	34559-34560	,	_	
175-10	34561-34564	and	_	
175-11	34565-34578	posttraumatic	_	
175-12	34579-34585	stress	_	
175-13	34586-34594	symptoms	_	
175-14	34595-34599	with	_	
175-15	34600-34618	neuropsychological	_	
175-16	34619-34627	outcomes	_	
175-17	34628-34637	following	_	
175-18	34638-34642	Iraq	_	
175-19	34643-34646	war	_	
175-20	34647-34657	deployment	_	
175-21	34658-34661	The	_	
175-22	34662-34667	fifth	_	
175-23	34668-34675	edition	_	
175-24	34676-34678	of	_	
175-25	34679-34682	the	_	
175-26	34683-34692	Addiction	_	
175-27	34693-34701	Severity	_	
175-28	34702-34707	Index	_	
175-29	34708-34724	Military-related	_	
175-30	34725-34729	PTSD	_	
175-31	34730-34733	and	_	
175-32	34734-34742	intimate	_	
175-33	34743-34756	relationships	_	
175-34	34756-34757	:	_	
175-35	34758-34762	from	_	
175-36	34763-34774	description	_	
175-37	34775-34777	to	_	
175-38	34778-34791	theory-driven	_	
175-39	34792-34800	research	_	
175-40	34801-34804	and	_	
175-41	34805-34817	intervention	_	
175-42	34818-34829	development	_	
175-43	34830-34833	The	_	
175-44	34834-34836	α1	_	
175-45	34836-34837	-	_	
175-46	34837-34847	Adrenergic	_	
175-47	34848-34856	Receptor	_	
175-48	34857-34867	Antagonist	_	
175-49	34867-34868	,	_	
175-50	34869-34878	Doxazosin	_	
175-51	34878-34879	,	_	
175-52	34880-34887	Reduces	_	
175-53	34888-34895	Alcohol	_	
175-54	34896-34904	Drinking	_	
175-55	34905-34907	in	_	
175-56	34908-34926	Alcohol-Preferring	_	
175-57	34927-34928	(	_	
175-58	34928-34929	P	_	
175-59	34929-34930	)	_	
175-60	34931-34935	Rats	_	
175-61	34936-34941	Tools	_	
175-62	34942-34944	of	_	
175-63	34945-34948	the	_	
175-64	34949-34954	trade	_	
175-65	34954-34955	:	_	
175-66	34956-34975	psychophysiological	_	
175-67	34976-34988	interactions	_	
175-68	34989-34992	and	_	
175-69	34993-35003	functional	_	
175-70	35004-35016	connectivity	_	
175-71	35017-35021	PTSD	_	
175-72	35022-35031	treatment	_	
175-73	35032-35035	and	_	
175-74	35036-35037	5	_	
175-75	35037-35038	-	_	
175-76	35038-35042	year	_	
175-77	35043-35052	remission	_	
175-78	35053-35058	among	_	
175-79	35059-35067	patients	_	
175-80	35068-35072	with	_	
175-81	35073-35082	substance	_	
175-82	35083-35086	use	_	
175-83	35087-35090	and	_	
175-84	35091-35104	posttraumatic	_	
175-85	35105-35111	stress	_	
175-86	35112-35121	disorders	_	
175-87	35122-35129	Changes	_	
175-88	35130-35132	in	_	
175-89	35133-35139	plasma	_	
175-90	35140-35153	noradrenaline	_	
175-91	35154-35157	and	_	
175-92	35158-35167	serotonin	_	
175-93	35168-35174	levels	_	
175-94	35175-35178	and	_	
175-95	35179-35186	craving	_	
175-96	35187-35193	during	_	
175-97	35194-35201	alcohol	_	
175-98	35202-35212	withdrawal	_	
175-99	35213-35221	Prazosin	_	
175-100	35222-35225	for	_	
175-101	35226-35234	veterans	_	
175-102	35235-35239	with	_	
175-103	35240-35253	Posttraumatic	_	
175-104	35254-35260	stress	_	
175-105	35261-35269	disorder	_	
175-106	35270-35273	and	_	
175-107	35274-35282	comorbid	_	
175-108	35283-35290	alcohol	_	
175-109	35291-35301	dependence	_	
175-110	35301-35302	:	_	
175-111	35303-35304	a	_	
175-112	35305-35313	clinical	_	
175-113	35314-35319	trial	_	
175-114	35320-35333	Noradrenergic	_	
175-115	35334-35336	vs	_	
175-116	35337-35349	serotonergic	_	
175-117	35350-35364	antidepressant	_	
175-118	35365-35369	with	_	
175-119	35370-35372	or	_	
175-120	35373-35380	without	_	
175-121	35381-35391	naltrexone	_	
175-122	35392-35395	for	_	
175-123	35396-35404	veterans	_	
175-124	35405-35409	with	_	
175-125	35410-35414	PTSD	_	
175-126	35415-35418	and	_	
175-127	35419-35427	comorbid	_	
175-128	35428-35435	alcohol	_	
175-129	35436-35446	dependence	_	
175-130	35447-35456	Substance	_	
175-131	35457-35460	Use	_	
175-132	35461-35472	Comorbidity	_	
175-133	35473-35478	among	_	
175-134	35479-35487	Veterans	_	
175-135	35488-35492	with	_	
175-136	35493-35506	Posttraumatic	_	
175-137	35507-35513	stress	_	
175-138	35514-35522	Disorder	_	
175-139	35523-35526	and	_	
175-140	35527-35532	Other	_	
175-141	35533-35544	Psychiatric	_	
175-142	35545-35552	Illness	_	
175-143	35553-35566	Posttraumatic	_	
175-144	35567-35573	stress	_	
175-145	35574-35582	disorder	_	
175-146	35583-35586	and	_	
175-147	35587-35594	alcohol	_	
175-148	35595-35598	use	_	
175-149	35599-35607	disorder	_	
175-150	35607-35608	:	_	
175-151	35609-35610	a	_	
175-152	35611-35619	critical	_	
175-153	35620-35626	review	_	
175-154	35627-35629	of	_	
175-155	35630-35643	pharmacologic	_	
175-156	35644-35654	treatments	_	
175-157	35655-35667	Subsyndromal	_	
175-158	35668-35681	posttraumatic	_	
175-159	35682-35688	stress	_	
175-160	35689-35697	disorder	_	
175-161	35698-35700	is	_	
175-162	35701-35711	associated	_	
175-163	35712-35716	with	_	
175-164	35717-35723	health	_	
175-165	35724-35727	and	_	
175-166	35728-35740	psychosocial	_	
175-167	35741-35753	difficulties	_	
175-168	35754-35756	in	_	
175-169	35757-35765	veterans	_	
175-170	35766-35768	of	_	
175-171	35769-35779	Operations	_	
175-172	35780-35788	Enduring	_	
175-173	35789-35796	Freedom	_	
175-174	35797-35800	and	_	
175-175	35801-35806	Iraqi	_	
175-176	35807-35814	Freedom	_	
175-177	35815-35825	Prevalence	_	
175-178	35826-35829	and	_	
175-179	35830-35834	Axis	_	
175-180	35835-35836	I	_	
175-181	35837-35848	comorbidity	_	
175-182	35849-35851	of	_	
175-183	35852-35856	full	_	
175-184	35857-35860	and	_	
175-185	35861-35868	partial	_	
175-186	35869-35882	posttraumatic	_	
175-187	35883-35889	stress	_	
175-188	35890-35898	disorder	_	
175-189	35899-35901	in	_	
175-190	35902-35905	the	_	
175-191	35906-35912	United	_	
175-192	35913-35919	States	_	
175-193	35919-35920	:	_	
175-194	35921-35928	results	_	
175-195	35929-35933	from	_	
175-196	35934-35938	Wave	_	
175-197	35939-35940	2	_	
175-198	35941-35943	of	_	
175-199	35944-35947	the	_	
175-200	35948-35956	National	_	
175-201	35957-35970	Epidemiologic	_	
175-202	35971-35977	Survey	_	
175-203	35978-35980	on	_	
175-204	35981-35988	Alcohol	_	
175-205	35989-35992	and	_	
175-206	35993-36000	Related	_	
175-207	36001-36011	Conditions	_	
175-208	36012-36022	Prevalence	_	
175-209	36023-36026	and	_	
175-210	36027-36031	Axis	_	
175-211	36032-36033	I	_	
175-212	36034-36045	comorbidity	_	
175-213	36046-36048	of	_	
175-214	36049-36053	full	_	
175-215	36054-36057	and	_	
175-216	36058-36065	partial	_	
175-217	36066-36079	posttraumatic	_	
175-218	36080-36086	stress	_	
175-219	36087-36095	disorder	_	
175-220	36096-36098	in	_	
175-221	36099-36102	the	_	
175-222	36103-36109	United	_	
175-223	36110-36116	States	_	
175-224	36116-36117	:	_	
175-225	36118-36125	results	_	
175-226	36126-36130	from	_	
175-227	36131-36135	Wave	_	
175-228	36136-36137	2	_	
175-229	36138-36140	of	_	
175-230	36141-36144	the	_	
175-231	36145-36153	National	_	
175-232	36154-36167	Epidemiologic	_	
175-233	36168-36174	Survey	_	
175-234	36175-36177	on	_	
175-235	36178-36185	Alcohol	_	
175-236	36186-36189	and	_	
175-237	36190-36197	Related	_	
175-238	36198-36208	Conditions	_	
175-239	36209-36215	Higher	_	
175-240	36216-36228	pretreatment	_	
175-241	36229-36234	blood	_	
175-242	36235-36243	pressure	_	
175-243	36244-36246	is	_	
175-244	36247-36257	associated	_	
175-245	36258-36262	with	_	
175-246	36263-36270	greater	_	
175-247	36271-36284	posttraumatic	_	
175-248	36285-36291	stress	_	
175-249	36292-36300	disorder	_	
175-250	36301-36308	symptom	_	
175-251	36309-36318	reduction	_	
175-252	36319-36321	in	_	
175-253	36322-36330	soldiers	_	
175-254	36331-36338	treated	_	
175-255	36339-36343	with	_	
175-256	36344-36352	prazosin	_	
175-257	36353-36358	Trial	_	
175-258	36359-36361	of	_	
175-259	36362-36370	prazosin	_	
175-260	36371-36374	for	_	
175-261	36375-36389	post-traumatic	_	
175-262	36390-36396	stress	_	
175-263	36397-36405	disorder	_	
175-264	36406-36408	in	_	
175-265	36409-36417	military	_	
175-266	36418-36426	veterans	_	
175-267	36427-36428	A	_	
175-268	36429-36437	parallel	_	
175-269	36438-36443	group	_	
175-270	36444-36451	placebo	_	
175-271	36452-36462	controlled	_	
175-272	36463-36468	study	_	
175-273	36469-36471	of	_	
175-274	36472-36480	prazosin	_	
175-275	36481-36484	for	_	
175-276	36485-36491	trauma	_	
175-277	36492-36502	nightmares	_	
175-278	36503-36506	and	_	
175-279	36507-36512	sleep	_	
175-280	36513-36524	disturbance	_	
175-281	36525-36527	in	_	
175-282	36528-36534	combat	_	
175-283	36535-36543	veterans	_	
175-284	36544-36548	with	_	
175-285	36549-36563	post-traumatic	_	
175-286	36564-36570	stress	_	
175-287	36571-36579	disorder	_	
175-288	36580-36581	A	_	
175-289	36582-36590	parallel	_	
175-290	36591-36596	group	_	
175-291	36597-36604	placebo	_	
175-292	36605-36615	controlled	_	
175-293	36616-36621	study	_	
175-294	36622-36624	of	_	
175-295	36625-36633	prazosin	_	
175-296	36634-36637	for	_	
175-297	36638-36644	trauma	_	
175-298	36645-36655	nightmares	_	
175-299	36656-36659	and	_	
175-300	36660-36665	sleep	_	
175-301	36666-36677	disturbance	_	
175-302	36678-36680	in	_	
175-303	36681-36687	combat	_	
175-304	36688-36696	veterans	_	
175-305	36697-36701	with	_	
175-306	36702-36716	post-traumatic	_	
175-307	36717-36723	stress	_	
175-308	36724-36732	disorder	_	
175-309	36733-36742	Reduction	_	
175-310	36743-36745	of	_	
175-311	36746-36756	nightmares	_	
175-312	36757-36760	and	_	
175-313	36761-36766	other	_	
175-314	36767-36771	PTSD	_	
175-315	36772-36780	symptoms	_	
175-316	36781-36783	in	_	
175-317	36784-36790	combat	_	
175-318	36791-36799	veterans	_	
175-319	36800-36802	by	_	
175-320	36803-36811	prazosin	_	
175-321	36811-36812	:	_	
175-322	36813-36814	a	_	
175-323	36815-36833	placebo-controlled	_	
175-324	36834-36839	study	_	
175-325	36840-36841	A	_	
175-326	36842-36847	trial	_	
175-327	36848-36850	of	_	
175-328	36851-36859	prazosin	_	
175-329	36860-36863	for	_	
175-330	36864-36870	combat	_	
175-331	36871-36877	trauma	_	
175-332	36878-36882	PTSD	_	
175-333	36883-36887	with	_	
175-334	36888-36898	nightmares	_	
175-335	36899-36901	in	_	
175-336	36902-36912	activeduty	_	
175-337	36913-36921	soldiers	_	
175-338	36922-36930	returned	_	
175-339	36931-36935	from	_	
175-340	36936-36940	Iraq	_	
175-341	36941-36944	and	_	
175-342	36945-36956	Afghanistan	_	
175-343	36957-36966	Doxazosin	_	
175-344	36967-36969	XL	_	
175-345	36970-36977	reduces	_	
175-346	36978-36986	symptoms	_	
175-347	36987-36989	of	_	
175-348	36990-37003	posttraumatic	_	
175-349	37004-37010	stress	_	
175-350	37011-37019	disorder	_	
175-351	37020-37022	in	_	
175-352	37023-37031	veterans	_	
175-353	37032-37036	with	_	
175-354	37037-37041	PTSD	_	
175-355	37041-37042	:	_	
175-356	37043-37044	a	_	
175-357	37045-37050	pilot	_	
175-358	37051-37059	clinical	_	
175-359	37060-37065	trial	_	
175-360	37066-37075	Doxazosin	_	
175-361	37076-37078	XL	_	
175-362	37079-37086	reduces	_	
175-363	37087-37095	symptoms	_	
175-364	37096-37098	of	_	
175-365	37099-37112	posttraumatic	_	
175-366	37113-37119	stress	_	
175-367	37120-37128	disorder	_	
175-368	37129-37131	in	_	
175-369	37132-37140	veterans	_	
175-370	37141-37145	with	_	
175-371	37146-37150	PTSD	_	
175-372	37150-37151	:	_	
175-373	37152-37153	a	_	
175-374	37154-37159	pilot	_	
175-375	37160-37168	clinical	_	
175-376	37169-37174	trial	_	
175-377	37175-37183	Bringing	_	
175-378	37184-37187	the	_	
175-379	37188-37191	war	_	
175-380	37192-37196	back	_	
175-381	37197-37201	home	_	
175-382	37201-37202	:	_	
175-383	37203-37209	Mental	_	
175-384	37210-37216	health	_	
175-385	37217-37226	disorders	_	
175-386	37227-37232	among	_	
175-387	37233-37236	103	_	
175-388	37237-37240	788	_	
175-389	37241-37243	US	_	
175-390	37244-37252	veterans	_	
175-391	37253-37262	returning	_	
175-392	37263-37267	from	_	
175-393	37268-37272	Iraq	_	
175-394	37273-37276	and	_	
175-395	37277-37288	Afghanistan	_	
175-396	37289-37293	seen	_	
175-397	37294-37296	at	_	
175-398	37297-37307	Department	_	
175-399	37308-37310	of	_	
175-400	37311-37319	Veterans	_	
175-401	37320-37327	Affairs	_	
175-402	37328-37338	Facilities	_	
175-403	37339-37342	The	_	
175-404	37343-37361	mini-international	_	
175-405	37362-37378	neuropsychiatric	_	
175-406	37379-37388	interview	_	
175-407	37389-37390	(	_	
175-408	37390-37394	MINI	_	
175-409	37394-37395	)	_	
175-410	37395-37396	:	_	
175-411	37397-37400	the	_	
175-412	37401-37412	development	_	
175-413	37413-37416	and	_	
175-414	37417-37427	validation	_	
175-415	37428-37430	of	_	
175-416	37431-37432	a	_	
175-417	37433-37443	structured	_	
175-418	37444-37454	diagnostic	_	
175-419	37455-37466	psychiatric	_	
175-420	37467-37476	interview	_	
175-421	37477-37480	for	_	
175-422	37481-37486	DSMIV	_	
175-423	37487-37490	and	_	
175-424	37491-37494	ICD	_	
175-425	37494-37495	-	_	
175-426	37495-37497	10	_	
175-427	37498-37501	The	_	
175-428	37502-37507	alpha	_	
175-429	37507-37508	-	_	
175-430	37508-37509	1	_	
175-431	37510-37520	adrenergic	_	
175-432	37521-37531	antagonist	_	
175-433	37532-37541	doxazosin	_	
175-434	37542-37545	for	_	
175-435	37546-37555	treatment	_	
175-436	37556-37558	of	_	
175-437	37559-37566	cocaine	_	
175-438	37567-37577	dependence	_	
175-439	37577-37578	:	_	
175-440	37579-37580	a	_	
175-441	37581-37586	pilot	_	
175-442	37587-37592	study	_	
175-443	37593-37596	A.J	_	
175-444	37596-37597	.	_	

#Text=Saxon, A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder
#Text=A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence
#Text=Enhanced negative emotion and alcohol craving, and altered physiological responses following stress and cue exposure in alcohol dependent individuals
#Text=
#Text=Pharmacological treatment of comorbid PTSD and substance use disorder: recent progress
#Text=Pharmacotherapy of posttraumatic stress disorder: a review of meta-analyses and treatment guidelines
#Text=
#Text=Assessment of Alcohol Withdrawal: the revised clinical institute withdrawal assessment for alcohol scale (CIWA-Ar)
#Text=Invisible Wounds of War
#Text=Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma posttraumatic stress disorder: a placebo-controlled study
#Text=Integrated treatment programs for individuals with concurrent substance use disorders and trauma experiences: a systematic review and meta-analysis
#Text=Psychological treatments for concurrent posttraumatic stress disorder and substance use disorder: a systematic review
#Text=
#Text=
#Text=Adherence to pharmacotherapy in patients with alcohol and opioid dependence
#Text=A randomized, placebo-controlled, clinical trial of prazosin for the treatment of alcohol use disorder
#Text=Pharmacogenetics of dopamine B-hydroxylase in cocaine depenence therapy with doxazosin
#Text=Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder
#Text=A new depression scale designed to be sensitive to change
#Text=Study design overview.
176-1	37598-37603	Saxon	_	
176-2	37603-37604	,	_	
176-3	37605-37606	A	_	
176-4	37607-37612	pilot	_	
176-5	37613-37618	trial	_	
176-6	37619-37621	of	_	
176-7	37622-37630	prazosin	_	
176-8	37630-37631	,	_	
176-9	37632-37634	an	_	
176-10	37635-37640	alpha	_	
176-11	37640-37641	-	_	
176-12	37641-37642	1	_	
176-13	37643-37653	adrenergic	_	
176-14	37654-37664	antagonist	_	
176-15	37664-37665	,	_	
176-16	37666-37669	for	_	
176-17	37670-37678	comorbid	_	
176-18	37679-37686	alcohol	_	
176-19	37687-37697	dependence	_	
176-20	37698-37701	and	_	
176-21	37702-37715	posttraumatic	_	
176-22	37716-37722	stress	_	
176-23	37723-37731	disorder	_	
176-24	37732-37733	A	_	
176-25	37734-37739	pilot	_	
176-26	37740-37745	trial	_	
176-27	37746-37748	of	_	
176-28	37749-37752	the	_	
176-29	37753-37758	alpha	_	
176-30	37758-37759	-	_	
176-31	37759-37760	1	_	
176-32	37761-37771	adrenergic	_	
176-33	37772-37782	antagonist	_	
176-34	37782-37783	,	_	
176-35	37784-37792	prazosin	_	
176-36	37792-37793	,	_	
176-37	37794-37797	for	_	
176-38	37798-37805	alcohol	_	
176-39	37806-37816	dependence	_	
176-40	37817-37825	Enhanced	_	
176-41	37826-37834	negative	_	
176-42	37835-37842	emotion	_	
176-43	37843-37846	and	_	
176-44	37847-37854	alcohol	_	
176-45	37855-37862	craving	_	
176-46	37862-37863	,	_	
176-47	37864-37867	and	_	
176-48	37868-37875	altered	_	
176-49	37876-37889	physiological	_	
176-50	37890-37899	responses	_	
176-51	37900-37909	following	_	
176-52	37910-37916	stress	_	
176-53	37917-37920	and	_	
176-54	37921-37924	cue	_	
176-55	37925-37933	exposure	_	
176-56	37934-37936	in	_	
176-57	37937-37944	alcohol	_	
176-58	37945-37954	dependent	_	
176-59	37955-37966	individuals	_	
176-60	37968-37983	Pharmacological	_	
176-61	37984-37993	treatment	_	
176-62	37994-37996	of	_	
176-63	37997-38005	comorbid	_	
176-64	38006-38010	PTSD	_	
176-65	38011-38014	and	_	
176-66	38015-38024	substance	_	
176-67	38025-38028	use	_	
176-68	38029-38037	disorder	_	
176-69	38037-38038	:	_	
176-70	38039-38045	recent	_	
176-71	38046-38054	progress	_	
176-72	38055-38070	Pharmacotherapy	_	
176-73	38071-38073	of	_	
176-74	38074-38087	posttraumatic	_	
176-75	38088-38094	stress	_	
176-76	38095-38103	disorder	_	
176-77	38103-38104	:	_	
176-78	38105-38106	a	_	
176-79	38107-38113	review	_	
176-80	38114-38116	of	_	
176-81	38117-38130	meta-analyses	_	
176-82	38131-38134	and	_	
176-83	38135-38144	treatment	_	
176-84	38145-38155	guidelines	_	
176-85	38157-38167	Assessment	_	
176-86	38168-38170	of	_	
176-87	38171-38178	Alcohol	_	
176-88	38179-38189	Withdrawal	_	
176-89	38189-38190	:	_	
176-90	38191-38194	the	_	
176-91	38195-38202	revised	_	
176-92	38203-38211	clinical	_	
176-93	38212-38221	institute	_	
176-94	38222-38232	withdrawal	_	
176-95	38233-38243	assessment	_	
176-96	38244-38247	for	_	
176-97	38248-38255	alcohol	_	
176-98	38256-38261	scale	_	
176-99	38262-38263	(	_	
176-100	38263-38270	CIWA-Ar	_	
176-101	38270-38271	)	_	
176-102	38272-38281	Invisible	_	
176-103	38282-38288	Wounds	_	
176-104	38289-38291	of	_	
176-105	38292-38295	War	_	
176-106	38296-38304	Prazosin	_	
176-107	38305-38312	effects	_	
176-108	38313-38315	on	_	
176-109	38316-38325	objective	_	
176-110	38326-38331	sleep	_	
176-111	38332-38340	measures	_	
176-112	38341-38344	and	_	
176-113	38345-38353	clinical	_	
176-114	38354-38362	symptoms	_	
176-115	38363-38365	in	_	
176-116	38366-38374	civilian	_	
176-117	38375-38381	trauma	_	
176-118	38382-38395	posttraumatic	_	
176-119	38396-38402	stress	_	
176-120	38403-38411	disorder	_	
176-121	38411-38412	:	_	
176-122	38413-38414	a	_	
176-123	38415-38433	placebo-controlled	_	
176-124	38434-38439	study	_	
176-125	38440-38450	Integrated	_	
176-126	38451-38460	treatment	_	
176-127	38461-38469	programs	_	
176-128	38470-38473	for	_	
176-129	38474-38485	individuals	_	
176-130	38486-38490	with	_	
176-131	38491-38501	concurrent	_	
176-132	38502-38511	substance	_	
176-133	38512-38515	use	_	
176-134	38516-38525	disorders	_	
176-135	38526-38529	and	_	
176-136	38530-38536	trauma	_	
176-137	38537-38548	experiences	_	
176-138	38548-38549	:	_	
176-139	38550-38551	a	_	
176-140	38552-38562	systematic	_	
176-141	38563-38569	review	_	
176-142	38570-38573	and	_	
176-143	38574-38587	meta-analysis	_	
176-144	38588-38601	Psychological	_	
176-145	38602-38612	treatments	_	
176-146	38613-38616	for	_	
176-147	38617-38627	concurrent	_	
176-148	38628-38641	posttraumatic	_	
176-149	38642-38648	stress	_	
176-150	38649-38657	disorder	_	
176-151	38658-38661	and	_	
176-152	38662-38671	substance	_	
176-153	38672-38675	use	_	
176-154	38676-38684	disorder	_	
176-155	38684-38685	:	_	
176-156	38686-38687	a	_	
176-157	38688-38698	systematic	_	
176-158	38699-38705	review	_	
176-159	38708-38717	Adherence	_	
176-160	38718-38720	to	_	
176-161	38721-38736	pharmacotherapy	_	
176-162	38737-38739	in	_	
176-163	38740-38748	patients	_	
176-164	38749-38753	with	_	
176-165	38754-38761	alcohol	_	
176-166	38762-38765	and	_	
176-167	38766-38772	opioid	_	
176-168	38773-38783	dependence	_	
176-169	38784-38785	A	_	
176-170	38786-38796	randomized	_	
176-171	38796-38797	,	_	
176-172	38798-38816	placebo-controlled	_	
176-173	38816-38817	,	_	
176-174	38818-38826	clinical	_	
176-175	38827-38832	trial	_	
176-176	38833-38835	of	_	
176-177	38836-38844	prazosin	_	
176-178	38845-38848	for	_	
176-179	38849-38852	the	_	
176-180	38853-38862	treatment	_	
176-181	38863-38865	of	_	
176-182	38866-38873	alcohol	_	
176-183	38874-38877	use	_	
176-184	38878-38886	disorder	_	
176-185	38887-38903	Pharmacogenetics	_	
176-186	38904-38906	of	_	
176-187	38907-38915	dopamine	_	
176-188	38916-38929	B-hydroxylase	_	
176-189	38930-38932	in	_	
176-190	38933-38940	cocaine	_	
176-191	38941-38950	depenence	_	
176-192	38951-38958	therapy	_	
176-193	38959-38963	with	_	
176-194	38964-38973	doxazosin	_	
176-195	38974-38986	Double-blind	_	
176-196	38987-39005	placebo-controlled	_	
176-197	39006-39011	pilot	_	
176-198	39012-39017	study	_	
176-199	39018-39020	of	_	
176-200	39021-39031	sertraline	_	
176-201	39032-39034	in	_	
176-202	39035-39043	military	_	
176-203	39044-39052	veterans	_	
176-204	39053-39057	with	_	
176-205	39058-39071	posttraumatic	_	
176-206	39072-39078	stress	_	
176-207	39079-39087	disorder	_	
176-208	39088-39089	A	_	
176-209	39090-39093	new	_	
176-210	39094-39104	depression	_	
176-211	39105-39110	scale	_	
176-212	39111-39119	designed	_	
176-213	39120-39122	to	_	
176-214	39123-39125	be	_	
176-215	39126-39135	sensitive	_	
176-216	39136-39138	to	_	
176-217	39139-39145	change	_	
176-218	39146-39151	Study	_	
176-219	39152-39158	design	_	
176-220	39159-39167	overview	_	
176-221	39167-39168	.	_	

#Text=Neuroimaging procedures design overview.
177-1	39169-39181	Neuroimaging	_	
177-2	39182-39192	procedures	_	
177-3	39193-39199	design	_	
177-4	39200-39208	overview	_	
177-5	39208-39209	.	_	

#Text=Core Assessment Measures.
178-1	39210-39214	Core	_	
178-2	39215-39225	Assessment	_	
178-3	39226-39234	Measures	_	
178-4	39234-39235	.	_	

#Text=Measurements\tTimeline (WEEK)\t \t\t−1\t0\t1\t2\t3\t4\t5\t6\t7\t8\t9\t10\t11\t12\t18\t \tDemographic, medical and diagnosic assessments\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tDemographic form\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tMINI diagnostic interview\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tHistory & physical examination\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tSubstance-related assessments\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tTimeline follow back (TLFB)\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tObsessive compulsive drinking scale (OCDS)\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tAlcohol use disorders identification test (AUDIT)\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tClinician institute withdrawal assessment of alcohol – revised (CIWA-Ar)\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tEthyl glucuronide\tX\tX\t\t\t\tX\t\t\t\tX\t\t\t\tX\tX\t \tVisual analog scales\tX\t\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tBreathalyzer\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tUrine drug screen\tX\t\tX\t\t\tX\t\t\t\tX\t\t\t\tX\tX\t \tFagerstrom test for nicotine dependence\tX\t\t\t\t\t\t\t\t\t\t\t\t\tX\tX\t \tAddiction Severity index – family history\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tQuick drinking screen\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tBrief addiction monitor (BAM)\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tTrauma and PTSD assessments\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tClinician administered PTSD Scale for DSM-5 (CAPS-5)\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tPTSD checklist for DSM-5 (PCL-5)\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tLife events checklist (LEC)\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tChildhood trauma questionnaire (CTQ)\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tDeployment risk & resiliency inventory-2 (DRRI)\tX\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tRevised conflicts tactics scale (CTS2)\tX\t\t\t\t\tX\t\t\t\tX\t\t\t\tX\tX\t \tPosttraumatic cognitions inventory (PTCI)\t\tX\t\tX\t\tX\t\tX\t\tX\t\tX\t\tX\tX\t \tFrequency of nightmares questionnaire\tX\t\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tHealth & safety monitoring\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tAdverse events\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tVital signs\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tConcomitant medications form\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t \tPatient health questionnaire-9 (PHQ-9)\tX\t\t\tX\t\tX\t\tX\t\tX\t\tX\t\tX\tX\t \tPregnancy test (Female subjects)\tX\t\t\t\t\tX\t\t\t\tX\t\t\t\t\t\t \tVeterans RAND 12 item health survey (VR-12)\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tHistory of head injuries\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tTreatment adherence\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tRiboflavin test\t\tX\t\t\t\tX\t\t\t\tX\t\t\t\tX\t\t \tMedication adherence log\t\t\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\tX\t\t \tOther measures\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t \tNeuroimaging procedures\tX\t\t\t\t\t\t\t\t\t\t\t\t\tX\t\t \tSelf-injurious thoughts and behaviors interview (SITBI)\tX\t\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \tInsomnia severity index (ISI)\tX\t\t\tX\t\tX\t\tX\t\tX\t\tX\t\tX\tX\t \tDifficulties in emotion regulation scale (DERS)\t\tX\t\t\t\t\t\tX\t\t\t\t\t\tX\tX\t \t
#Text=Note.
179-1	39236-39248	Measurements	_	
179-2	39249-39257	Timeline	_	
179-3	39258-39259	(	_	
179-4	39259-39263	WEEK	_	
179-5	39263-39264	)	_	
179-6	39268-39269	−	_	
179-7	39269-39270	1	_	
179-8	39271-39272	0	_	
179-9	39273-39274	1	_	
179-10	39275-39276	2	_	
179-11	39277-39278	3	_	
179-12	39279-39280	4	_	
179-13	39281-39282	5	_	
179-14	39283-39284	6	_	
179-15	39285-39286	7	_	
179-16	39287-39288	8	_	
179-17	39289-39290	9	_	
179-18	39291-39293	10	_	
179-19	39294-39296	11	_	
179-20	39297-39299	12	_	
179-21	39300-39302	18	_	
179-22	39305-39316	Demographic	_	
179-23	39316-39317	,	_	
179-24	39318-39325	medical	_	
179-25	39326-39329	and	_	
179-26	39330-39339	diagnosic	_	
179-27	39340-39351	assessments	_	
179-28	39369-39380	Demographic	_	
179-29	39381-39385	form	_	
179-30	39386-39387	X	_	
179-31	39404-39408	MINI	_	
179-32	39409-39419	diagnostic	_	
179-33	39420-39429	interview	_	
179-34	39430-39431	X	_	
179-35	39448-39455	History	_	
179-36	39456-39457	&	_	
179-37	39458-39466	physical	_	
179-38	39467-39478	examination	_	
179-39	39479-39480	X	_	
179-40	39497-39514	Substance-related	_	
179-41	39515-39526	assessments	_	
179-42	39544-39552	Timeline	_	
179-43	39553-39559	follow	_	
179-44	39560-39564	back	_	
179-45	39565-39566	(	_	
179-46	39566-39570	TLFB	_	
179-47	39570-39571	)	_	
179-48	39572-39573	X	_	
179-49	39574-39575	X	_	
179-50	39576-39577	X	_	
179-51	39578-39579	X	_	
179-52	39580-39581	X	_	
179-53	39582-39583	X	_	
179-54	39584-39585	X	_	
179-55	39586-39587	X	_	
179-56	39588-39589	X	_	
179-57	39590-39591	X	_	
179-58	39592-39593	X	_	
179-59	39594-39595	X	_	
179-60	39596-39597	X	_	
179-61	39598-39599	X	_	
179-62	39600-39601	X	_	
179-63	39604-39613	Obsessive	_	
179-64	39614-39624	compulsive	_	
179-65	39625-39633	drinking	_	
179-66	39634-39639	scale	_	
179-67	39640-39641	(	_	
179-68	39641-39645	OCDS	_	
179-69	39645-39646	)	_	
179-70	39647-39648	X	_	
179-71	39655-39656	X	_	
179-72	39662-39663	X	_	
179-73	39664-39665	X	_	
179-74	39668-39675	Alcohol	_	
179-75	39676-39679	use	_	
179-76	39680-39689	disorders	_	
179-77	39690-39704	identification	_	
179-78	39705-39709	test	_	
179-79	39710-39711	(	_	
179-80	39711-39716	AUDIT	_	
179-81	39716-39717	)	_	
179-82	39718-39719	X	_	
179-83	39736-39745	Clinician	_	
179-84	39746-39755	institute	_	
179-85	39756-39766	withdrawal	_	
179-86	39767-39777	assessment	_	
179-87	39778-39780	of	_	
179-88	39781-39788	alcohol	_	
179-89	39789-39790	–	_	
179-90	39791-39798	revised	_	
179-91	39799-39800	(	_	
179-92	39800-39807	CIWA-Ar	_	
179-93	39807-39808	)	_	
179-94	39809-39810	X	_	
179-95	39827-39832	Ethyl	_	
179-96	39833-39844	glucuronide	_	
179-97	39845-39846	X	_	
179-98	39847-39848	X	_	
179-99	39852-39853	X	_	
179-100	39857-39858	X	_	
179-101	39862-39863	X	_	
179-102	39864-39865	X	_	
179-103	39868-39874	Visual	_	
179-104	39875-39881	analog	_	
179-105	39882-39888	scales	_	
179-106	39889-39890	X	_	
179-107	39892-39893	X	_	
179-108	39894-39895	X	_	
179-109	39896-39897	X	_	
179-110	39898-39899	X	_	
179-111	39900-39901	X	_	
179-112	39902-39903	X	_	
179-113	39904-39905	X	_	
179-114	39906-39907	X	_	
179-115	39908-39909	X	_	
179-116	39910-39911	X	_	
179-117	39912-39913	X	_	
179-118	39914-39915	X	_	
179-119	39916-39917	X	_	
179-120	39920-39932	Breathalyzer	_	
179-121	39933-39934	X	_	
179-122	39935-39936	X	_	
179-123	39937-39938	X	_	
179-124	39939-39940	X	_	
179-125	39941-39942	X	_	
179-126	39943-39944	X	_	
179-127	39945-39946	X	_	
179-128	39947-39948	X	_	
179-129	39949-39950	X	_	
179-130	39951-39952	X	_	
179-131	39953-39954	X	_	
179-132	39955-39956	X	_	
179-133	39957-39958	X	_	
179-134	39959-39960	X	_	
179-135	39961-39962	X	_	
179-136	39965-39970	Urine	_	
179-137	39971-39975	drug	_	
179-138	39976-39982	screen	_	
179-139	39983-39984	X	_	
179-140	39986-39987	X	_	
179-141	39990-39991	X	_	
179-142	39995-39996	X	_	
179-143	40000-40001	X	_	
179-144	40002-40003	X	_	
179-145	40006-40016	Fagerstrom	_	
179-146	40017-40021	test	_	
179-147	40022-40025	for	_	
179-148	40026-40034	nicotine	_	
179-149	40035-40045	dependence	_	
179-150	40046-40047	X	_	
179-151	40060-40061	X	_	
179-152	40062-40063	X	_	
179-153	40066-40075	Addiction	_	
179-154	40076-40084	Severity	_	
179-155	40085-40090	index	_	
179-156	40091-40092	–	_	
179-157	40093-40099	family	_	
179-158	40100-40107	history	_	
179-159	40108-40109	X	_	
179-160	40126-40131	Quick	_	
179-161	40132-40140	drinking	_	
179-162	40141-40147	screen	_	
179-163	40148-40149	X	_	
179-164	40156-40157	X	_	
179-165	40163-40164	X	_	
179-166	40165-40166	X	_	
179-167	40169-40174	Brief	_	
179-168	40175-40184	addiction	_	
179-169	40185-40192	monitor	_	
179-170	40193-40194	(	_	
179-171	40194-40197	BAM	_	
179-172	40197-40198	)	_	
179-173	40199-40200	X	_	
179-174	40207-40208	X	_	
179-175	40214-40215	X	_	
179-176	40216-40217	X	_	
179-177	40220-40226	Trauma	_	
179-178	40227-40230	and	_	
179-179	40231-40235	PTSD	_	
179-180	40236-40247	assessments	_	
179-181	40265-40274	Clinician	_	
179-182	40275-40287	administered	_	
179-183	40288-40292	PTSD	_	
179-184	40293-40298	Scale	_	
179-185	40299-40302	for	_	
179-186	40303-40306	DSM	_	
179-187	40306-40307	-	_	
179-188	40307-40308	5	_	
179-189	40309-40310	(	_	
179-190	40310-40314	CAPS	_	
179-191	40314-40315	-	_	
179-192	40315-40316	5	_	
179-193	40316-40317	)	_	
179-194	40318-40319	X	_	
179-195	40326-40327	X	_	
179-196	40333-40334	X	_	
179-197	40335-40336	X	_	
179-198	40339-40343	PTSD	_	
179-199	40344-40353	checklist	_	
179-200	40354-40357	for	_	
179-201	40358-40361	DSM	_	
179-202	40361-40362	-	_	
179-203	40362-40363	5	_	
179-204	40364-40365	(	_	
179-205	40365-40368	PCL	_	
179-206	40368-40369	-	_	
179-207	40369-40370	5	_	
179-208	40370-40371	)	_	
179-209	40372-40373	X	_	
179-210	40374-40375	X	_	
179-211	40376-40377	X	_	
179-212	40378-40379	X	_	
179-213	40380-40381	X	_	
179-214	40382-40383	X	_	
179-215	40384-40385	X	_	
179-216	40386-40387	X	_	
179-217	40388-40389	X	_	
179-218	40390-40391	X	_	
179-219	40392-40393	X	_	
179-220	40394-40395	X	_	
179-221	40396-40397	X	_	
179-222	40398-40399	X	_	
179-223	40400-40401	X	_	
179-224	40404-40408	Life	_	
179-225	40409-40415	events	_	
179-226	40416-40425	checklist	_	
179-227	40426-40427	(	_	
179-228	40427-40430	LEC	_	
179-229	40430-40431	)	_	
179-230	40432-40433	X	_	
179-231	40440-40441	X	_	
179-232	40447-40448	X	_	
179-233	40449-40450	X	_	
179-234	40453-40462	Childhood	_	
179-235	40463-40469	trauma	_	
179-236	40470-40483	questionnaire	_	
179-237	40484-40485	(	_	
179-238	40485-40488	CTQ	_	
179-239	40488-40489	)	_	
179-240	40490-40491	X	_	
179-241	40508-40518	Deployment	_	
179-242	40519-40523	risk	_	
179-243	40524-40525	&	_	
179-244	40526-40536	resiliency	_	
179-245	40537-40546	inventory	_	
179-246	40546-40547	-	_	
179-247	40547-40548	2	_	
179-248	40549-40550	(	_	
179-249	40550-40554	DRRI	_	
179-250	40554-40555	)	_	
179-251	40556-40557	X	_	
179-252	40574-40581	Revised	_	
179-253	40582-40591	conflicts	_	
179-254	40592-40599	tactics	_	
179-255	40600-40605	scale	_	
179-256	40606-40607	(	_	
179-257	40607-40611	CTS2	_	
179-258	40611-40612	)	_	
179-259	40613-40614	X	_	
179-260	40619-40620	X	_	
179-261	40624-40625	X	_	
179-262	40629-40630	X	_	
179-263	40631-40632	X	_	
179-264	40635-40648	Posttraumatic	_	
179-265	40649-40659	cognitions	_	
179-266	40660-40669	inventory	_	
179-267	40670-40671	(	_	
179-268	40671-40675	PTCI	_	
179-269	40675-40676	)	_	
179-270	40678-40679	X	_	
179-271	40681-40682	X	_	
179-272	40684-40685	X	_	
179-273	40687-40688	X	_	
179-274	40690-40691	X	_	
179-275	40693-40694	X	_	
179-276	40696-40697	X	_	
179-277	40698-40699	X	_	
179-278	40702-40711	Frequency	_	
179-279	40712-40714	of	_	
179-280	40715-40725	nightmares	_	
179-281	40726-40739	questionnaire	_	
179-282	40740-40741	X	_	
179-283	40743-40744	X	_	
179-284	40745-40746	X	_	
179-285	40747-40748	X	_	
179-286	40749-40750	X	_	
179-287	40751-40752	X	_	
179-288	40753-40754	X	_	
179-289	40755-40756	X	_	
179-290	40757-40758	X	_	
179-291	40759-40760	X	_	
179-292	40761-40762	X	_	
179-293	40763-40764	X	_	
179-294	40765-40766	X	_	
179-295	40767-40768	X	_	
179-296	40771-40777	Health	_	
179-297	40778-40779	&	_	
179-298	40780-40786	safety	_	
179-299	40787-40797	monitoring	_	
179-300	40815-40822	Adverse	_	
179-301	40823-40829	events	_	
179-302	40830-40831	X	_	
179-303	40832-40833	X	_	
179-304	40834-40835	X	_	
179-305	40836-40837	X	_	
179-306	40838-40839	X	_	
179-307	40840-40841	X	_	
179-308	40842-40843	X	_	
179-309	40844-40845	X	_	
179-310	40846-40847	X	_	
179-311	40848-40849	X	_	
179-312	40850-40851	X	_	
179-313	40852-40853	X	_	
179-314	40854-40855	X	_	
179-315	40856-40857	X	_	
179-316	40858-40859	X	_	
179-317	40862-40867	Vital	_	
179-318	40868-40873	signs	_	
179-319	40874-40875	X	_	
179-320	40876-40877	X	_	
179-321	40878-40879	X	_	
179-322	40880-40881	X	_	
179-323	40882-40883	X	_	
179-324	40884-40885	X	_	
179-325	40886-40887	X	_	
179-326	40888-40889	X	_	
179-327	40890-40891	X	_	
179-328	40892-40893	X	_	
179-329	40894-40895	X	_	
179-330	40896-40897	X	_	
179-331	40898-40899	X	_	
179-332	40900-40901	X	_	
179-333	40902-40903	X	_	
179-334	40906-40917	Concomitant	_	
179-335	40918-40929	medications	_	
179-336	40930-40934	form	_	
179-337	40935-40936	X	_	
179-338	40937-40938	X	_	
179-339	40939-40940	X	_	
179-340	40941-40942	X	_	
179-341	40943-40944	X	_	
179-342	40945-40946	X	_	
179-343	40947-40948	X	_	
179-344	40949-40950	X	_	
179-345	40951-40952	X	_	
179-346	40953-40954	X	_	
179-347	40955-40956	X	_	
179-348	40957-40958	X	_	
179-349	40959-40960	X	_	
179-350	40961-40962	X	_	
179-351	40963-40964	X	_	
179-352	40967-40974	Patient	_	
179-353	40975-40981	health	_	
179-354	40982-40995	questionnaire	_	
179-355	40995-40996	-	_	
179-356	40996-40997	9	_	
179-357	40998-40999	(	_	
179-358	40999-41002	PHQ	_	
179-359	41002-41003	-	_	
179-360	41003-41004	9	_	
179-361	41004-41005	)	_	
179-362	41006-41007	X	_	
179-363	41010-41011	X	_	
179-364	41013-41014	X	_	
179-365	41016-41017	X	_	
179-366	41019-41020	X	_	
179-367	41022-41023	X	_	
179-368	41025-41026	X	_	
179-369	41027-41028	X	_	
179-370	41031-41040	Pregnancy	_	
179-371	41041-41045	test	_	
179-372	41046-41047	(	_	
179-373	41047-41053	Female	_	
179-374	41054-41062	subjects	_	
179-375	41062-41063	)	_	
179-376	41064-41065	X	_	
179-377	41070-41071	X	_	
179-378	41075-41076	X	_	
179-379	41084-41092	Veterans	_	
179-380	41093-41097	RAND	_	
179-381	41098-41100	12	_	
179-382	41101-41105	item	_	
179-383	41106-41112	health	_	
179-384	41113-41119	survey	_	
179-385	41120-41121	(	_	
179-386	41121-41123	VR	_	
179-387	41123-41124	-	_	
179-388	41124-41126	12	_	
179-389	41126-41127	)	_	
179-390	41128-41129	X	_	
179-391	41136-41137	X	_	
179-392	41143-41144	X	_	
179-393	41145-41146	X	_	
179-394	41149-41156	History	_	
179-395	41157-41159	of	_	
179-396	41160-41164	head	_	
179-397	41165-41173	injuries	_	
179-398	41174-41175	X	_	
179-399	41182-41183	X	_	
179-400	41189-41190	X	_	
179-401	41191-41192	X	_	
179-402	41195-41204	Treatment	_	
179-403	41205-41214	adherence	_	
179-404	41232-41242	Riboflavin	_	
179-405	41243-41247	test	_	
179-406	41249-41250	X	_	
179-407	41254-41255	X	_	
179-408	41259-41260	X	_	
179-409	41264-41265	X	_	
179-410	41269-41279	Medication	_	
179-411	41280-41289	adherence	_	
179-412	41290-41293	log	_	
179-413	41296-41297	X	_	
179-414	41298-41299	X	_	
179-415	41300-41301	X	_	
179-416	41302-41303	X	_	
179-417	41304-41305	X	_	
179-418	41306-41307	X	_	
179-419	41308-41309	X	_	
179-420	41310-41311	X	_	
179-421	41312-41313	X	_	
179-422	41314-41315	X	_	
179-423	41316-41317	X	_	
179-424	41318-41319	X	_	
179-425	41323-41328	Other	_	
179-426	41329-41337	measures	_	
179-427	41355-41367	Neuroimaging	_	
179-428	41368-41378	procedures	_	
179-429	41379-41380	X	_	
179-430	41393-41394	X	_	
179-431	41398-41412	Self-injurious	_	
179-432	41413-41421	thoughts	_	
179-433	41422-41425	and	_	
179-434	41426-41435	behaviors	_	
179-435	41436-41445	interview	_	
179-436	41446-41447	(	_	
179-437	41447-41452	SITBI	_	
179-438	41452-41453	)	_	
179-439	41454-41455	X	_	
179-440	41462-41463	X	_	
179-441	41469-41470	X	_	
179-442	41471-41472	X	_	
179-443	41475-41483	Insomnia	_	
179-444	41484-41492	severity	_	
179-445	41493-41498	index	_	
179-446	41499-41500	(	_	
179-447	41500-41503	ISI	_	
179-448	41503-41504	)	_	
179-449	41505-41506	X	_	
179-450	41509-41510	X	_	
179-451	41512-41513	X	_	
179-452	41515-41516	X	_	
179-453	41518-41519	X	_	
179-454	41521-41522	X	_	
179-455	41524-41525	X	_	
179-456	41526-41527	X	_	
179-457	41530-41542	Difficulties	_	
179-458	41543-41545	in	_	
179-459	41546-41553	emotion	_	
179-460	41554-41564	regulation	_	
179-461	41565-41570	scale	_	
179-462	41571-41572	(	_	
179-463	41572-41576	DERS	_	
179-464	41576-41577	)	_	
179-465	41579-41580	X	_	
179-466	41586-41587	X	_	
179-467	41593-41594	X	_	
179-468	41595-41596	X	_	
179-469	41600-41604	Note	_	
179-470	41604-41605	.	_	

#Text=Baseline occurs at Week −1.
180-1	41606-41614	Baseline	_	
180-2	41615-41621	occurs	_	
180-3	41622-41624	at	_	
180-4	41625-41629	Week	_	
180-5	41630-41631	−	_	
180-6	41631-41632	1	_	
180-7	41632-41633	.	_	

#Text=Medication initiation occurs at Week 0.
181-1	41634-41644	Medication	_	
181-2	41645-41655	initiation	_	
181-3	41656-41662	occurs	_	
181-4	41663-41665	at	_	
181-5	41666-41670	Week	_	
181-6	41671-41672	0	_	
181-7	41672-41673	.	_	

#Text=Follow-up assessment occurs at Week 18.
182-1	41674-41683	Follow-up	_	
182-2	41684-41694	assessment	_	
182-3	41695-41701	occurs	_	
182-4	41702-41704	at	_	
182-5	41705-41709	Week	_	
182-6	41710-41712	18	_	
182-7	41712-41713	.	_	
